Use of electronic health records to investigate the role of

acute inflammation and infection in vascular disease by Minassian, C
Minassian, C (2014) Use of electronic health records to investigate
the role of acute inflammation and infection in vascular disease. Doc-
toral thesis, London School of Hygiene Tropical Medicine.
Downloaded from: http://researchonline.lshtm.ac.uk/1856016/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
1 
 
Use of electronic health records to investigate the role of 
acute inflammation and infection in vascular disease 
Caroline Minassian 
July 2014 
Department of Non-communicable Disease Epidemiology 
Faculty of Epidemiology and Population Health 
London School of Hygiene & Tropical Medicine,  
University of London 
 
Thesis submitted in fulfilment of the requirements for the 
degree of Doctor of Philosophy 
This work was funded by the Wellcome Trust 
 
2 
 
Declaration  
I, Caroline Minassian, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
 
 
 
 
 
Caroline Minassian 
July 2014 
 
3 
 
Abstract  
Previous studies have demonstrated that acute systemic inflammation after surgery or 
infection is associated with a transient increase in the risk of vascular events. This 
suggests that vascular risk is not stable but fluctuates within short periods in response 
to inflammatory stimuli. While an association between respiratory tract infection and 
vascular events is well-documented, the effects of other acute infections and 
inflammatory stimuli are less certain.  
The principal aim of this project was to investigate further the role of acute 
inflammation and infection in vascular disease, employing the unique opportunities 
offered by electronic health record databases. Two large observational studies were 
undertaken. First, the self-controlled case series method and Medicaid claims data 
from the United States were used to examine the short-term effects of invasive dental 
treatment, a novel acute inflammatory model, on the risk of vascular events. Second, 
a matched case-control study using primary care data from the United Kingdom 
General Practice Research Database investigated the role of acute maternal infection 
in the development of pre-eclampsia – a vascular disorder of pregnancy.  
The case series analysis of 1152 adults with a vascular event demonstrated a 
transiently increased vascular event rate in the four weeks after invasive dental 
treatment relative to unexposed time periods. The analysis of 1533 pre-eclampsia 
cases and 14236 controls who had completed a pregnancy without pre-eclampsia 
revealed an increased risk of pre-eclampsia associated with antibiotic prescriptions 
and urinary infection, but not respiratory infection, during pregnancy.  
The findings suggest that exposures sufficient to produce an acute inflammatory 
response may play an important role in the occurrence of vascular outcomes. Future 
research on the effects of other acute inflammatory triggers and the mediating 
mechanisms involved should help establish a clearer role for acute inflammation and 
infection in vascular disease and inform preventative strategies during periods of 
increased vascular risk.  
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Chapter 1  Introduction 
Vascular disease, notably coronary heart disease (CHD) and stroke, is a leading 
cause of chronic disease morbidity and mortality worldwide.1,2 An estimated 15.6 
million individuals died of cardiovascular disease (CVD) in 2010, the majority due to 
CHD (7.0 million) or stroke (5.9 million), representing a quarter of all global deaths.3 
The burden of CVD continues to rise and is projected to generate approximately 23.3 
million deaths worldwide in 2030.4  
The main pathological process underlying most vascular disease is atherosclerosis, 
the accumulation of lipid-containing material known as plaque or atheroma within 
the inner lining of blood vessels. It is a gradual process which can lead to the 
narrowing of the arteries if plaque deposits build up over time. When an artery 
becomes blocked due to plaque activation or rupture of unstable plaques resulting in 
thrombus formation or distal embolisation, this may culminate in an acute thrombotic 
event such as ischaemic stroke or myocardial infarction (MI).  
While the mechanisms involved in the transition between stable and unstable 
atherosclerotic plaques are not completely understood, there is growing evidence that 
inflammation plays a key role.5 Inflammatory and immune cells constitute an 
important component of plaques.6 Furthermore, inflammation has been implicated in 
all phases of the atherosclerotic process: in early atherogenesis, in the progression of 
plaques, and finally in plaque activation and rupture resulting in arterial occlusion.7 
One of the earliest characteristics of atherosclerosis is the impairment in vascular 
endothelial function, which can derive from inflammation, and which has been 
shown to predict long-term atherosclerotic disease progression and vascular events.8 
Numerous prospective studies have shown that low-grade chronic systemic 
inflammation, as indicated by elevated levels of inflammatory biomarkers such as C-
reactive protein (CRP), is associated with an increased risk of future CHD and 
ischaemic stroke, which persists after adjustment for conventional cardiovascular 
risk factors.9,10 Among the potential sources of chronic inflammation which have 
been investigated are chronic infections such as periodontal disease, which has been 
shown to be associated with raised levels of CRP11,12 and an increased risk of 
cardiovascular events in the long term13,14. While studies of specific pathogens, 
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including Chlamydia pneumoniae, herpes simplex virus and cytomegalovirus, have 
yielded mixed findings, their cumulative effect or overall “pathogen burden” has 
been shown to predict CRP levels and CHD risk.15 
A possible aetiological role for acute inflammation in vascular disease has also 
received attention in recent years. There is accumulating evidence suggesting that 
episodes of acute bacterial or viral infection may trigger a short-term increase in the 
risk of vascular events. An increased risk of acute MI associated with recent acute 
respiratory tract infection (RTI) has been well-documented.16 Evidence from 
observational studies also supports the notion that acute infection is an important 
trigger for ischaemic stroke, particularly in the week preceding stroke.17 Four large 
studies using electronic primary care data have shown that acute RTI is associated 
with a transiently increased risk of vascular events.18–21 The effect was strongest in 
the few days after infection (up to ten days), with relative risks (RR) ranging from 
2.10 (95% confidence interval (CI) 1.38-3.21)20 to 4.95 (95% CI 4.43-5.53)19 for MI, 
and 1.92 (95% CI 1.24-2.97)20 to 3.19 (95% CI 2.81-3.62)19 for stroke, and gradually 
resolved over time. Three of these studies also investigated the effect of urinary tract 
infection (UTI): while one found no association with UTI,18 two found a similar, 
transient increase in vascular event risk after UTI,19,20 although in one the effect was 
confined to stroke20. These findings suggest that the risk of vascular events fluctuates 
transiently in response to acute inflammatory stimuli.  
Various pathophysiological mechanisms have been proposed to explain the short-
term increased risk of vascular events following acute infection observed in these 
earlier studies, including changes in plaque composition and stability, increased local 
coagulability due to disturbances in immunohaematological mechanisms, increased 
concentrations of CRP and proinflammatory cytokines, and endothelial 
dysfunction.17 In support of the last, vaccination of healthy individuals has been 
shown to elicit a mild systemic inflammatory response which leads to a transient 
impairment in function of the arterial endothelium.22 Such acute changes in the 
inflammatory state associated with acute infection may also give rise to a short-term 
alteration of endothelial function. Endothelial dysfunction may thus represent a 
common pathway through which acute infection/inflammation, among several other 
risk factors, may contribute to vascular risk.19  
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Another area of vascular disease in which inflammation has also been implicated is 
pre-eclampsia: a vascular disorder of unknown origin unique to pregnancy. Pre-
eclampsia shares many features with atherosclerotic vascular disease. Notably, 
several well-established cardiovascular risk factors are associated with an increased 
risk of pre-eclampsia including a history of hypertension, obesity, diabetes and 
chronic renal disease.23 Accordantly, women who develop pre-eclampsia are at an 
increased risk of CVD in later life.24–26 A recent meta-analysis of studies assessing 
vascular risk after pre-eclampsia reported an approximately two-fold increased risk 
of CHD and stroke among women who had previously developed pre-eclampsia 
compared to parous women who had not.27 A frequent finding in the uterine spiral 
arteries of women who develop pre-eclampsia is acute atherosis (lesions involving 
the accumulation of lipid-filled cells, resembling the early stages of atherosclerosis), 
which is thought to contribute to reduced placental perfusion.28 Endothelial 
dysfunction is evident among women prior to the development of pre-eclampsia.29 
There are thus clear similarities between pre-eclampsia and other vascular diseases 
when investigating the role of inflammation.  
1.1 Rationale for research 
While an association between acute RTI and vascular events has been consistently 
demonstrated, the effects of other acute infections and inflammatory stimuli are less 
certain. Thus, a clear role for acute inflammation and infection in vascular disease 
has not yet been established. If acute inflammation does alter the occurrence of 
vascular events then similar effects should be seen for other inflammatory stimuli, 
and in other vascular disorders. Gaining a clearer understanding of how acute 
inflammation may be involved in vascular disease will give further insight into 
factors that influence the timing of vascular events, which in turn may help inform 
strategies for prevention or treatment at times of increased inflammation. 
1.2 Aim and research questions  
The overall aim of this project was to build on the previous work described above by 
investigating further the role of acute inflammation and infection in the occurrence of 
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vascular outcomes. To this end, two large observational studies were undertaken, 
each using electronic health records (EHRs) to address a specific research question.  
1.2.1 Invasive dental treatment: a potential trigger for vascular events 
The first study carried out for this thesis investigated a novel, acute inflammatory 
stimulus, invasive dental treatment, as a potential trigger for vascular events. While 
previous studies have examined whether invasive treatment of periodontal disease 
may be effective in reducing CVD risk by diminishing the infectious burden,30 the 
aim of this study was to assess whether such treatment, or other invasive dental 
procedures sufficient to result in bacteraemia and induce an acute inflammatory 
response, may heighten the risk of vascular events in the short term.  
The Medicaid claims database of the United States (US), in which both dental 
procedures and health outcomes are recorded, provided a unique opportunity to 
address this question. Using an innovative case-only design, the relative incidence of 
vascular events (ischaemic stroke and MI) in pre-defined periods after invasive 
dental treatment compared to all other observed time periods was estimated.  
1.2.2 Acute maternal infections and pre-eclampsia  
The second study undertaken as part of this thesis investigated the role of acute 
maternal infection in the pathogenesis of pre-eclampsia. The aim was to establish 
whether acute infections during pregnancy, sufficient to be likely to produce 
systemic effects, are associated with an increased risk of pre-eclampsia.  
Using primary care data from the United Kingdom (UK) General Practice Research 
Database (GRPD) and a matched case-control study design, the effects of two 
specific acute infections on pre-eclampsia risk were assessed, namely UTI and RTI, 
in addition to maternal antibiotic drug prescriptions: a likely proxy for acute 
infection.  
1.3 Outline of the thesis 
The thesis comprises nine chapters. The background, methods and findings relating 
to the first study of invasive dental treatment and the risk of vascular events are 
presented first (Chapters 2 to 4); those relating to the second study of acute maternal 
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infection and pre-eclampsia are subsequently presented in Chapters 5 to 8. Both 
studies have been published. The papers “Invasive dental treatment and risk for 
vascular events: a self-controlled case series”31 and “Acute maternal infection and 
risk of pre-eclampsia: a population-based case-control study”32, are included as 
Appendices (Appendix A and Appendix B), together with additional supplementary 
material.  
Chapter 2 presents a review of the published literature on the risk of vascular events 
associated with invasive dental treatment.  
Chapter 3 describes the methods used in the study of invasive dental treatment and 
vascular events, including the study objectives, an overview of the Medicaid 
database, followed by a description of the case series method, a discussion of its 
strengths and advantages for the research question, and its application to the study.  
The dental study findings are described in Chapter 4.  
Chapter 5 presents a literature review of published articles on the association 
between pre-eclampsia and acute maternal infections.  
Chapter 6 provides a detailed account of the methods used in the matched case-
control study of pre-eclampsia and acute infection, including the study objectives, an 
overview of the GPRD, the matching procedure, the statistical methods used, and the 
analysis strategy.  
Chapter 7 describes the algorithm developed as part of this project to identify and 
estimate the timing of pregnancies in the GPRD, for application in the pre-eclampsia 
study. 
The results of the pre-eclampsia study are reported in Chapter 8.  
In Chapter 9, the main findings of the dental and pre-eclampsia studies are 
summarised and brought into context of what was previously known on the topics, 
the suitability of the data sources to address the research questions are considered, 
and the implications of the findings for future research and clinical practice are 
discussed. 
21 
 
1.4 Funding 
This project was funded by the Wellcome Trust. 
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Chapter 2  A literature review of invasive dental treatment and 
vascular events 
This chapter reports on the literature review of studies assessing the association 
between invasive dental treatment and the risk of vascular events. The initial phase 
of the review was carried out prior to the planned analyses of the dental study 
(described in Chapter 3) and was subsequently updated for completeness. Following 
a brief overview of what is known of the link between dental infections, invasive 
dental treatment and CVD, the review methodology is described. Studies identified 
in the initial review phase, prior to completion of the dental study, are summarised 
first followed by additional studies identified in the updated search. The chapter 
concludes with a summary of the main findings of the review and a rationale for the 
dental study. 
2.1 Background 
Exposure to low-grade dental infections, particularly periodontal disease (a common 
chronic infection of the oral cavity caused by bacteria) has long been implicated in 
the aetiology of CVD. Several epidemiological studies have shown periodontal 
disease to be associated with raised levels of CRP and other inflammatory 
biomarkers,11,12,33,34 and with endothelial dysfunction35–37.  
The first study reporting a link between dental infections and acute MI, published in 
1989,38 precipitated a number of subsequent studies examining the association 
between periodontal disease and cardiovascular events39–41. Meta-analyses of these 
studies have consistently shown an increased risk of cardiovascular events associated 
with periodontitis in the long term.13,14,42,43 More recent population-based findings 
from the Scottish Health Survey have shown poor oral hygiene - a major cause of 
periodontal disease - to be associated with raised markers of inflammation (CRP and 
fibrinogen) and an increased risk of hospital admissions for both fatal and non-fatal 
cardiovascular events.44  
23 
 
2.1.1 Invasive dental treatment: an acute inflammatory stimulus  
While treating periodontal disease may effect a positive influence on longer-term 
CVD risk by reducing the infectious burden,30,45,46 studies have shown that intensive 
periodontal therapy can lead to a transient impairment of flow-mediated dilatation of 
the brachial artery (a measure of endothelial function), and raised markers of 
inflammation and endothelial activation in the week after treatment, followed by a 
longer-term improvement in these measures relative to baseline.47–49 The more 
invasive the dental treatment, the more marked were these effects.49 This work 
suggests that invasive dental treatment, particularly periodontal therapy, provides a 
useful model of acute inflammation. Furthermore, if the probability of a vascular 
event occurring is associated with changes in the underlying inflammatory state and 
endothelial function, then dental procedures sufficient to produce an acute 
inflammatory response may transiently increase the risk of vascular events, despite 
providing longer-term vascular benefits by reducing the infectious and inflammatory 
burden.  
2.2 Methods  
2.2.1 Aim of review 
The aim of the literature review was to summarise published evidence on the effect 
of invasive dental treatment on the risk of vascular events, namely ischaemic stroke 
and MI.  
2.2.2 Search strategy 
The search was conducted using the Medline database which is indexed using the 
Medical Subject Headings (MeSH) system. A list of relevant MeSH keywords and 
free-text words for dental treatment and vascular events (ischaemic stroke and MI), 
was compiled. These were combined in an algorithm which was applied in Medline 
to identify all potentially relevant studies from inception to August 2010. The search 
was subsequently updated to February 2014, to identify any additional studies 
published after completion of the dental study (undertaken as part of this thesis, see 
Chapter 3). 
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For each study identified, the abstract was assessed with reference to the inclusion 
criteria described below. Reference lists of all studies fulfilling the inclusion criteria 
were scanned to identify any further studies or search terms that might have been 
missed in the initial search: subsequent searches were then conducted using any 
additional terms. For each included study, information on participant selection, 
exposure and outcome ascertainment, the main findings (including effect sizes and 
CIs when reported), and the extent of adjustment for confounding was recorded. 
Full details of the search algorithm used are given in Appendix C-Table C.1. 
2.2.3 Inclusion and exclusion criteria 
Studies presenting original data, published in English, and which included fatal or 
non-fatal MI and/or stroke as an outcome and invasive dental treatment as an 
exposure were included. Invasive dental treatment was defined as any course of 
treatment or single procedure sufficient to result in bacteraemia, including 
periodontal therapy or dental extractions. Case reports, case-only studies with no 
comparison group (or with no comparison time period) and review articles without 
original data were excluded.  
2.3 Results  
The search generated 259 citations of which 249 were deemed not relevant (they did 
not report on the association between invasive dental treatment as defined above and 
vascular events). The remaining 10 publications were identified as potentially 
relevant. Of these, seven were excluded for the following reasons: 
Four were case reports50–52 or case series with no comparison group,53 and a fifth 
lacked data relating invasive dental treatment and cardiovascular events54.  
The sixth publication reported on a multicentre pilot intervention study designed to 
assess the effects of periodontal therapy versus community dental care on the 
prevention of secondary cardiac events, and which found no difference in the 
incidence of adverse events between the treatment and control groups over a six 
month period.55 However, the authors only presented findings for adverse 
cardiovascular and dental events combined. Furthermore, the nature of community 
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dental care was unclear as 48% of subjects randomized to community care received 
some preventive or periodontal treatment, which further complicates interpretation of 
the findings. Thus no conclusions could be drawn from this study on the effects of 
periodontal treatment on the risk of subsequent cardiovascular events.  
Finally, a recent case-control study which examined the relationship between history 
of non-fatal MI and history of tooth extractions due to infection among adult males 
reported a positive association (OR 1.64, 95% CI 1.24-2.16).56 However, this study 
was excluded due to uncertainty regarding the temporal sequence of events: both the 
disease history of MI and extractions were self-reported and their timing was not 
ascertained in the study, a limitation acknowledged by the authors. Furthermore, the 
reference group included, among those with no extractions, individuals with 
extractions due to trauma or other causes (not infection), and thus was not truly 
unexposed to invasive dental treatment. 
2.3.1 Included studies 
Three cohort studies fulfilled the inclusion criteria: two from Taiwan,57,58 one from 
the US,59 all three conducted within administrative healthcare claims databases. 
However, these studies were identified in the updated search (post-August 2010), 
after the dental study (described in Chapter 3) was completed. While the findings of 
these studies did not inform the dental study analyses, they are nevertheless relevant 
to this thesis, and are thus summarised below.  
The most recent, a population-based Taiwanese study,58 assessed the association 
between periodontal treatment and the incidence of ischaemic stroke among 719,436 
beneficiaries of Taiwan’s National Health Insurance program who were followed up 
over a ten year period (2000 to 2010). Comparing both treated and untreated 
individuals with periodontal disease to individuals without periodontal disease, the 
authors found a significantly lower rate of stroke in the intensive treatment 
periodontal disease group (Hazard ratio (HR) 0.95, 95% CI 0.91-0.99), and a 
significantly higher stroke rate among the untreated periodontal disease group 
(individuals with neither dental prophylaxis nor intensive treatment) (HR 1.15, 95% 
CI 1.07–1.24), after adjusting for age, sex, hypertension, diabetes and atrial 
fibrillation. Individuals with periodontal disease who received dental prophylaxis 
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only had the lowest stroke rate. The authors concluded that periodontal disease is an 
important risk factor for ischaemic stroke, and the treatment of periodontal disease 
reduces the incidence of stroke. However, the study had important limitations, for 
example, the potential for confounding by other unmeasured risk factors for stroke, 
notably smoking, body mass index (BMI), socioeconomic status (SES), alcohol 
consumption, diet, and other comorbidities such as inflammatory diseases. Smoking 
in particular is an important risk factor for both CVD and periodontal disease, and 
may influence the outcome of periodontal treatment. In addition, the apparent 
protective effect of treatment may in part be attributed to unmeasured differences in 
health-seeking behaviour between treated and untreated individuals. Finally, the 
study did not assess the timing of any increased risk following dental treatment; 
rather the focus was on the long-term effect of periodontal treatment on stroke risk 
up to ten years after treatment. 
The earlier Taiwanese study,57 conducted in the same database, examined the effect 
of tooth scaling (a component of periodontal therapy) on the risk of ischaemic stroke 
and MI among beneficiaries aged ≥50 years (10,887 exposed to tooth scaling at 
baseline and propensity score matched with 10,989 with no tooth scaling) over a 
seven year period (2000-2007). Tooth scaling was found to be associated with a 
reduced risk of developing MI (HR 0.69, 95% CI 0.57-0.85), and stroke (HR 0.85, 
95% CI 0.78-0.93) after adjustment for age, gender, history of hypertension, 
hyperlipidaemia, dysrhythmia, diabetes and chronic kidney disease. However, this 
study was also prone to residual confounding due to a lack of adjustment for some 
important CVD risk factors, such as smoking, BMI, and other socioeconomic and 
lifestyle factors. Furthermore, the study also assessed long-term rather than acute 
effects of dental treatment on vascular risk.  
The third study of 2035 beneficiaries of Medicare (the US health insurance program 
for individuals aged ≥65 years), who had all experienced an ischaemic vascular 
event, examined whether dental treatment in the one, two, three and six month 
periods immediately after this first event increased the risk of having a subsequent 
event.59 During an average follow-up of four years, the researchers observed no 
increased risk of a second vascular event associated with dental treatment of any 
type, or with invasive procedures considered separately, performed in any of these 
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periods (up to six months) after the initial event. However, the study did not assess 
the timing of the second vascular event relative to the dental treatment. Furthermore, 
only high-risk individuals who had already suffered a vascular event were included, 
which limits the generalisability of the findings. 
2.4 Comment 
The initial phase of the literature search preceding the planned dental study analyses 
described in Chapter 3 yielded no studies that fulfilled the inclusion and exclusion 
criteria outlined above (section 2.2.3). In the updated search following completion of 
the dental study, three studies were identified which met the inclusion criteria. Thus, 
the rationale for the dental study is presented in light of what was already known on 
the association between invasive dental treatment and vascular risk, followed by a 
brief summary of what subsequent studies have shown.  
2.4.1 Rationale for the dental study 
While recent work has shown that invasive dental treatment such as periodontal 
therapy gives rise to an acute inflammatory response and transient impairment of 
endothelial function, it is not known whether such treatment confers an 
inflammation-induced fluctuation in vascular risk. Studies examining any such acute 
effect of invasive dental treatment are lacking. Such an effect, if observed, would 
have important implications for preventative measures at the time of invasive dental 
treatment, particularly among individuals at high risk of vascular events. Hence the 
dental study (described in Chapter 3) sought to test the hypothesis of an 
inflammation-induced, acute rise in vascular risk following exposure to invasive 
dental treatment. 
2.4.2 Summary of evidence since the dental study  
The three studies fulfilling the inclusion criteria, published after the dental study, 
each used a cohort design and were prone to residual confounding due to between-
person differences in unmeasured, shared risk factors for both periodontal disease 
and vascular events such as SES or smoking. Such factors could play a role in 
explaining, at least in part, the protective effect of dental treatment on cardiovascular 
risk seen in the Taiwanese studies,57,58 or the null effect observed in the US study59. 
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Additionally, the focus of these studies was on the longer-term effect of dental 
treatment on vascular event risk over a period of several years. None of the studies 
assessed whether dental treatment might trigger a short-lived fluctuation in vascular 
event risk in the period immediately after treatment. Thus no conclusions could be 
drawn from these studies regarding any such acute effect of the dental treatment. 
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Chapter 3  Methods - Invasive dental treatment and vascular events 
This chapter describes the methods of a self-controlled case series (SCCS) study 
using Medicaid administrative claims data to assess the risk of ischaemic stroke and 
MI following invasive dental treatment. All Medicaid enrolees exposed to invasive 
dental treatment and with a primary hospital discharge diagnosis of ischaemic stroke 
or MI occurring between January 2002 and December 2006 were selected. Hence the 
study only included exposed cases. Incidence ratios (IRs) and 95% CIs for vascular 
events occurring in periods immediately after invasive dental treatment versus all 
other observed time periods were derived from within-person comparisons using 
conditional Poisson regression. 
3.1 Study hypothesis and objectives 
The hypothesis was that invasive dental procedures sufficient to invoke an acute 
systemic inflammatory response may lead to a transient increased risk of vascular 
events (ischaemic stroke and MI). 
The primary objective was to: 
 Compare the risk of vascular events in periods following exposure to invasive 
dental treatment with the risk in periods not exposed to invasive dental treatment, 
and to quantify any increased risk.  
Secondary objectives were to: 
 Estimate separately the effect of invasive dental treatment on the risk of 
ischaemic stroke and on the risk of MI, in periods following the treatment. 
 Investigate to what extent intra-person risk factors for vascular events that change 
with time may contribute to the effect of invasive dental treatment on the risk of 
vascular events (if such an effect is observed).  
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3.2 Description of the data source 
3.2.1 The Medicaid Database 
There are no longitudinal data linking dental procedures with health outcomes in the 
UK. Therefore the study used Medicaid claims data from the US, in which both 
dental and medical details are recorded. Medicaid is the US health care program 
established in 1965 to provide medical coverage for low-income individuals and 
families without private health insurance. Coverage includes physician and hospital 
bills, drug treatment costs, and long-term care. An estimated 50 million individuals 
received Medicaid assistance in 2009, corresponding to approximately one in six US 
citizens.60  
Eligibility for enrolment in Medicaid is income-related, the main criterion being 
limited income and financial resources, and is evaluated monthly. The Medicaid 
database used for this study comprised pooled, anonymised claims data from nine 
geographically dispersed, anonymised states. It included details of all health care 
provided to beneficiaries, including inpatient and outpatient services, outpatient 
prescription drugs and details of enrolment, in addition to basic demographic 
information. The data have high levels of completeness and validity and undergo 
frequent quality checks to ensure selected fields are valid (including diagnosis codes, 
procedure codes, and dates of service), and that data across fields are reasonable 
against norms (e.g. diagnosis against gender or age).61  
3.2.2 Data structure and key elements 
Data were provided in separate SAS files. A unique person-level identifier allowed 
linkage of information across files. Most files contained multiple records per 
individual; the meaning of a single record varied across files. Files of interest for the 
study are described in Table 3.1 below. 
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Table 3.1 Medicaid files used for the dental study. 
Data file Each record represents: 
Inpatient admissions  One hospital admission including the dates of admission and discharge, 
the primary diagnosis (the main reason for admission, usually the 
discharge diagnosis), the primary procedure performed during an 
admission, and up to 15 additional secondary diagnoses and procedures. 
Inpatient Services  One service claim associated with an inpatient admission including the 
date of service, one procedure and up to two diagnoses. Multiple 
services make up one hospital admission. 
Outpatient services One service claim rendered in an outpatient facility, doctor’s office, or 
hospital outpatient facility, including the date of service, one procedure 
and up to two diagnoses. Multiple services make up one outpatient visit. 
Outpatient pharmaceutical 
claims 
One prescription drug claim from mail-order programs or retail 
pharmacy including the drug code, therapeutic class, and the date the 
prescription was filled. 
Enrolment An individual’s annual enrolment (January to December) with monthly 
flags indicating enrolment status, and demographic information 
including year of birth, gender and ethnicity. 
3.2.2.1 Coding systems 
In Medicaid, clinical diagnoses are coded using the International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), a classification system 
based on the World Health Organization's Ninth Revision, International 
Classification of Diseases (ICD-9). 
Procedures are recorded using the Healthcare Common Procedure Coding System 
which includes two levels of codes. Level 1 comprises the American Medical 
Association's Current Procedural Terminology and includes medical, surgical and 
diagnostic procedures. Level 2 consists primarily of non-physician services and 
includes the American Dental Association’s Current Dental Terminology (CDT),62 a 
coding system for the billing of dental procedures and supplies. 
Prescription drug claims are recorded using the National Drug Code coding system; 
each code belongs to a therapeutic class based on the American Hospital Formulary 
Service Classification Compilation.  
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3.3 The Self-controlled Case Series Method 
This study used a case-only approach, the SCCS method,63 to examine the risk of 
vascular events following exposure to invasive dental treatment. 
3.3.1 Origin and description of the method 
The SCCS method uses within-person comparisons to investigate the association 
between time-varying exposures and outcome events in a population of individuals 
all of whom experienced the outcome of interest. It is derived from a Poisson cohort 
model by conditioning on the number of events and exposure history experienced by 
an individual over a pre-defined observation period: the time during which if an 
event arose the individual would be sampled. While the method was originally 
developed to investigate associations between vaccination and acute adverse 
events,64,65 it has subsequently been applied in other settings, for example to 
investigate the risk of MI,21 stroke,19 and deep vein thrombosis and pulmonary 
embolism66 following acute infection, and it has been extensively used in 
pharmacoepidemiology67–71.  
The SCCS method provides an alternative to the more established cohort method for 
estimating the relative incidence of an event: that is the ratio of the rate of events in a 
defined period following exposure to the rate of events in the absence of exposure 
(the baseline period). A pictorial representation of the method is shown in Figure 3.1. 
Only cases are sampled: there is no comparison group of individuals. Comparisons 
are within-person. To take this into account, the likelihood is conditional on an 
outcome event having occurred during the observation period, and is thus based on 
the probability density that an individual’s event occurred when it did in relation to 
exposure, given that their event occurred during the observation period. 
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Figure 3.1 Pictorial representation of the self-controlled case series method. 
The Figure represents a single participant experiencing two exposures during their observation period. 
The outcome event(s) could occur at any time during the observation period. The baseline period 
refers to all time an individual is observed and not “at risk” following an exposure. 
3.3.2 Application of the method to this study 
Individuals who have undergone invasive dental treatment may differ from those 
who have not in ways which can be difficult to measure and control for. Some of 
these differences may be associated with the future risk of vascular events which 
makes a conventional cohort design a less reliable approach for assessing this 
association. Therefore, the SCCS method was used to make within-person 
comparisons in individuals who experienced a vascular event (the outcome of 
interest). Because no comparisons are made between individuals, between-person 
confounding is not an issue when using this method.  
Conditional Poisson regression was used to estimate the relative incidence of 
vascular events occurring during pre-defined risk periods after exposure to invasive 
dental treatment relative to all other observed time periods, in the same individuals. 
The null hypothesis was that the rate of vascular events remains constant from day to 
day and is not affected by exposure to invasive dental treatment. Further details of 
the analytical approach using this method for this study are provided in section 3.8.  
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3.3.3 Advantages 
The SCCS design provided major advantages for the study question. The main 
advantage is that inference is within individuals; hence both recorded and unrecorded 
characteristics which may vary between individuals but are stable within individuals 
over the observation period, such as genetic factors, gender, SES and underlying 
health status, are implicitly controlled for. This minimised the potential for 
confounding in this study. The method only uses exposed cases (in this study, 
individuals who experienced both a vascular event and invasive dental treatment), 
which reduced the possibility of under-ascertainment of exposure to invasive dental 
treatment. In addition, it allowed the time-varying effect of age on the baseline 
incidence of vascular events to be controlled for. The method also often has high 
statistical efficiency relative to the cohort method from which it is derived.63 
3.3.4 Limitations and assumptions  
The SCCS method only produces estimates of relative incidence, not absolute 
incidence. Hence this study reports only IRs. The method also requires some 
variability in the timing of, or age at, the event: it would fail if all events occurred at 
the same age (an unlikely scenario, and not an issue in this study). In addition, the 
validity of the method rests on some important assumptions:72 first, that the 
occurrence of an event does not affect an individual’s subsequent exposure; second, 
that the occurrence of an event does not alter the duration of the observation period; 
and third, that events are independent within an individual. Details of how this study 
addressed these assumptions are discussed further in section 3.8.4. 
3.4 Participants 
Study participants were derived from a population of 9, 901, 464 Medicaid 
beneficiaries for whom data were available in the Medicaid database from 1st 
January 2002 to 31st December 2006. This comprised approximately 28 million 
person-years of observation.  
All incident cases of ischaemic stroke or MI occurring during the study period were 
identified from primary discharge diagnoses on hospital admission records, coded 
using the ICD-9-CM classification system.  
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3.4.1 Eligibility criteria 
Candidates were individuals who had a first hospital admission record for ischaemic 
stroke or MI at least 24 weeks after their enrolment in Medicaid began. This ensured 
a minimum of 24 weeks observation prior to the outcome, which reduced the 
possibility that an individual’s first vascular event record was a repeated record for 
an earlier event.  
3.4.1.1 Exclusions 
The following three exclusion criteria were applied: 
1. Age < 20 years at time of first stroke or MI. 
Individuals were excluded if they were younger than 20 years of age at the time of 
their first hospital admission record for stroke or MI, because the aetiology of their 
stroke or MI could have differed from older individuals.  
2. First vascular event occurred outside the maximum continuous enrolment period. 
Eligibility for Medicaid is ascertained on a monthly basis, therefore gaps were 
sometimes found in an individual’s enrolment. Medical events or procedures 
occurring during such gaps are unlikely to be recorded in the database. Thus, if an 
individual underwent dental procedures during a gap in enrolment, this could lead to 
misclassification of exposure to invasive dental treatment. To avoid this source of 
bias, each individual’s maximum period of continuous enrolment was identified and 
their observation was restricted to this period. This ensured the study only included 
person-time during which individuals would have had health care services 
reimbursed by Medicaid if they had occurred. Individuals whose first recorded stroke 
or MI occurred outside this period were subsequently excluded from the relevant 
analyses.  
3. No record of invasive dental treatment during the observation period. 
All candidates not excluded for reasons 1 or 2 above were eligible for inclusion in 
the study. However, in a case series analysis, individuals who were not exposed 
during their observation period do not contribute to the estimate of association 
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between the exposure and outcome. The primary analysis was therefore restricted to 
eligible individuals who had both a vascular event and invasive dental treatment 
during their maximum continuous enrolment period in Medicaid. 
3.4.2 Statistical power 
A crude estimate of the number of potentially eligible individuals with a vascular 
event was derived from preliminary searches of beneficiaries’ data. More than 
30,000 individuals were identified with an ICD-9-CM diagnostic code for ischaemic 
stroke or MI (defined below in sections 3.5.1 and 3.5.2) during the study period. The 
binomial method73 was used to estimate the power of the study to detect an IR for 
vascular events of 1.6 or greater in the first four weeks after invasive dental treatment 
compared to baseline.  
Assuming at least 5% of potentially eligible individuals had undergone invasive 
dental treatment over a mean observation period of four years, the study had more 
than 90% power (at 5% significance) to detect an IR of at least 1.7 in the first four 
weeks after invasive dental treatment (compared to baseline); and more than 80% 
power to detect an IR of at least 1.6 in the first four weeks after treatment.  
3.5 Outcome measures 
The primary outcome of this study was the IR for vascular events (ischaemic stroke 
and MI) in the first four weeks after exposure to invasive dental treatment compared 
to baseline (unexposed time periods).  
The accuracy of hospital discharge diagnostic codes for stroke and MI classifications 
in administrative claims databases has been examined and validated, with studies 
estimating positive predictive value of 90-96% for stroke74,75 and 89-97% for MI76–
80.  
3.5.1 Ischaemic stroke 
Based on the criteria used by Tirschwell and Longstreth,74 ischaemic stroke was 
defined as any one of the following ICD-9-CM codes as the primary discharge 
diagnosis on an inpatient admission record, with an admission date during the study 
period (1st January 2002 to 31st December 2006): 
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433.x1 Occlusion and stenosis of precerebral arteries (where “x” can vary to specify 
a specific arterial distribution, and the fifth digit 1 indicates “with cerebral 
infarction”).  
434.x1 Occlusion of cerebral arteries (where “x” can vary to specify the type of 
occlusion (thrombus, embolus or unspecified), and the fifth digit 1 indicates “with 
cerebral infarction”).  
436 Acute, but ill-defined, cerebrovascular disease.  
The stroke was excluded if any one of the following ICD-9-CM codes for traumatic 
brain injury was recorded as a secondary diagnosis (in any of the 15 secondary 
diagnosis fields) for the same hospitalization: 800-804 Fracture of skull; 850-854 
Intracranial injury, excluding those with skull fracture.  
3.5.2 Myocardial infarction 
Acute MI was defined according to the criteria used by Kiyota and co-workers,80 as 
any one of the following ICD-9-CM codes as the primary discharge diagnosis on an 
inpatient admission record, with an admission date during the study period and a 
hospital length of stay lasting at least three days (unless the patient died, in which 
case less than three days was allowed) and no more than 180 days: 
410.x1 Acute MI (where “x” can vary to specify the site of the MI, and the fifth digit 
1 designates the initial episode of care for a newly diagnosed MI). 
3.5.3 Timing of events 
For both ischaemic stroke and MI, the date of admission to hospital was used to 
estimate the timing of the event.  
3.5.4 Multiple events 
The majority of individuals experienced a single vascular event during their 
observation period. However, a few individuals had multiple primary discharge 
diagnoses for stroke or MI on hospital admission records (see Chapter 4, Table 4.2). 
In this study, analyses were restricted to the first primary discharge diagnosis for a 
vascular event. This approach was taken in order to uphold an important assumption 
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of the case series method, that outcome events are independent within individuals, as 
discussed in section 3.8.4. Restricting to first events also avoided the difficulty in 
establishing whether these multiple primary discharge diagnoses represented 
multiple events or were in fact repeat hospitalisations for the same event.  
3.6 Exposures 
3.6.1 Invasive dental procedures 
The exposure of interest in the study was invasive dental treatment. As mentioned 
earlier in section 3.2.2.1, dental procedures are recorded in Medicaid using the CDT 
coding system62. A complete list of CDT codes for invasive dental procedures was 
compiled in collaboration with a consultant in periodontology. The codes and 
corresponding terms are listed in Appendix D -Table D.1.  
Data on claims for invasive dental procedures were extracted from inpatient and 
outpatient service records. All CDT codes for these procedure claims were further 
reviewed by the consultant periodontist and separated into two groups:  
Invasive-inflammatory: dental procedures which may feasibly result in bacteraemia 
and induce an acute, local and systemic inflammatory response (Table 3.2).  
Invasive-not inflammatory: dental procedures which were less severe and unlikely 
to induce an inflammatory response (Table 3.3).  
Only invasive-inflammatory procedures were included in the study. These included 
periodontal therapy (surgical and non-surgical treatment involving tooth scaling, root 
planing and probing), and other invasive dental surgical procedures such as dental 
implant placement and tooth extractions, also known to be associated with 
bacteraemia81,82 and with raised markers of inflammation83.  
Thus, exposure to invasive dental treatment was defined as any one of the CDT 
codes listed in Table 3.2 on inpatient or outpatient service records, with a procedure 
date during the observation period.  
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Table 3.2 Invasive-inflammatory dental procedures in Medicaid. 
CDT a 
code 
Description of procedure 
D3410 Apicoectomy/periradicular surgery-anterior 
D3421 Apicoectomy/periradicular surgery-bicuspid (first root) 
D4210 Gingivectomy or gingivoplasty - four or more contiguous teeth or bounded teeth spaces 
per quadrant 
D4211 Gingivectomy or gingivoplasty - one to three contiguous teeth or bounded teeth spaces per 
quadrant 
D4341 Periodontal scaling and root planing - four or more teeth per quadrant 
D4342 Periodontal scaling and root planing - one to three teeth, per quadrant 
D6010 Surgical placement of implant body:  endosteal implant 
D7210 Surgical removal of erupted tooth requiring elevation of mucoperiosteal flap and removal 
of bone and/or section of tooth 
D7230 Removal of impacted tooth-partially bony 
D7240 Removal of impacted tooth-completely bony 
D7241 Removal of impacted tooth-completely bony, with unusual surgical complications 
D7250 Surgical removal of residual tooth roots (cutting procedure) 
D7260 Oral antral fistula closure 
D7261 Primary closure of a sinus perforation 
D7280 Surgical access of an unerupted tooth 
D7290 Surgical repositioning of teeth 
D7310 Alveoloplasty in conjunction with extractions - four or more teeth or tooth spaces, per 
quadrant 
D7311 Alveoloplasty in conjunction with extractions - one to three teeth or tooth spaces, per 
quadrant 
D7320 Alveoloplasty not in conjunction with extractions - four or more teeth or tooth spaces, per 
quadrant 
D7321 Alveoloplasty not in conjunction with extractions - one to three teeth or tooth spaces, per 
quadrant 
D7340 Vestibuloplasty-ridge extension (second epithelialization) 
D7410 Excision of benign lesion up to 1.25 cm 
D7411 Excision of benign lesion greater than 1.25 cm 
D7450 Removal of benign odontogenic cyst or tumor-lesion diameter up to 1.25 cm 
D7460 Removal of benign nonodontogenic cyst or tumor-lesion diameter up to 1.25 cm 
D7461 Removal of benign nonodontogenic cyst or tumor-lesion diameter greater than 1.25 cm 
D7471 Removal of lateral exostosis (maxilla or mandible) 
D7473 Removal of torus mandibularis 
D7485 Surgical reduction of osseous tuberosity 
D7510 Incision and drainage of abscess-intraoral soft tissue 
D7520 Incision and drainage of abscess-extraoral soft tissue 
D7540 Removal of reaction-producing foreign bodies-musculoskeletal system 
D7550 Partial ostectomy/sequestrectomy for removal of non-vital bone 
D7730 Mandible-open reduction 
D7912 Complicated suture-greater than 5 cm 
D7960 Frenulectomy (frenectomy or frenotomy)-separate procedure 
D7970 Excision of hyperplastic tissue-per arch 
D7972 Surgical reduction of fibrous tuberosity 
D7999 Unspecified oral surgery procedure, by report 
a Current Dental Terminology 
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Table 3.3 Invasive-not inflammatory dental procedures in Medicaid. 
CDTa code Description of procedure 
D7111 Extraction, coronal remnants - deciduous tooth 
D7140 Extraction, erupted tooth or exposed root (elevation and/or forceps removal) 
D7220 Removal of impacted tooth-soft tissue 
D7286 Biopsy of oral tissue - soft 
D7971 Excision of pericoronal gingiva 
a Current Dental Terminology 
3.6.1.1 Defining treatment episodes 
Some individuals had multiple records of invasive dental procedures. Within 
individuals, procedure records at least one week apart were considered to be repeat 
procedures; procedure records within one week of a previous record were excluded, 
as these were assumed to correspond to the same treatment episode. The methods 
used in the analysis to deal with repeat procedures are described in section 3.8.1.1.  
3.6.2 Time-varying covariates  
For descriptive purposes and analyses exploring the effects of time-varying 
covariates (see section 3.8.3), additional information was extracted on diseases and 
drug exposures which may have been temporally associated with both the occurrence 
of vascular events and invasive dental treatment and hence may have introduced 
within-person confounding.  
3.6.2.1 Comorbidities 
Study participants with a diagnosis of diabetes, hypertension, CHD or rheumatoid 
arthritis on inpatient admission or outpatient claim records prior to their invasive 
dental treatment were identified. These conditions were defined by the following 
ICD-9-CM diagnostic codes, recorded as the primary discharge diagnosis or any of 
the 15 secondary diagnoses for a hospital admission, or in either of the two diagnoses 
fields for an outpatient claim: 
Diabetes: 250 (Diabetes mellitus); 
Hypertension: 401-405 (Hypertensive disease); 
CHD: 410-414 (Ischaemic heart disease) and 429.2 (Cardiovascular disease, 
unspecified); 
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Rheumatoid arthritis: 714 (Rheumatoid arthritis and other inflammatory 
polyarthropathies). 
3.6.2.2 Drug exposures 
Prescriptions within the antiplatelet, salicylate and non-steroidal anti-inflammatory 
drug (NSAID) therapeutic classes dispensed at any time before invasive dental 
treatment or up to one month after the treatment (see section 3.8.3) were identified 
from outpatient pharmaceutical claims records.  
3.7 Data extraction and preparation 
Data were extracted on demographic characteristics (year of birth, gender and 
ethnicity); enrolment details (start and end dates of continuous periods of enrolment 
in Medicaid); hospital admissions for vascular events (primary discharge diagnoses 
for ischaemic stroke and MI as defined in sections 3.5.1 and 3.5.2); claims for 
invasive dental procedures (CDT codes listed in Table 3.2); and potential time-
varying covariates (diabetes, hypertension, CHD, and use of antiplatelets, salicylates 
and NSAIDs, as defined in section 3.6.2 above).  
Key variables were checked for missing values and outliers (none were found). Dates 
corresponding to each individual’s enrolment, inpatient admissions, inpatient and 
outpatient procedures, and drug prescriptions were all valid and within the study 
period. All date fields were complete.  
Duplicate records for hospital admissions (when an individual had more than one 
admission record on the same day) were identified. Just 0.3% of all hospital 
admission records were duplicates and on all such duplicate records the individual’s 
date of admission and discharge were the same. When an individual had a duplicate 
admission record for a vascular event, the record with the latest discharge date was 
selected. Thus, an individual’s length of hospital stay and status at discharge (e.g. 
“died”) were determined from the admission record with the latest discharge date. 
Information on age was limited to year of birth. Therefore, estimates of age were 
derived assuming each individual’s date of birth to be 1st July of their birth year, 
allowing a maximum error margin of six months for age.  
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3.8 Statistical analysis 
Analyses were performed to assess the short-term effect of invasive dental treatment 
on the risk of vascular events overall and separately by type of event (ischaemic 
stroke or MI).  
3.8.1 Primary analysis 
Individuals who experienced their first vascular event and at least one invasive dental 
procedure during their observation period were included in the primary analysis of 
vascular events. The observation period for each individual was the time during 
which if a vascular event occurred the individual would be sampled i.e. their 
continuous enrolment period in Medicaid between January 2002 and December 
2006. Thus each individual was followed up from the start of their continuous 
enrolment period until they died or their continuous enrolment period ended 
(whichever occurred first), regardless of when they experienced their vascular event. 
The risk period (during which invasive dental treatment might trigger an acute 
systemic inflammatory response) started on the day after an invasive dental 
procedure, extending up to 24 weeks, and was subdivided into the following periods: 
weeks 1-4, 5-8, 9-12, 13-16 and weeks 17-24, as the risk during the last eight weeks 
was assumed to be constant. All other observation time was taken as the baseline 
(unexposed) period. The choice of 24 weeks was based on previous work which 
suggested any increased risk would return to baseline by 24 weeks,19,66 thus allowing 
the resolution of any increased risk to be fully described. The decision to start the 
risk period one day after a dental procedure was based on current evidence that the 
host response and vascular function are affected at their maximum 24 hours after 
invasive dental treatment.47–49,84 Figure 3.2 illustrates the application of the method 
to this study and the time intervals used. 
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Figure 3.2 Pictorial representation of the timing of vascular events and dental procedures. 
The Figure illustrates four possible scenarios for the timing of vascular events and invasive dental 
procedures, each representing a single participant: A was followed up for the duration of the study 
period, had two 24-week risk periods each following an invasive dental procedure and a vascular 
event during the second risk period; B was followed up for part of the study period, had one dental 
procedure followed by a vascular event at baseline; C was followed up from the start of the study 
period, had a vascular event at baseline prior to a dental procedure and died before the end of the 
study period; D was followed up for most of the study period, had two dental procedures and a 
vascular event during the first risk period. All participants included in a particular analysis had at least 
one dental procedure and at least one vascular event. Each risk period began the day after a procedure 
and lasted 24 weeks (not drawn to scale relative to length of baseline periods), divided into the 
following intervals: 1-4, 5-8, 9-12, 13-16 and 17-24 weeks. 
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Conditional Poisson regression was used to estimate IRs and 95% CIs for vascular 
events occurring within each stratum of the risk period compared to baseline. Age 
effects were adjusted for using 5-year age groups (20-24, 25-29, 30-34....≥85 years). 
Each individual’s observation period was split into successive time intervals 
determined by changes in age group and exposure status, thus allowing individuals to 
contribute to different age groups over time. The crude age effect (IR for vascular 
events for a five-year increase in age) was estimated in a model including age group 
alone. Data were analysed using Stata software, version 10 (StataCorp., College 
Station, Texas). 
3.8.1.1 Multiple invasive dental procedures 
Some individuals had more than one invasive dental procedure during their 
observation period. When dealing with repeat procedures, each procedure was 
followed by a 24-week risk period. The same level of risk was assumed following 
each procedure, thus not allowing for a dose-effect. In the case of overlapping risk 
periods, when two or more procedures occurred within 24 weeks of each other, a 
simple convention was adopted which allowed later procedures to take precedence 
over earlier ones.63 Thus, when an individual had two or more dental procedures and 
a later procedure occurred at some time during the risk period of an earlier 
procedure, a new 24-week risk period began from this time point. This meant that 
although the later procedure took precedence, it did not replace the earlier procedure; 
the earlier procedure was not ignored.  
Figure 3.3 illustrates this convention with two possible scenarios. First, if an 
individual had a dental procedure followed by a vascular event two weeks later, and 
then a second dental procedure 20 weeks after the first, the vascular event would not 
have been classified as occurring during baseline; it would have been classified as 
occurring in the risk period corresponding to the first procedure, as shown in 
Scenario A.  However, a vascular event occurring two weeks after the second dental 
procedure would have been classified as occurring during the risk period of this 
second procedure rather than during the risk period of the first, as shown in Scenario 
B. This convention was chosen as it reflects the actual exposure experience: in both 
scenarios the vascular event occurred two weeks after a dental procedure. 
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Figure 3.3 Pictorial representation of overlapping risk periods. 
To eliminate the possibility that this convention (allowing later procedures to take 
precedence over earlier ones if risk periods overlap) might have contributed to an 
observed effect in earlier time frames, the primary analysis was repeated excluding 
individuals whose repeat procedures had overlapping risk periods.  
3.8.2 Analyses by event type 
The same methods as for the primary analysis (section 3.8.1) were used to assess the 
effect of invasive dental treatment on ischaemic stroke and MI separately. 
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Individuals whose first ischaemic stroke and at least one invasive dental procedure 
occurred during the observation period were included in the analysis of ischaemic 
stroke; individuals whose first MI and at least one invasive dental procedure 
occurred during the observation period were included in the analysis of MI. Thus, it 
was possible for an individual to be included in one of these analyses but not in the 
primary analysis of vascular events, if their first stroke (or MI) in the observation 
period was preceded by an earlier first MI (or stroke) before the start of the 
observation period.  
3.8.3 Addressing time-varying confounding 
As described in section 3.3.3, a major advantage of the SCCS method is that no 
comparisons are made between individuals; hence fixed covariates, measured and 
unmeasured, are implicitly controlled for in the analysis. However, there is still scope 
for confounding if intra-person risk factors for the study outcome (first vascular 
event) that change over time are also associated with the timing of exposure 
(invasive dental treatment).  
Age 
As the baseline risk of vascular events (the risk in the absence of exposure to 
invasive dental treatment) varies with age, each individual’s follow-up was split into 
successive time intervals determined by changes in age (using 5-year groupings) and 
exposure status, as described previously in section 3.8.1. The time-varying effect of 
age was controlled for by including the age group factor as a covariate in each 
model. In addition, the primary analysis was repeated allowing for finer adjustment 
for age using 2-year groupings.  
Withholding of antiplatelet or salicylate medication  
It was recognised that the possible withholding of potentially protective antiplatelet 
or salicylate drugs prior to an invasive dental procedure among high-risk individuals 
on such treatment regimens may have introduced confounding. Among these 
patients, a brief period of stopping drug treatment was unlikely to be accurately 
recorded in their records. Therefore, a sensitivity analysis was done restricted to 
patients who had no recorded use of antiplatelets or salicylates prior to invasive 
47 
 
dental treatment. The rationale was that among such patients the issue of stopping 
medication at the time of dental treatment was unlikely to arise.  
Use of NSAIDs after dental treatment 
Individuals may have received NSAIDs after invasive dental procedures for pain 
control, and studies have suggested that the use of some NSAIDs may increase the 
risk of vascular events.85 Thus the use of NSAIDs may also have confounded any 
association observed with invasive dental treatment. To address this possibility, a 
sensitivity analysis was conducted excluding individuals with a NSAID prescription 
around the time of their invasive dental treatment (from the four weeks before 
treatment up to four weeks after treatment), or those with a recorded diagnosis of 
rheumatoid arthritis at any time prior to invasive dental treatment (who were likely to 
be taking NSAIDs).  
Pre-existing conditions 
Confounding may also have arisen if diseases known to be associated with an 
increased risk of vascular events, specifically diabetes, hypertension or CHD, 
developed or worsened in the period leading up to invasive dental treatment. This 
was dealt with in sensitivity analyses excluding patients newly diagnosed with these 
conditions (defined in section 3.6.2.1) in the 12 months prior to invasive dental 
treatment. Since those who remained were either disease-free, or developed the 
disease after invasive dental treatment or more than a year before treatment, the 
scope for confounding was minimised.  
3.8.4 Addressing the assumptions underlying the SCCS method 
As stated previously in section 3.3.4, three key assumptions underlie the validity of 
the case series method. These assumptions and the methods used in this study to 
address them are discussed below. 
Assumption 1: The occurrence of an outcome event should not affect the probability 
of subsequent exposure. 
This is perhaps the most restrictive assumption underlying the SCCS method.72 The 
assumption may not hold true if the event of interest increases the mortality rate (as 
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is the case for ischaemic stroke or MI). To address the issue of fatal vascular events, 
a sensitivity analysis was conducted excluding individuals who died during the 
hospital stay for their vascular event or whose enrolment ended within a month after 
their event, possibly indicating death.  
Assumption 2: The occurrence of an outcome event should not censor or alter the 
duration of the observation period. 
In a case series study, each individual’s observation period is usually determined 
using pre-defined calendar time boundaries and/or age limits, and must be 
independent of the timing of the event. This assumption may also be violated when 
the outcome of interest is likely to increase the short-term death rate. Thus, the 
sensitivity analyses described above (relating to Assumption 1) also dealt with this 
assumption. 
 Assumption 3: Outcome events are independent within an individual. 
The case series method requires that the occurrence of an outcome event should not 
affect the rate at which subsequent events may occur. If this assumption fails, a 
reasonable strategy is to restrict the analysis to first events, provided that these are 
not common.63,86,87 In this study, analyses were confined to each case’s first vascular 
event during the observation period (i.e. the first occurring during baseline or during 
a risk period). This was done because the recurrence times of each vascular outcome 
cannot be assumed to be independent within individuals: the occurrence of a first 
stroke or MI is known to increase the risk of further strokes or MIs. Primary 
discharge diagnoses for vascular events subsequent to the first event in an 
individual’s observation period were not included in the analyses, yet each individual 
was followed up for the duration of their continuous enrolment period in Medicaid. 
Thus their pre-defined observation period was preserved.  
3.8.5 Additional sensitivity analyses 
Including unexposed cases 
In a case series analysis, individuals not exposed at any time during follow-up do not 
contribute to the estimates of association between the exposure and outcome. 
However, including these unexposed individuals can help to control for confounding 
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by age, as they contribute information on the age-specific incidence of the outcome. 
A sensitivity analysis including unexposed cases (individuals who had a vascular 
event but no invasive dental treatment during their observation period) was 
performed in order to check that the effect estimates did not vary. 
Restricting to dental extractions 
Given that the vast majority of dental procedures included in the analyses were 
dental extractions (see Chapter 4, Table 4.4), a sensitivity analysis was conducted 
including only these homogenous exposures.  
Restricting to “healthy” claimants 
Finally, to assess whether a similar effect was observed among individuals with no 
history of diabetes, hypertension or CHD (as defined in section 3.6.2.1) prior to their 
invasive dental treatment, the primary analysis was repeated among this “healthy” 
subgroup. 
3.9 Ethics approval 
Ethics approval for this study was granted by the London School of Hygiene and 
Tropical Medicine Ethics Committee (application number 5284). 
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Chapter 4  Results - Invasive dental treatment and vascular events 
This chapter reports on the SCCS analysis of invasive dental treatment and vascular 
events. The first two sections describe the identification of eligible cases and 
summarise their baseline characteristics. The remaining sections present the results 
of the case series analyses: the primary analysis, comparing the rate of vascular 
events in the six months after exposure to invasive dental treatment with the rate 
during unexposed periods; secondary analyses by event type (ischaemic stroke and 
MI), and a range of sensitivity analyses as outlined in Chapter 3. The chapter 
concludes with a discussion of the main findings, strengths and potential limitations 
of the study.  
4.1 Identifying eligible individuals 
The identification of eligible cases with a vascular event and the subset who had also 
been exposed to invasive dental treatment (and were thus included in the case series 
analyses) is described below and illustrated in participant flow diagrams: Figure 4.1 
(primary analysis) and Appendix E-Figures E.1 and E.2 (secondary analyses).  
4.1.1 Individuals with a first recorded vascular event 
Study participants came from a base population of 9,901,464 individuals enrolled in 
Medicaid for all or part of the study period (from 1st January 2002 to 31st December 
2006). 32060 individuals were identified with a hospital admission for ischaemic 
stroke (n=17741) and/or MI (n=14783) during the study period, of whom 11691 
were excluded from the primary analysis on the basis of their first vascular event 
record, for one of the following reasons (outlined previously in Chapter 3, section 
3.4.1.1) as shown in Figure 4.1:   
 less than 24 weeks of observation prior to the first vascular event record 
(n=10822 excluded); 
 age less than 20 years at the time of the first vascular event record (n=104 
excluded); 
 first vascular event record occurred outside the continuous enrolment period 
(n=765 excluded).  
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Figure 4.1 Participant flow diagram – primary analysis of vascular events. 
MI=myocardial infarction 
a Individuals who had both an ischaemic stroke and an MI during the study period. 
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These same exclusion criteria were applied to cases with a first ischaemic stroke 
(Appendix E-Figure E.1) and to cases with a first MI (Appendix E-Figure E.2), prior 
to the secondary analyses which assessed the effect of invasive dental treatment on 
ischaemic stroke and MI separately. Individuals were excluded from these analyses 
on the basis of the first event record of that type. Thus, 6457 cases with a first 
ischaemic stroke and 5299 with a first MI were excluded from the secondary 
analyses. 
After applying these exclusions, 20369 cases with a first vascular event, 11284 with 
a first ischaemic stroke and 9484 with a first MI remained who were eligible for 
inclusion in the study. 
4.1.2 Exposed cases 
As described in Chapter 3, section 3.4.1.1, in a case series analysis only exposed 
cases contribute to estimates of the exposure effects: thus only cases who had been 
exposed to invasive dental treatment at least once during the observation period were 
included in the primary analysis of vascular events overall (n=1152), and in the 
analyses by event type: ischaemic stroke (n=650) and MI (n=525). 
4.2 Descriptive data  
4.2.1 Eligible cases 
Of the 20369 eligible individuals with a first vascular event, the median age at the 
time of diagnosis was 67.3 years (interquartile range (IQR) 56.5-79.6), 34.3 percent 
were male, the median observation period was 3.8 years (IQR 2.1-5.0) and 7.7% died 
during their hospital stay. The predominance of female cases was in accordance with 
the demographic of the underlying population of Medicaid beneficiaries, of whom 
58.1% (n=5,749,877) were female.  
Eligible individuals with a first ischaemic stroke (n=11284) were slightly older at the 
time of diagnosis (median age 68.8 years, IQR 57.5-80.4) than eligible individuals 
with a first MI (n=9484) (median age 65.2 years, IQR 55.3-78.4), and fewer died 
during their hospital stay (5.6%) than those with MI (10.3%). The majority of both 
ischaemic stroke and MI cases were female, although a slightly larger proportion of 
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MIs were among males (37.7%) versus 31.4% of strokes. The observation periods of 
both groups were similar: median 3.8 years (IQR 2.1-5.0) for ischaemic stroke cases 
and 3.7 years (IQR 2.0-4.8) for MI cases. 
4.2.2 Cases included in the case series analysis 
1152 (5.7%) eligible individuals with a first vascular event had at least one invasive 
dental procedure during the observation period, and were thus included in the 
primary analysis of vascular events. 629 had an ischaemic stroke only, 504 had an 
MI only and 19 had both a stroke and an MI. 55.5% of these first vascular events 
were ischaemic strokes (n=639).  
650 (5.8%) eligible individuals with a first ischaemic stroke and 525 (5.5%) with a 
first MI had at least one invasive dental procedure during the observation period, and 
were thus included in the secondary analyses by event type. These secondary 
analyses included four additional individuals (two in each analysis) who had 
experienced both an ischaemic stroke and an MI, but who were excluded from the 
primary analysis because their earlier vascular event met one or more of the 
exclusion criteria. 
Table 4.1 summarises the characteristics of individuals included in the primary and 
secondary analyses. 
Of the 1152 individuals included in the primary analysis, the median age at the time 
of diagnosis of the first vascular event was 57.7 years (IQR 47.6-69.9), 39.8% were 
male, the median observation period was 4.8 years (IQR 3.7-5.0) and 4.1% died 
during their hospital stay (2.6% of those first admitted for ischaemic stroke; 5.7% of 
those first admitted for MI). The majority of cases were of white (48.4%) or black 
(40.2%) ethnicity, 1.5% were Hispanic and the remaining 9.9% were classified as 
“other”. A large majority of cases had pre-existing hypertension (70.2%) prior to 
their invasive dental treatment. Pre-existing diabetes (41.2 %) and CHD (40.8%) 
were also common. 
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Table 4.1 Characteristics of study participants. 
Characteristic  
n (%) 
Vascular event 
patients 
(N=1152)a 
Ischaemic stroke 
patients  
(N=650)b 
Myocardial 
infarction patients 
(N=525)b 
Gender    
Male 458 (39.8) 233 (35.9) 236 (45.0) 
Female 694 (60.2) 417 (64.2) 289 (55.1) 
Ethnicity    
White 558 (48.4) 282 (43.4) 282 (53.7) 
Black 463 (40.2) 303 (46.6) 171 (32.6) 
Hispanic 17 (1.5) 9 (1.4) 8 (1.5) 
Other 114 (9.9) 56 (8.6) 64 (12.2) 
Age at first event (years)    
20-29 24 (2.1) 21 (3.2) 3 (0.6) 
30-39 74 (6.4) 41 (6.3) 33 (6.3) 
40-49 258 (22.4) 117 (18.0) 147 (28.0) 
50-59 282 (24.5) 156 (24.0) 138 (26.3) 
60-69 228 (19.8) 139 (21.4) 93 (17.7) 
70-79 167 (14.5) 100 (15.4) 67 (12.8) 
80-89 111 (9.6) 72 (11.1) 40 (7.6) 
≥90 8 (0.7) 4 (0.6) 4 (0.8) 
Median (IQR) 57.7 (47.6-69.9) 59.2 (48.8-71.1) 55.4 (47.0-67.1) 
Diabetes diagnosed at any time 
prior to IDT 
474 (41.2) 269 (41.4) 214 (40.8) 
Hypertension diagnosed at any 
time prior to IDT 
809 (70.2) 463 (71.2) 366 (69.7) 
Coronary heart disease 
diagnosed at any time prior to 
IDT 
470 (40.8) 211 (32.5) 278 (53.0) 
Continuous enrolment in 
Medicaid (years) Median (IQR) 
4.8 (3.7-5.0) 4.8 (3.7-5.0) 4.7 (3.6-5.0) 
Abbreviations: IQR = interquartile range; IDT = invasive dental treatment  
a Individuals included in the primary analysis   
b23 patients experienced both an ischaemic stroke and a myocardial infarction during their observation period: 19 were included 
in each analysis (vascular events overall and by event type) and four (two from each analysis by event type) were excluded 
from the primary analysis of vascular events because their earlier event met the exclusion criteria. 
Ischaemic stroke cases (n=650) were slightly older (median age at diagnosis 59.2 
years, IQR 48.8-71.1) than MI cases (n=525) (median age 55.4 years, IQR 47.0-
67.1), and were less likely to die during their hospital stay than MI cases (2.6% 
versus 5.7%). A larger proportion of MI cases were male (45.0% versus 35.9% of 
stroke cases), and of white ethnicity (53.7% versus 43.4% of stroke cases). The 
observation periods of both groups were similar (median 4.8 years (IQR 3.7-5.0) for 
ischaemic stroke and 4.7 years (IQR 3.6-5.0) for MI). The prevalence of pre-existing 
hypertension was similar and high among stroke cases (71.2%) and MI cases 
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(69.7%) and approximately 41% of both had pre-existing diabetes. Pre-existing CHD 
was more prevalent among MI cases (53.0%) than among stroke cases (32.5%). 
89.1% of cases in the primary analysis had a single vascular event during the 
observation period. The remaining 10.9% had up to five primary discharge diagnoses 
for a vascular event; however, as described in Chapter 3, section 3.5.4, all analyses 
were restricted to first events. For descriptive purposes, the number of subsequent 
primary discharge diagnoses for vascular events excluded from the primary analysis, 
and from the analyses by event type, are shown in Table 4.2 below. 
Table 4.2 Cases with a subsequent diagnosis for a vascular event and number of subsequent 
events excluded from the analyses. 
Outcome Number of cases 
included in analysis 
Cases with a 
subsequent eventa  
n (%) 
Number of subsequent 
events excluded 
(range) 
Vascular event  1152 126 (10.9) 158 (2-5) 
Ischaemic stroke  650 73 (11.2) 93 (2-5) 
Myocardial Infarction  525 38 (7.2) 46 (2-3) 
a Primary discharge diagnosis of outcome (ischaemic stroke or MI) for a subsequent hospital admission  
Table 4.3 summarises the exposure experience of cases over the observation period. 
1574 episodes of invasive dental treatment were included in the primary analysis of 
vascular events. 74.7% of cases included in the primary analysis had just a single 
episode of invasive dental treatment over the observation period (n=861), 24.4% had 
between two and four episodes of treatment (n=281), and the remaining 0.9% had 
five or more treatment episodes (n=10). 204 cases (17.7%) had two or more episodes 
with overlapping risk periods. The median number of days between successive 
treatment episodes was 56.5 days (IQR 21-245). 
Table 4.3 Episodes of invasive dental treatment among study participants 
Episodes of invasive 
dental treatment  
Vascular event 
patients N=1152a 
n (%) 
Ischaemic stroke 
patients N=650 
n (%) 
Myocardial infarction 
patients N=525 
n (%) 
1 episode 861 (74.7) 493 (75.8) 385 (73.3) 
2-4 episodes 281 (24.4) 150 (23.1) 137 (26.1) 
≥5 episodes 10 (0.87) 7 (1.08) 3 (0.57) 
Total episodes (range)  1574 (1-11) 893 (1-11) 714 (1-5) 
a Individuals included in the primary analysis   
The frequency distribution of dental procedures is shown in Table 4.4. 
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Table 4.4 Distribution of invasive dental procedures in study participants’ records. 
CDTa procedure code and description n (%) individuals with at least one procedure record: 
Vascular event 
patients 
(N=1152)b 
Ischemic stroke 
patients  
(N=650) 
Myocardial 
infarction patients 
(N=525) 
D7210: surgical removal of erupted tooth requiring elevation of mucoperiosteal flap and removal of bone 
and/or section of tooth 
847 (73.5) 499 (76.8) 364 (69.3) 
D7250: surgical removal of residual tooth roots (cutting procedure) 151 (13.1) 90 (13.8) 67 (12.8) 
D7310: alveoloplasty in conjunction with extractions - four or more teeth or tooth spaces, per quadrant 104 (9.0) 49 (7.5) 55 (10.5) 
D7510: incision and drainage of abscess-intraoral soft tissue  25 (2.2) 15 (2.3) 11 (2.1) 
D4341: periodontal scaling and root planing - four or more teeth per quadrant 23 (2.0) 7 (1.1) 16 (3.0) 
D7320: alveoloplasty not in conjunction with extractions – four or more teeth or tooth spaces, per quadrant 16 (1.4) 9 (1.4) 8 (1.5) 
D7240: removal of impacted tooth-completely bony 15 (1.3) 10 (1.5) 5 (1.0) 
D7230: removal of impacted tooth-partially bony 13 (1.1) 8 (1.2) 6 (1.1) 
D4211: gingivectomy or gingivoplasty - one to three contiguous teeth or bounded teeth spaces per quadrant 6 (0.5) 3 (0.5) 5 (1.0) 
D7471: removal of lateral exostosis (maxilla or mandible) 5 (0.4) 3 (0.5) 2 (0.4) 
D4210: gingivectomy or gingivoplasty - four or more contiguous teeth or bounded teeth spaces per quadrant 4 (0.3) 1 (0.2) 3 (0.6) 
D7241: removal of impacted tooth-completely bony, with unusual surgical complications 4 (0.3) 3 (0.5) 1 (0.2) 
D7999: unspecified oral surgery procedure, by report 4 (0.3) 0 4 (0.8) 
D7540: removal of reaction-producing foreign bodies-musculoskeletal system 3 (0.3) 3 (0.5) 0 
D3410: apicoectomy/periradicular surgery-anterior 2 (0.2) 1 (0.2) 1 (0.2) 
D7960: frenulectomy (frenectomy or frenotomy)-separate procedure 2 (0.2) 0 2 (0.4) 
D7970: excision of hyperplastic tissue-per arch 2 (0.2) 0 2 (0.4) 
D3421: apicoectomy/periradicular surgery-bicuspid (first root) 1 (0.1) 1 (0.2) 0 
D4342: periodontal scaling and root planing - one to three teeth, per quadrant 1 (0.1) 1 (0.2) 0  
D7290: surgical repositioning of teeth 1 (0.1) 0 1 (0.2) 
D7321: alveoloplasty not in conjunction with extractions – one to three teeth or tooth spaces, per quadrant 1 (0.1) 0 1 (0.2) 
D7410: excision of benign lesion up to 1.25 cm 1 (0.1) 0 1 (0.2) 
D7460: removal of benign nonodontogenic cyst or tumor-lesion diameter up to 1.25 cm 1 (0.1) 0 1 (0.2) 
D7461: removal of benign nonodontogenic cyst or tumor-lesion diameter greater than 1.25 cm 1 (0.1) 0 1 (0.2) 
D7520: incision and drainage of abscess-extraoral soft tissue 1 (0.1) 1 (0.2) 0 
D7550: partial ostectomy/sequestrectomy for removal of non-vital bone 1 (0.1) 1 (0.2) 0 
a Current Dental Terminology; b Individuals included in the primary analysis 
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The three most commonly occurring procedures (CDT codes D7210, D7250 and 
D7310) involved surgical removal of one or more tooth and/or bone, constituting 
89.4% of all procedures included in the primary analysis. More than 90% of cases in 
the primary analysis (n=1059) had at least one of these extractions. 
4.3 Primary analysis of vascular events 
The primary analysis assessed the rate of vascular events in the 24 weeks after 
invasive dental treatment compared to all other observed time periods (baseline). 
Age-adjusted IRs and the number of vascular events occurring in each pre-defined, 
post-exposure risk period (weeks 1-4, 5-8, 9-12, 13-16 and weeks 17-24) and in all 
risk periods combined compared to baseline are shown in Table 4.5. 
After adjusting for age in 5-year groups, the rate of vascular events (n=1152) was 
significantly raised in the first four weeks after invasive dental treatment compared 
to baseline (age-adjusted IR 1.50, 95% CI 1.09-2.06), and appeared to gradually 
resolve over the subsequent 20 weeks. Combining all risk periods yielded a less 
marked increased rate of vascular events over the entire 24 weeks after invasive 
dental treatment compared to baseline, which did not reach statistical significance 
(age-adjusted IR 1.15, 95% CI 0.98-1.36). No vascular events occurred on the same 
day as an invasive dental procedure. The earliest vascular events after invasive dental 
treatment occurred one day after the procedure (one ischaemic stroke and one MI); 
eight events occurred within the first week and 40 within the first four weeks after a 
procedure.  
Considering the crude age effect alone, the rate of vascular events was found to 
increase steadily with age (IR for a 5-year increase in age 1.60, 95% CI 1.36-1.87). 
In order to maximise the control for confounding by age, the primary analysis was 
repeated including unexposed cases: individuals who had a vascular event but no 
invasive dental treatment during their observation period, and hence contributed only 
to the age effects. The inclusion of these additional cases (n=19217) did not alter the 
effect estimates of invasive dental treatment on vascular events (age-adjusted IR in 
weeks 1-4 post-treatment 1.50, 95% CI 1.09-2.06) (Appendix F-Table F.1). In 
addition, the primary analysis was repeated adjusting for age in 2-year (rather than 5-
year) age groups. This finer level of stratification by age made no material difference 
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to the findings (age-adjusted IR in weeks 1-4 post treatment 1.49, 95% CI 1.09-2.06) 
(Appendix F-Table F.2). 
Table 4.5 Results of the primary analysis: age-adjusted incidence ratios of a first vascular event 
in risk periods after invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular eventb (N=1152)   
Baseline periodc 975 1 
Post-procedure risk period   
Weeks 1-4 40 1.50 (1.09-2.06) 
Weeks 5-8 29 1.11 (0.77-1.61) 
Weeks 9-12 30 1.16 (0.81-1.68) 
Weeks 13-16 25 0.96 (0.64-1.43) 
Weeks 17-24 53 1.08 (0.82-1.43) 
All risk periods (weeks 1-24) 177 1.15 (0.98-1.36) 
a IR denotes age-adjusted incidence ratio. 
b Vascular events are 639 ischemic strokes (55.5%) and 513 MIs (44.5%). 
c Baseline period is all observation time except for the 24 week period following an invasive dental procedure.  
4.4 Analyses by event type  
Examining ischaemic stroke and MI separately yielded similar findings to the 
primary analysis, although these were not statistically significant.  
The rate of MI (n=525) was higher in the first four weeks after invasive dental 
treatment compared to baseline (age-adjusted IR 1.56, 95% CI 0.98-2.47), and 
appeared to resolve thereafter. For ischaemic stroke (n=650), a slightly elevated risk 
was observed during the first four weeks after invasive dental treatment (age-
adjusted IR 1.39, 95% CI 0.89-2.15), although the increase was less marked and the 
pattern of resolution over the subsequent 20 weeks was less clear. No ischaemic 
strokes or MIs occurred on the same day as an invasive dental procedure.  
Table 4.6 shows the age-adjusted incidence rate ratios for ischaemic stroke and for 
MI in each pre-defined risk period following invasive dental treatment compared to 
baseline.  
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Table 4.6 Results of secondary analyses stratified by event type: age-adjusted incidence ratios of 
a first ischaemic stroke or myocardial infarction in risk periods after invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Ischaemic stroke (N=650)    
Baseline periodb 553 1 
Post-procedure risk period   
Weeks 1-4 21 1.39 (0.89-2.15) 
Weeks 5-8 14 0.94 (0.55-1.60) 
Weeks 9-12 18 1.21 (0.76-1.95) 
Weeks 13-16 11 0.73 (0.40-1.32) 
Weeks 17-24 33 1.18 (0.83-1.69) 
All risk periods (weeks 1-24) 97 1.10 (0.88-1.38) 
Myocardial infarction (N=525)   
Baseline periodb 443 1 
Post-procedure risk period   
Weeks 1-4 19 1.56 (0.98-2.47) 
Weeks 5-8 16 1.35 (0.82-2.23) 
Weeks 9-12 13 1.12 (0.64-1.95) 
Weeks 13-16 14 1.20 (0.70-2.05) 
Weeks 17-24 20 0.90 (0.57-1.42) 
All risk periods (weeks 1-24) 82 1.18 (0.93-1.50) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
4.5 Sensitivity analyses 
In addition to the analyses incorporating a more refined adjustment for age, a series 
of additional sensitivity analyses were conducted as outlined in Chapter 3, sections 
3.8.3-3.8.5. The results of each of these analyses with respect to the primary outcome 
(age-adjusted IRs for vascular events in the first four weeks after exposure to 
invasive dental treatment compared to baseline) are described below and summarised 
in Table 4.7 (see Appendix F-Tables F.3-F.11 for detailed results of each of these 
analyses: age-adjusted IRs and the number of vascular events in each post-exposure 
risk period over 24 weeks). 
4.5.1 Addressing time-varying confounding 
In addition to the time-varying effect of age, which was taken into account in all 
analyses a priori, other possible sources of confounding were addressed in analyses 
excluding individuals who may have been at increased risk of vascular events at the 
time of their invasive dental treatment, as follows:  
60 
 
 individuals with antiplatelet or salicylate drug prescriptions (n=486) at any 
time prior to invasive dental treatment. Among this group, the possible 
withholding of medication prior to dental treatment because of concern for 
bleeding complications might have been an issue; 
 individuals likely to be taking NSAIDs (n=687) around the time of invasive 
dental treatment (those with an NSAID prescription within four weeks either 
side of the dental treatment or with a rheumatoid arthritis diagnosis at any 
time prior to dental treatment); 
 individuals newly diagnosed with diabetes (n=224), hypertension (n=398) or 
CHD (n=239) in the year before invasive dental treatment.  
Each of these analyses yielded similar or stronger effects compared with the primary 
analysis, with age-adjusted IRs in weeks 1-4 following invasive dental treatment 
ranging from 1.46, 95% CI 1.02-2.10 when restricting to cases with no evidence of 
diabetes, to 2.23, 95% CI 1.56-3.18 when restricting to cases not taking antiplatelet 
or salicylate drugs (Table 4.7; Appendix F-Tables F.3-F.7).  
4.5.2 Addressing fatal events  
As discussed in Chapter 3, section 3.8.4, the validity of the case series method rests 
on the assumption that the occurrence of an outcome event does not affect the 
probability of exposure. To address the issue of fatal vascular events violating this 
assumption (individuals who die are no longer at risk of exposure to invasive dental 
treatment) the primary analysis was repeated excluding cases (n=83) who died 
during the hospital stay for their vascular event or whose enrolment in Medicaid 
ended within one month after their event (and hence may have died as a result of the 
event). This restriction made no material difference to the findings: age-adjusted IR 
in weeks 1-4 following invasive dental treatment 1.62, 95% CI 1.17-2.24 (Table 4.7; 
Appendix F-Table F.8). 
4.5.3 Additional exclusions 
Further sensitivity analyses were conducted as outlined in Chapter 3, excluding 
individuals with: 
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 two or more dental procedures with overlapping risk periods (n=204), to 
assess whether the decision to allow the later procedure to take precedence 
over the earlier one (when the risk periods after each procedure overlapped) 
might have contributed to the more marked effect observed in earlier (post-
procedure) time frames; 
 one or more invasive dental procedures that were not extractions (n=135), to 
assess whether a similar effect was observed when restricting the analysis to 
the more common, homogenous exposures (extractions);  
 a history of diabetes, hypertension or CHD prior to invasive dental treatment 
(n=924), to assess whether a similar effect was observed amongst the 
remaining “healthy” subgroup.  
These analyses made no material difference to the findings, and if anything yielded 
marginally stronger effects in weeks 1-4 following invasive dental treatment (Table 
4.7; Appendix F-Tables F.9-F.11). 
Table 4.7 Results of sensitivity analyses. 
Analysis of vascular event rate in weeks 1-4 post-
procedure compared to baselinea 
Cases included in 
analysis (n) 
IRb (95% CI) 
Primary analysis:   
Vascular eventsc  1152 1.50 (1.09-2.06) 
   
Sensitivity analyses excluding cases with:   
Antiplatelet or salicylate drug prescription record at any 
time prior to IDT (n=486 excluded ) 
666 2.23 (1.56-3.18) 
 
NSAID prescription four weeks prior to four weeks post 
IDT or rheumatoid arthritis diagnosis at any time prior 
to IDT (n=687 excluded) 
465 1.84 (1.17-2.89) 
Earliest record of diabetes within 12 months prior to 
IDT (n=224 excluded) 
928 1.46 (1.02-2.10) 
 
Earliest record of hypertension within 12 months prior to 
IDT (n=398 excluded) 
754 1.64 (1.12-2.40) 
 
Earliest record of CHD within 12 months prior to IDT 
(n=239 excluded) 
913 1.70 (1.21-2.40) 
Enrolment ending or death within a month after the 
vascular event (n=83 excluded) 
1069 1.62 (1.17-2.24) 
 
Overlapping risk periods (n=204 excluded) 948 1.65 (1.17-2.33) 
Procedures that were not extractions (n=135 excluded) 1017 1.58 (1.13-2.21) 
Diagnosis of diabetes, hypertension or CHD at any time 
prior to IDT (n=924 excluded) 
228 1.76 (0.92-3.36) 
Abbreviations: IDT=invasive dental treatment; CHD=coronary heart disease 
a Baseline period is all observation time except for 24 week risk period following an invasive dental procedure. 
b IR denotes age-adjusted incidence ratio in weeks 1-4 following an invasive dental procedure. 
c Vascular events are 639 ischaemic strokes (55.5%) and 513 MIs (44.5%). 
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4.6 Discussion 
4.6.1 Summary of main findings 
The study findings suggest that among adults aged 20 years or more, invasive dental 
treatment may be associated with an increased rate of vascular events in the first four 
weeks after treatment relative to all unexposed time periods (age-adjusted IR 1.50, 
95% CI 1.09-2.06). The increased rate appeared to be transient, returning to baseline 
over the subsequent 20 weeks. Separate analyses of ischaemic stroke and MI 
suggested similar, transient increased rates of both of these outcomes in the four 
weeks after invasive dental treatment (age-adjusted IR 1.39, 95% CI 0.89-2.15 for 
ischaemic stroke and 1.56, 0.98-2.47 for MI), although the findings were not 
statistically significant.  
4.6.2 Study strengths 
In studies investigating the risk of vascular events following inflammatory exposures 
such as invasive dental treatment, the potential for confounding is great because 
individuals who undergo treatment may differ from those who do not in ways which 
are difficult to control for. Poor dental health and CVD share a number of 
aetiological factors, including socioeconomic and life-style factors such as cigarette 
smoking and diet. Furthermore, individuals who opt for dental treatment may be 
more likely to take other precautionary measures regarding general aspects of their 
health, including their cardiovascular health. The major strength of this study is the 
use of a case series analysis, which overcame the potential problem of confounding 
associated with the influence of such factors which may vary among individuals to 
which other observational study designs are prone. This was achieved by all 
comparisons being within-person; thus fixed covariates were implicitly controlled 
for. Confounding would only have occurred if intra-person risk factors for vascular 
events that change with time were also associated with the timing of invasive dental 
treatment. In addition, to produce the effect observed, any such factors would need to 
have a strong acute effect on vascular event risk and their time-dependent effect 
would need to be operating in a large proportion of included cases. Thus, while a 
small effect of such time varying factors cannot be excluded, the overall impact on 
the study results is likely to be minimal.  
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As expected, a clear age effect was observed demonstrating an increased risk of 
vascular events with increasing age; thus, all analyses were age-adjusted in 5-year 
age bands, and subsequently the primary analysis was repeated allowing for finer 
age-adjustment (2-year bands) which yielded similar results. The findings are 
therefore unlikely to be explained by the time-varying effect of age or age-related 
factors.  
The influence of additional time-varying covariates identified as potential 
confounders were explored in sensitivity analyses, as described in section 4.5.1. In 
each of these analyses, a short-term increase in the rate of vascular events after 
invasive dental treatment persisted, indicating that these factors are unlikely to 
provide alternative explanations for the effect observed in this study. For example, 
possible confounding by the cessation of antiplatelet or salicylate medication before 
invasive dental treatment, which may feasibly trigger a subsequent vascular event in 
the short term, was addressed using a pragmatic approach of restricting the analysis 
to cases who had no recorded use of antiplatelet or salicylate drugs prior to their 
dental treatment. Because the issue of discontinuing medication at the time of dental 
treatment was unlikely to arise among these individuals, any observed increase in 
vascular event risk after dental treatment was unlikely to be attributable to a 
temporary cessation of antiplatelets or salicylates. Furthermore, because of the risk 
that aspirin cessation might precipitate a vascular event88 and continued aspirin use 
during dental surgical procedures has been shown not to lead to excessive post-
operative bleeding,89 the continuation of antiplatelet therapy throughout such 
procedures is recommended practice in the US and elsewhere90–92. Thus, the 
withholding of such medication is unlikely to have been commonplace among the 
study population.  
In addition, it was recognised that the development or worsening of diabetes, 
hypertension or CHD might increase both the risk of periodontal disease (and hence 
the likelihood of associated invasive dental procedures) and of vascular events. To 
allow for this, sensitivity analyses were performed restricted to cases with no 
evidence for each of these three conditions developing in the year leading up to 
invasive dental treatment. Since those remaining either had no pre-existing diabetes, 
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hypertension or CHD or they developed disease after their invasive dental treatment 
or more than a year before treatment, the scope for confounding was reduced.  
The sensitivity analysis which excluded known or suspected fatal cases (described in 
section 4.5.2) demonstrated that the study findings were robust with regards to 
assumptions underlying the case series method.  
Based on previous research showing that the host response and vascular function are 
affected at their maximum 24 hours after invasive dental treatment,47–49,84 the 
decision was taken to start the risk period the day after the dental procedure; hence 
the day of the procedure contributed to the baseline (unexposed) period. This avoided 
the problem of vascular events on the same day as a procedure, that were a 
consequence of other factors unrelated to the dental treatment, being included in the 
risk estimates. Any bias arising from this convention would have led to an 
underestimate of effect. However, no vascular events occurred on the same day as a 
dental procedure, hence this particular source of bias was not a concern in this study. 
When an individual had multiple invasive dental procedures with overlapping risk 
periods, all procedures were included, but the latest procedure was allowed to take 
precedence (see Figure 3.3, Chapter 3). The rationale for this choice was that the 
most proximate procedure to the vascular event was deemed the most relevant when 
examining the acute effect of invasive dental treatment on vascular event risk. The 
sensitivity analysis which excluded cases with overlapping risk periods yielded 
virtually identical results to the primary analysis, suggesting that this convention did 
not introduce any notable bias. 
4.6.3 Potential limitations of the study 
As described in Chapter 3, section 3.8.4, an important assumption of the case series 
method is that outcome events are independent. Thus all analyses were restricted to 
individuals’ first vascular events occurring during the observation period. Although 
excluding subsequent primary discharge diagnoses for stroke and MI may have 
potentially underestimated the absolute risk of vascular events, this is unlikely to 
have had any material effect on the relative risk (the primary outcome of this study). 
A similar approach was taken in an earlier SCCS study exploring the risk of stroke 
and MI after acute infection and vaccination.19  
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It was recognized that the ascertainment of use of antiplatelet agents, salicylates or 
NSAIDs may have been incomplete as some patients are likely to have received 
these medicines both through prescription and over-the-counter. The Medicaid 
database does not capture over-the-counter medications, thus the possibility of 
residual confounding by differential use of these agents around the time of invasive 
dental treatment cannot be excluded.  
Possible confounding by the proximity of invasive dental treatment to odontogenic 
infection or other acute conditions necessitating dental treatment must also be 
considered. The invasive dental procedures included in the main analysis did not 
necessarily follow an acute infection; however, data were not available on the reason 
for each dental procedure. While in the case of procedures carried out to treat an 
acute condition it was not possible to disentangle the effects of the condition from 
those of the treatment, it is unlikely that the entire association between invasive 
dental treatment and vascular events is due to such acute conditions. Even if the 
effect observed is in part attributed to the onset of acute infections coinciding with 
the timing of dental treatment, this would actually support an inflammatory 
mechanism for the association between invasive dental treatment and vascular 
events. 
While the possibility of case-ascertainment bias cannot be excluded, whereby 
individuals may have been more likely to be diagnosed with a vascular event in the 
first month after a dental procedure than in earlier or later time periods,  it is likely to 
be minimal given that both ischaemic stroke and MI are hard outcomes which 
manifest with clear clinical presentations. There was also scope for misclassification 
of exposure status. Not all Medicaid beneficiaries were necessarily eligible for dental 
care. While it was possible to determine who had made claims for dental care, there 
were no data indicating dental coverage. Individuals who did not qualify for dental 
coverage may have undergone invasive dental treatment (either self-funded or 
covered by another insurer), and this would not have been captured in the database. 
These individuals would thus have been misclassified as unexposed. However, this is 
unlikely to be a major problem in this study, as only individuals with at least one 
invasive dental procedure record (and thus with dental coverage) contributed to the 
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analyses, and the chance of their dental coverage changing over the course of their 
enrolment was likely to be small.  
The study was based on claims data, and a potential weakness may relate to the 
skewed nature of the population eligible for Medicaid. Eligibility is income-related. 
Eligible groups include low-income adults and their children, and individuals with 
certain disabilities. It is possible, for example, that patients with diseases which put 
them at greater risk of thrombotic events may be more likely to enter the Medicaid 
program in order to pay for needed care including dental care. While this may raise 
the question of generalisability of the study findings to other populations, it is 
unlikely to have biased the effect estimates as these were derived from within-person 
comparisons, with each individual serving as his or her control. Furthermore, the 
sensitivity analysis which restricted to “healthy” claimants (individuals with no 
previous record of diabetes, hypertension or CHD) showed a similar effect to that 
obtained in the primary analysis, though with less precision due to the fewer cases in 
this subset.  
The relatively small study population is another limitation. In a case series design, 
only individuals who are exposed at least once during follow-up contribute to the 
analyses. Given that invasive dental procedure claims were fairly uncommon among 
the study population, a relatively small proportion of the initial sample contributed to 
the analyses. The substantial reduction in sample size limited the power of the study 
to examine the effects of invasive dental treatment on ischaemic stroke and MI 
separately. 
4.6.4 Conclusion 
This study has shown that invasive dental procedures may be associated with a 
transient increase in the risk of ischaemic stroke and MI in adults in the four weeks 
after the dental treatment. The exact mechanisms underlying the observed association 
are uncertain. While the findings do not preclude the possibility that non-
inflammatory mechanisms may be involved, for example, possible discontinuation of 
antiplatelet medication before invasive dental treatment, or increased stress due to 
pain arising from the dental treatment, they nevertheless support the hypothesis that 
invasive dental procedures sufficient to produce acute inflammation may play an 
67 
 
important role in the occurrence of vascular events. A discussion of the study 
findings in context of what was previously known on the relationship between 
invasive dental treatment and vascular risk is presented in the concluding chapter of 
this thesis (Chapter 9, section 9.1). 
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Chapter 5  A literature review of pre-eclampsia and acute maternal 
infection 
This chapter reports on the literature review of studies assessing the association 
between acute maternal infections and pre-eclampsia. Following a brief overview of 
the clinical features of pre-eclampsia and the evidence implicating inflammation in 
its pathogenesis, the review methodology is described. The results of the review are 
presented in two parts: first, evidence on the association between UTI (the most 
commonly studied acute infection) and pre-eclampsia is summarised, followed by 
evidence on the effect of other acute infections. A summary of the main findings and 
rationale for the pre-eclampsia study (described in Chapter 6) concludes the chapter. 
5.1 Background 
Pre-eclampsia is a pregnancy-specific, multi-system vascular syndrome typically 
defined by the gestational onset of hypertension and proteinuria after 20 weeks’ 
gestation. It is a major cause of maternal and perinatal morbidity and mortality, its 
incidence ranging from 2 to 8% in nulliparous women.93 Globally, pre-eclampsia 
accounts for 10 to 15% of maternal deaths.94 
The presentation and progression of pre-eclampsia are highly variable. It may 
develop from a mild to a severe disease state, the latter characterised by sustained, 
severe hypertension (blood pressure ≥110 mm Hg diastolic or ≥160 mm Hg systolic), 
nephrotic-range proteinuria (≥5g in 24 hours) or other evidence of end-organ 
damage, or it may be severe at the time of diagnosis.94 In some women, pre-
eclampsia progresses to a convulsive phase, eclampsia, a rare but serious 
complication affecting 1 to 2% of severe cases,93 characterised by tonic-clonic 
seizures in a pregnant or recently delivered woman which may lead to coma. Other 
women may develop HELLP syndrome, a combined liver and blood clotting disorder 
characterised by “H”, haemolysis (rupture of red blood cells), “EL”, elevated liver 
enzymes in the blood (indicating liver dysfunction), and “LP”, a low platelet count. 
HELLP complicates 10 to 20% of severe cases of pre-eclampsia93 and may develop 
antepartum or postpartum.95  
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Despite advances in knowledge, our understanding of what causes pre-eclampsia 
remains incomplete, and we still have a limited ability to predict or prevent the 
disorder.94 Pre-eclampsia is a complex disease, and numerous theories have 
attempted to explain its pathogenesis. These include abnormal placentation in early 
pregnancy, maternal immune mechanisms, genetic factors, an imbalance of pro- and 
anti-angiogenic proteins, and an excessive systemic inflammatory response.23,96 
While poor early placentation is especially implicated in early-onset pre-eclampsia, 
maternal cardiovascular and metabolic factors associated with endothelial 
dysfunction, such as obesity, might play a greater role in the origins of late-onset 
disease.93,97 The aetiology of pre-eclampsia is thus generally considered to be 
multifactorial, involving a range of both maternal and placental contributions.98 
However, the common target of such factors is the maternal vascular endothelium, as 
evidenced by the characteristic widespread endothelial dysfunction observed among 
women preceding the onset of clinical disease.29,99  
It has been proposed that the vascular endothelial dysfunction of pre-eclampsia is 
part of a generalised intravascular inflammatory response.100 Indeed, a key feature of 
pre-eclampsia is the greater systemic inflammatory response of women who develop 
the syndrome compared to women who have normal pregnancies.96 This suggests 
that inflammation may play a central role in the pathogenesis, although the exact 
cause of the inflammation is not completely understood. While reduced placental 
perfusion as a result of inadequate placentation may be an important inflammatory 
stimulus for many women who develop pre-eclampsia, it is not necessarily a strong 
component of all pre-eclamptic pregnancies.101 It is likely that several factors, both 
placental and maternal in origin, contribute to the amplified maternal inflammatory 
response seen in pre-eclampsia and the development of the syndrome.96  
Based on this notion, a growing body of research implicates infection, a common 
cause of inflammation and of endothelial dysfunction, in the aetiology of pre-
eclampsia.102 An increased risk of pre-eclampsia associated with maternal 
periodontal disease, a source of chronic infection and inflammation, has been well-
documented.103–105 Studies based on serological markers of other chronic infections 
have also yielded positive findings,106–111 although temporal associations in these 
studies are uncertain.  
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Attention has also been directed towards acute infection possibly contributing to the 
development of the maternal syndrome. It is the potential role of acute infection in 
pre-eclampsia that this part of the thesis (Chapters 5-8) investigates.  
5.2 Methods 
5.2.1 Aim of review 
The aim of the literature review was to summarise published evidence on the effect 
of acute maternal infections on the risk of pre-eclampsia.  
5.2.2 Search strategy 
A systematic review and meta-analysis of observational studies which examined the 
relationship between maternal infections and pre-eclampsia was published in 
2008.102 This was updated by searching the Medline database for additional studies 
published since the original review was conducted (from 2007 to February 2014). 
Following a similar search strategy to the original review, an algorithm was 
developed (see Appendix C-Table C.2) and applied in Medline using MeSH 
keywords and free-text words for infection and pre-eclampsia. Hence, the initial 
search encompassed all types of infection (both chronic and acute), consistent with 
the original review. However, given the specific interest and relevance of the effect 
of acute maternal infections to this project, these form the focus of this review. 
The same procedures for identifying potentially relevant studies and extracting 
information were followed as for the literature review of invasive dental treatment 
and vascular events, described in Chapter 2, section 2.2.2.  
5.2.3 Inclusion and exclusion criteria 
Studies presenting original data, published in English, and which included pre-
eclampsia, eclampsia, HELLP syndrome, or gestational hypertension with 
proteinuria as an outcome and also investigated acute maternal infection as an 
exposure, were included. Gestational hypertension was defined as blood pressure of 
at least 90 mm Hg (diastolic) or at least 140 mm Hg (systolic) after 20 weeks’ 
gestation. Proteinuria was defined as the urinary excretion of ≥300 mg protein in 24 
hours, or ≥300mg/L (≥ 1+ reading on dipstick) in a random urine sample. Acute 
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maternal infection could be defined clinically, or via the presence of a specific 
infectious agent indicating acute infection, or immunoglobulin M (IgM) antibodies to 
that specific infectious agent. Studies examining only the association between acute 
maternal infection and hypertensive states without proteinuria were excluded, as 
were case reports, case-only studies with no comparison group (or with no 
comparison time period), and review articles that lacked original data. 
5.3 Results 
The literature search generated 653 citations of which nine fulfilled the inclusion 
criteria. This gave rise to a total of 29 included studies from both the original 2008 
review102 and the present search combined.  
The majority of studies (11 cohort,112–122 six case-control,123–128 three cross-
sectional129–131) presented data on the relationship between pre-eclampsia and UTI, 
one of the most commonly occurring acute maternal infections.132 The characteristics 
and main findings of these studies (17 from the original review;112–126,129,130 three 
from the present search127,128,131) are summarised in Table 5.1 and discussed in more 
detail below (section 5.3.1).  
The remaining studies presented data on other acute infections during pregnancy: six 
studies (one cohort133 and five case-control106,110,134–136) examined the relationship 
between pre-eclampsia and the presence of IgM antibodies to Chlamydia 
pneumoniae infection, a recognised respiratory tract pathogen (although one case-
control study was subsequently excluded as no antibodies were detected in either 
group)136; two population-based cross-sectional studies examined the association 
between pre-eclampsia and hospital diagnosed pneumonia,137,138 and one case-control 
study assessed the association with IgM antibody seroprevalence to 
cytomegalovirus139. The key features and findings of these studies (three from the 
original review;106,133,134 five from the present search110,135,137–139) are summarised in 
Table 5.2 and discussed below (section 5.3.2). 
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Table 5.1 Characteristics of studies examining the association between pre-eclampsia and maternal urinary tract infection and fulfilling the inclusion criteria. 
First author, 
year published 
Location Study design Sample size or 
cases/controls  
Participant selection 
(study period) 
Outcome or 
case definition 
Type and timing of 
exposure; method of 
ascertainment 
Adjustment or matching Main findings  
(Odds Ratio, 95% 
CI) 
Kashanian, 
2011128 a  
Tehran, Iran Case-control 318 cases with 
PE, 318 
normotensive 
controls  
Consecutive selection 
of controls (1 per case) 
from same hospital as 
case (2005-2006) 
PEb, obstetrician-
diagnosed 
UTI in pregnancy; 
ascertainment method 
not reported 
Maternal and gestational 
age, history of pre-
eclampsia, BMI, pre-
existing hypertension or 
diabetes, parity, blood Rh, 
education level, anaemia, 
method of contraception 
OR 2.2, 0.3-15.1 
Shamsi, 
2010127 a 
Karachi and Rawalpindi, 
Pakistan 
Case-control 131 cases with 
PE, 262 
controls 
without PE  
Consecutive selection 
of controls (2 per case) 
from same hospital as 
case (2006-2007) 
PEb, obstetrician-
diagnosed 
UTI in pregnancy; 
maternal self-report in 
postpartum interview 
Matched on hospital, day of 
delivery and parity. 
Adjusted for maternal age, 
SES, family history of 
diabetes mellitus, maternal 
weight, Rh factor 
No association in 
adjusted analysis 
(OR not reported); 
Prevalence of 
infection in cases 
versus controls: 
31.0% vs. 18.5% 
(p=0.006) 
Mazor-Dray, 
2009131 a 
Negev, Israel Population-based 
cross-sectional 
4,742 women 
with infection, 
199,093 
women without 
infection  
All hospital deliveries 
(1988-2007) 
PE, diagnosis 
recorded in 
perinatal database  
UTI in pregnancy or at 
delivery; record of 
positive urine culturec 
with symptoms of 
dysuria, urgency and 
frequency in perinatal 
database 
Maternal age and parity OR 1.3, 1.1-1.4  
Banhidy, 
2007130  
Hungary Population-based 
cross-sectional 
38,151  Mothers of newborns 
without congenital 
abnormalities selected 
from National birth 
Registry (1980-1996) 
PE, eclampsia or 
pregnancy-induced 
hypertension with 
oedema and 
albuminuria, in 
antenatal logbook 
UTI in pregnancy; 
positive urine culture, 
acute cystitis, 
cystopyelitis or 
pyelonephritis in 
antenatal logbook or 
maternal self-report in 
postpartum 
questionnaire 
None OR 1.3, 1.1-1.5                                             
Villar, 2006122 Rosario, Argentina; 
Havana, Cuba; Jeddah, 
Saudi Arabia; Khon Kaen, 
Thailand 
Cohort 32,147  Women enrolled in 53 
randomly selected 
antenatal clinics and 5 
hospitals (1996-1998) 
PEb, obstetrician-
diagnosed 
UTI in pregnancy; 
antenatal record, further 
ascertainment not 
reported 
Maternal age, parity, 
reproductive tract infection 
or surgery, history of 
spontaneous abortion 
OR 1.4, 1.1-1.7 
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First author, 
year published 
Location Study design Sample size or 
cases/controls  
Participant selection 
(study period) 
Outcome or 
case definition 
Type and timing of 
exposure; method of 
ascertainment 
Adjustment or matching Main findings  
(Odds Ratio, 95% 
CI) 
Lee, 2000121 Taiwan Retrospective 
cohort 
29,735  All hospital deliveries 
(1990-1998) 
PEb, diagnosis 
recorded in hospital 
obstetric database 
UTI in pregnancy; 
record of asymptomatic 
bacteriuria, cystitis or 
pyelonephritis and/or 
positive urine culture in 
obstetric database, or 
maternal self-report in 
first antenatal visit 
interview 
Maternal age, parity, pre-
pregnancy BMI, education, 
marital status, working 
during pregnancy, multiple 
gestation, infant gender, 
history of pre-eclampsia, 
diabetes mellitus, 
conception method, 
obstetric history, uterine 
fibroids 
OR 4.8, 1.5-15.8 
Mittendorf, 
1996126 
 
Boston, USA Nested case-
control 
386 cases with 
PE, 2355 
controls 
without PE  
Random selection of 
controls from same 
hospital as case (1977-
1980) 
PEb, obstetrician-
diagnosed 
UTI in pregnancy; 
ascertainment method 
not reported 
Maternal age, parity, pre-
pregnancy BMI, education, 
ethnicity, smoking, infant 
gender, prenatal care, 
history of abortion, working 
during pregnancy, marital 
status 
OR (all women) 
1.6, 1.1-2.5; OR 
(primiparas only) 
5.3, 2.9-9.7 
Abi-Said, 
1995125 
Houston, USA Case-control 66 cases with 
eclampsia, 264 
non pre-
eclamptic 
controls  
Consecutive selection 
of controls (4 per case) 
from same hospital as 
case (1977-1992) 
Eclampsia, 
diagnosis recorded 
in hospital medical 
records  
UTI in pregnancy; 
diagnosis in hospital 
records, further 
ascertainment not 
reported 
Matched on hospital and 
month of delivery. Adjusted 
for maternal age, parity, 
ethnicity, prenatal care, 
obesity, history of diabetes 
OR (eclampsia) 
4.2, 1.3-14.1 
Hsu, 1995120  
 
Baltimore, USA Retrospective 
cohort 
13,852  All hospital deliveries 
(1983-1987) 
Mild and severe 
PE, diagnosis 
recorded in hospital 
perinatal database 
UTI in antepartum, 
intrapartum and 
postpartum periods; 
record of positive urine 
culturec with or without 
signs or symptoms of 
cystitis or 
pyelonephritis in 
perinatal database 
Delivery by caesarean 
section, use of oxytocin, 
premature  rupture of 
membranes, gestational age 
at delivery 
OR for severe PE 
2.6, 2.0-3.4; no 
association with 
mild PE (OR not 
reported) 
Schieve, 
1994119  
 
 
Chicago, USA Retrospective 
cohort 
25,746  
 
Perinatal registry cohort 
of mother/infant pairs 
(1988-1989) 
PE included new 
onset hypertension 
without proteinuria, 
diagnosis in 
perinatal database 
UTI in antepartum 
period; record of 
positive urine culture or 
clinical presentation 
(physician diagnosis of 
UTI or pyelonephritis) 
in perinatal database 
Maternal age, ethnicity, 
outcome of previous 
pregnancy, hospital of 
delivery, genital tract 
infection 
OR 1.4, 1.2-1.7 
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First author, 
year published 
Location Study design Sample size or 
cases/controls  
Participant selection 
(study period) 
Outcome or 
case definition 
Type and timing of 
exposure; method of 
ascertainment 
Adjustment or matching Main findings  
(Odds Ratio, 95% 
CI) 
Qureshi, 
1994118 
Karachi, Pakistan Cohort 1597  All women presenting 
for antenatal care at 
University medical 
centre (1988-1990) 
PE, no further 
details 
Bacteriuria at first 
antenatal visit; positive 
urine culture 
None No association 
(OR not reported) 
Gilbert, 
1986117 
Melbourne, Australia Cohort 340  Women attending 
antenatal care clinics 
PE, no further 
details 
Bacteriuria at first 
antenatal visit; positive 
urine culture 
None Bacteriuria 
associated with a 
3-fold increased 
risk of PE 
(p<0.05) 
Hill, 1986124 Augusta, USA Case-control 100 
primigravid 
cases with PE, 
100 
primigravid 
and 100 
multigravid 
controls 
without PE  
Not reported PE defined as 
gestational 
hypertension with 
oedema and 
proteinuria 
Asymptomatic 
bacteriuria at delivery; 
positive urine culturec  
Matched on maternal age Prevalence of 
infection in cases 
versus controls 
19% vs. 3% 
(primigravidas) or 
vs. 6% 
(multigravidas) 
(p<0.005) 
(OR not reported) 
Savige, 
1983123  
Melbourne, Australia Case-control 51 cases with 
PE, 72 controls 
without PE  
Not reported PE defined as 
gestational 
hypertension with 
oedema, with or 
without proteinuria  
 
Bacteriuria at delivery 
(cases), at <26 weeks’ 
gestation (controls); 
positive urine culture 
None Bacteriuria 
associated with an 
increased risk of 
PE (OR not 
reported) 
Brumfitt, 
1975129 
London, UK Cross-sectional 426 women 
with infection, 
477 women 
without 
infection  
Unknown PE, no further 
details 
Bacteriuria at first 
antenatal visit; further 
ascertainment not 
reported 
None No association 
Little, 1966116 London, UK Cohort 5000  Women attending 
hospital antenatal 
clinics (1962-1965) 
Pre-eclamptic 
toxaemia, not 
necessarily in 
presence of 
hypertension, 
proteinuria and 
oedema, 
obstetrician- 
diagnosed 
Bacteriuria at first 
antenatal visit; positive 
urine culturec in 2 
consecutive samples 
within 10 days apart  
None No association  
(Risk of PE in 
infected versus 
uninfected: 7.5% 
vs. 6.9%)  
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First author, 
year published 
Location Study design Sample size or 
cases/controls  
Participant selection 
(study period) 
Outcome or 
case definition 
Type and timing of 
exposure; method of 
ascertainment 
Adjustment or matching Main findings  
(Odds Ratio, 95% 
CI) 
Stuart, 1965115  Jamaica Cohort 88 women with 
infection, 729 
women without 
infection all 
followed to 
term  
Consecutive pregnant 
women attending 
antenatal clinics of the 
University College 
Hospital (1961-1963) 
PE included new 
onset hypertension 
without proteinuria, 
obstetrician- 
diagnosed 
Bacteriuria at first 
antenatal visit; positive 
urine culturec in ≥2 
consecutive samples  
None Risk of PE in 
infected versus 
uninfected: 18.2% 
vs. 4.5% 
(p<0.001) 
Kincaid-
Smith, 1965114   
Melbourne, Australia Cohort 240 women 
with infection, 
500 women 
without 
infection 
Women recruited at 
antenatal clinic: 
infected women were 
compared with a  
random sample of 
uninfected women, all 
with completed 
pregnancies 
Pre-eclamptic 
toxaemia defined as 
2 or more of 
proteinuria, 
hypertension 
(≥140/90 mm Hg) 
or oedema, 
obstetrician- 
diagnosed  
Bacteriuria at first 
antenatal visit before 26 
weeks’ gestation; 
positive urine culturec 
in single midstream 
urine specimen 
None Risk of PE in 
infected versus 
uninfected: 10.8% 
vs. 6.0% (p<0.05) 
Low, 1964113 Toronto, Canada Cohort 771 Unknown PE, no further 
details 
Asymptomatic 
bacteriuria at first 
antenatal visit; further 
ascertainment not 
reported 
None No association  
Bryant, 
1964112 
Dallas, USA Cohort 32 women with 
infection, 44 
women without 
infection all 
followed to 
term 
Women attending 
antenatal clinic  
PE, no further 
details 
Asymptomatic 
bacteriuria at first 
antenatal visit; further 
ascertainment not 
reported 
Matched on maternal age, 
SES, parity, ethnicity 
No association  
OR denotes odds ratio adjusted for all specified variables; UTI=urinary tract infection; PE=pre-eclampsia; SES=socioeconomic status; BMI=body mass index 
a studies identified in new search (since 2007) 
b PE defined as de novo hypertension (blood pressure of at least 90 mm Hg diastolic or at least 140 mm Hg systolic) with proteinuria (≥300 mg in 24 hours, or ≥300mg/L (≥ 1+ on dipstick) in a urine specimen) after 20 
weeks’ gestation 
c defined as >100,000 bacteria per ml of urine 
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5.3.1 Studies of urinary tract infection 
Twenty studies conducted over a 47 year period (1964-2011) in a variety of 
geographical settings evaluated the relationship between UTI in pregnancy and pre-
eclampsia (see Table 5.1). Of these, 13 studies (seven cohort,114,115,117,119–122 four 
case-control,123–126 two cross-sectional130,131) reported an association between UTI 
and an increased risk of pre-eclampsia, with odds ratio (OR) point estimates (when 
reported) ranging between 1.3 and 4.8 after adjustment for at least maternal age; 
whereas seven studies (four cohort,112,113,116,118 two case-control,127,128 one cross-
sectional129) found no association. In the original review,102 Conde-Agudelo et al 
reported a significant association between pre-eclampsia and maternal UTI 
(summary OR 1.57, 95% CI 1.45-1.70). However, there was considerable between-
study heterogeneity (as confirmed by an I2 of 79%) among the 17 studies included in 
their fixed-effects meta-analysis. Findings from the three most recent studies, 
identified in the present search, were conflicting: one, a large population-based cross-
sectional study conducted in Israel reported an increased risk of pre-eclampsia 
among women with UTI in pregnancy after controlling for maternal age and parity 
(adjusted OR 1.3, 1.1-1.4),131 whereas the two case-control studies, one conducted in 
Iran,128 the other in Pakistan,127 found no evidence for an association between UTI 
and pre-eclampsia after adjusting for maternal age, parity, maternal BMI or weight, 
Rhesus factor, and other potential confounders.  
5.3.1.1 Possible reasons for the variability in study findings 
There could be a number of reasons for the heterogeneity observed between studies. 
Many methodological aspects varied between studies, including the design, timing, 
geographical location, the definitions of pre-eclampsia and of UTI, and the extent of 
adjustment for potential confounders (eight studies reported adjusting for at least 
maternal age and parity,112,121,122,125–128,131 whereas nine reported no adjustment for 
confounding113–118,123,129,130). In their meta-analysis, Conde-Agudelo et al explored 
possible sources of heterogeneity observed among the included studies, which could 
not be explained by differences in sample size (<100 pre-eclampsia cases versus 
≥100 cases), year of publication (before 1990 versus after 1990) or definition of UTI 
used (“asymptomatic or symptomatic bacteriuria” versus “urinary tract infection”) as 
the summary ORs obtained for these subgroups were similar to the overall summary 
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OR. However, smaller summary ORs (i.e. closer to the null) were obtained for 
studies that controlled for at least maternal age and some indicator of SES compared 
to studies that did not control for these (summary OR 1.40, 95% CI 1.27-1.55 versus 
2.05, 1.77-2.39) and for studies rated as high quality (on the basis of several criteria 
including the method of participant selection, assessment of exposure and outcome, 
and control for confounding) compared to those rated as lower quality (summary OR 
1.46, 95% CI 1.33-1.60 versus 1.99, 1.69-2.33). Study location also appeared to 
explain some of the heterogeneity, with European studies yielding the smallest 
summary OR (1.24, 1.08-1.41), and Australian studies the largest, by almost twofold 
(2.33, 1.52-3.56). 
Differences in the case definition of pre-eclampsia used between studies might also 
explain some of the variability in the findings. Pre-eclampsia was most commonly 
defined as new onset hypertension in association with proteinuria after 20 weeks’ 
gestation. However, some studies were less precise about the diagnosis of pre-
eclampsia, so it is possible that some cases of pregnancy-induced hypertension, for 
example, were misclassified as pre-eclampsia. Indeed, three studies used a combined 
outcome of pre-eclampsia and pregnancy-induced hypertension;115,119,123 all three 
reported a positive association with UTI. Two earlier studies of “pre-eclamptic 
toxaemia”, diagnosed in the presence of two or more of proteinuria, hypertension or 
oedema,114 or not otherwise specified,116 reported conflicting findings. One study 
assessed the association with UTI according to the severity of pre-eclampsia and 
observed a positive association with severe pre-eclampsia (OR 2.6, 2.0-3.4), but no 
association with mild pre-eclampsia.120 The single study of eclampsia reported a 
four-fold increased risk of eclampsia associated with UTI.125 
Differences in the method and timing of exposure ascertainment might also explain 
some of the heterogeneity between studies. Although infection status was most often 
ascertained by direct measurement (confirmed by positive urine culture), or taken 
from medical records, three studies,121,127,130 two of which reported a positive 
association with pre-eclampsia,121,130 relied on maternal self-report of UTI in 
postpartum interview: thus the findings may be prone to recall bias if, for example, 
women with pre-eclampsia were more likely to report having a UTI during 
pregnancy than women who did not develop pre-eclampsia. A number of studies 
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only assessed the presence of UTI at one time point during pregnancy112–
115,117,118,123,124,129 and may have been particularly prone to exposure 
misclassification, for example, if some women classified as “unexposed” acquired an 
earlier or later UTI which was undetected. Additionally, the temporal association 
between UTI and pre-eclampsia was uncertain in some studies.119,120,122–124,127,128,131 
It was not always clear whether an episode of UTI preceded the clinical onset of pre-
eclampsia, which renders the findings difficult to interpret. 
The apparent relationship between UTI and pre-eclampsia observed in some studies 
might also be explained, at least in part, by confounding. None of the studies 
reported adjusting for renal disease, which might act as a confounder of the 
association observed. In one, pyelographic abnormalities were detected in more than 
30% of women with bacteriuria in pregnancy.114 These underlying morbidities or 
impairment of renal function could provide an alternative explanation for the 
increased risk of pre-eclampsia seen among women with UTI. Another potential 
explanation for the observed association may be increased ascertainment of UTI 
among women with pre-eclampsia. Patients whose pregnancies are categorised as 
high-risk may be seen by clinicians more often than those considered lower risk, 
hence potentially leading to more UTI diagnoses in women who develop pre-
eclampsia.  
5.3.2 Studies of other acute maternal infections  
Eight studies conducted over a ten year period (2003-2012) in a variety of locations, 
evaluated the relationship between other acute (non-urinary tract) infections in 
pregnancy and pre-eclampsia (see Table 5.2). The five studies (one cohort,133 four 
case-control106,110,134,135) which assessed the presence of IgM antibodies to 
Chlamydia pneumoniae during the second half of pregnancy or at delivery all 
reported no association between pre-eclampsia and Chlamydia pneumoniae IgM 
seroprevalence. Three of these adjusted for at least maternal age and gestational 
age.106,110,135 However, the sample sizes of all five studies were small, with the 
number of cases ranging between 37 and 69, which limited the power of these studies 
to reliably assess the association. Furthermore, while the cohort study assessed 
maternal antibody status twice during pregnancy (approximately mid-way and at 
term)133 all four case-control studies assessed antibody status just once towards the 
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end of pregnancy or at delivery106,110,134,135. Thus it was not possible to establish the 
temporal sequence of events (the onset of infection in relation to the onset of pre-
eclampsia) in these studies.  
Both cross-sectional studies of hospital-diagnosed pneumonia during pregnancy 
reported a significant positive association with pre-eclampsia after adjusting for 
maternal age, among other potential confounders. The most recent, conducted in 
Taiwan, observed a three-fold increased risk of pre-eclampsia/eclampsia,138 while the 
earlier study from Israel observed a 2.6-fold increased risk of severe pre-eclampsia, 
though no association with mild pre-eclampsia137. However, the Israeli study 
provided no details on how pre-eclampsia (mild versus severe) was diagnosed. Thus, 
while the absence of an association with mild pre-eclampsia may reflect a true 
difference in the mechanisms involved in different subtypes, it may also be due to 
misclassification of pre-eclampsia in the mild cases. In addition, the timing of 
pneumonia during pregnancy was not reported in this study, which further 
complicates interpretation of the findings. However, the majority of women in the 
Taiwanese study who acquired pneumonia (93.6%) were hospitalised during the first 
trimester, prior to the onset of pre-eclampsia, thus the findings are compatible with a 
causal association. 
The single study which assessed seroprevalence of maternal IgM antibodies to  
cytomegalovirus, a large population-based case-control study in Norway, found no 
evidence for an association with pre-eclampsia after adjusting for maternal age, 
smoking and parity (OR 1.07, 95% CI 0.48-2.36).139 However, maternal antibody 
status was determined only once, approximately mid-way through pregnancy, thus 
women classified as seronegative at this time may have been previously infected 
during pregnancy, or may have acquired an infection later in pregnancy. 
Accordingly, the relationship between acute cytomegalovirus infection and pre-
eclampsia has not been determined. 
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Table 5.2 Characteristics of studies examining the association between pre-eclampsia and other (non-UTI) acute maternal infections and fulfilling the inclusion 
criteria. 
First author, year 
published 
Location Study design Sample size or 
cases/controls 
Participant selection 
(study period) 
Outcome or  
case definition 
Type and timing of 
exposure; method of 
ascertainment 
Adjustment or matching Main findings 
(Odds ratio, 95% CI) 
Chlamydia 
pneumoniae 
        
Ustun, 2010110 a Malatya, Turkey Case-control 40 cases with PE, 
40 normotensive 
controls 
Consecutive selection 
of controls (1 per case) 
from same hospital as 
case over 12 month 
period (year 
unspecified) 
PEb, 
obstetrician- 
diagnosed 
CP infection in third 
trimester; IgM 
antibody status in 
serum sample  
Matched on maternal and 
gestational age, BMI 
No association between PE 
and seroprevalence of IgM 
antibodies to CP (30.0% in 
cases versus 27.5% in 
controls, p>0.05) 
Xie, 2010135 a Vancouver, 
Canada 
Case-control 50 cases with PE, 
57 controls with 
normal 
pregnancies at 
term  
Consecutive selection 
of 1-2 controls per case  
PEb, 
obstetrician- 
diagnosed 
CP infection at >20 
weeks’ gestation; 
IgM antibody status 
in serum sample  
Matched on maternal and 
gestational age, parity 
No association between PE 
and seroprevalence of IgM 
antibodies to CP (2.0% in 
cases versus 0% in controls, 
p>0.05) 
Aral, 2006134 Kahramanmaras, 
Turkey 
Case-control 69 cases with PE, 
47 controls with 
normal obstetric 
history 
Not reported PE, no further 
details 
CP infection at 
delivery; IgM 
antibody status in 
serum sample 
None No association between PE 
and seroprevalence of IgM 
antibodies to CP (30.4% in 
cases versus 23.4% in 
controls, p>0.05) 
Goulis, 2005133 London, UK Cohort 32 multiparas 
and 37 
primiparas  
Pregnant women 
recruited in hospital for 
separate study of pre-
eclampsia prevention 
(placebo arm only)  
PEb, 
obstetrician- 
diagnosed 
CP infection at 16-22 
and 28-40 weeks’ 
gestation; IgM 
antibody status in 
serum sample  
None No association between PE 
and seroprevalence of IgM 
antibodies to CP. No 
difference in median IgM 
antibody level in pre-
eclamptic versus normal 
pregnancies either mid-
gestation or at term 
Heine, 2003106 Pittsburgh, USA Case-control 37 cases with PE, 
37 controls with 
normal term 
pregnancies 
Serum samples 
randomly selected from 
nulliparous pregnant 
women with and 
without pre-eclampsia 
at term 
PEb, 
obstetrician- 
diagnosed 
CP infection at 
admission for 
labour/delivery; IgM 
antibody status in 
serum sample 
Maternal and gestational age, 
smoking, ethnicity 
No association between PE 
and seroprevalence of IgM 
antibodies to CP 
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First author, year 
published 
Location Study design Sample size or 
cases/controls 
Participant selection 
(study period) 
Outcome or  
case definition 
Type and timing of 
exposure; method of 
ascertainment 
Adjustment or matching Main findings 
(Odds ratio, 95% CI) 
Pneumonia         
Chen, 2012138 a Taipei, Taiwan Population-
based cross-
sectional 
1462 women 
with pneumonia, 
7310 women 
without 
pneumonia 
 
All women with 
pneumonia in 
pregnancy and random 
sample of uninfected 
women (5 per woman 
with pneumonia) 
selected from all live 
singleton births (in 
2005) 
PE or 
eclampsia, 
diagnosis 
recorded in 
national birth 
registry 
Hospitalised with 
pneumonia during 
pregnancy; diagnosis 
(ICD-9-CM  
codes 480–483.8, 
485–486 or 487.0) 
recorded in national 
health insurance 
dataset 
Matched on maternal age; 
adjusted for education level, 
marital status, geographic 
region, gestational diabetes, 
gestational hypertension, CHD, 
anaemia, hyperlipidaemia, 
obesity, alcohol abuse, infant 
sex, parity, and paternal age 
OR (PE/eclampsia) 3.05, 
2.01-4.63 
Romanyuk, 
2011137 a 
Be'er-Sheva, 
Israel 
Population-
based cross-
sectional 
181,765 All hospital deliveries 
(1988-2008) 
Mild or severe 
PE, no further 
details 
Hospitalised with 
pneumonia during 
pregnancy, physician-
diagnosis confirmed 
by chest radiograph 
Adjusted for maternal age, 
fertility treatments, placental 
abruption, intra-uterine growth 
restriction and previous 
caesarean delivery 
OR for severe PE 2.6, 1.2-
5.7; no association with 
mild PE (OR not reported) 
Cytomegalovirus         
Strand, 2012139 a Norway Population-
based, nested 
case-control 
1470 cases with 
PE, 991 non pre-
eclamptic 
controls 
Cases and controls 
randomly selected from 
pregnancy cohort 
(1999-2006) 
PEb or 
eclampsia, 
diagnosis 
recorded in 
national birth 
registry 
CMV infection at 17-
18 weeks’ gestation; 
IgM antibody status 
in serum sample 
Adjusted for maternal age, 
parity and smoking in 
pregnancy 
No association between 
CMV IgM seropositivity 
and PE/eclampsia, OR 1.07, 
0.48-2.36 
OR denotes odds ratio adjusted for all specified variables; PE=pre-eclampsia; CP=Chlamydia pneumoniae; BMI=body mass index; CHD=coronary heart disease; ICD-9-CM = International Classification of Diseases, 
Ninth Revision, Clinical Modification; CMV=cytomegalovirus 
a studies identified in new search (since 2007) 
b PE defined as de novo hypertension (blood pressure of at least 90 mm Hg diastolic or at least 140 mm Hg systolic) with proteinuria (≥300 mg in 24 hours, or ≥300mg/L (≥ 1+ on dipstick) in a urine specimen) after 20 
weeks’ gestation.
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5.4 Summary of review  
This literature review of pre-eclampsia and acute infection has yielded some 
evidence for an increased pre-eclampsia risk associated with maternal UTI, although 
with conflicting findings from other studies. In addition, both studies of maternal 
pneumonia reported a significant positive association with pre-eclampsia, although in 
one the effect was confined to severe cases. However, there was no evidence for an 
association between pre-eclampsia and acute Chlamydia pneumoniae infection. The 
only study of maternal cytomegalovirus IgM antibody status found no association 
with pre-eclampsia, and data on other acute infections are lacking.  
5.4.1 Rationale for the pre-eclampsia study 
In some of these earlier studies, temporality of the association between infection and 
the development of pre-eclampsia was uncertain, which brings into question the 
causal nature of the association. In others, infection status was ascertained at a single 
time point, thus rendering these studies prone to misclassification of exposure. 
Studies of UTI may have been especially prone to bias by increased ascertainment of 
UTI in pregnancy among women at risk of pre-eclampsia, or to residual confounding 
by risk factors such as renal disease. Furthermore, factors such as gestational age at 
the time of infection or the number of infection episodes throughout pregnancy were 
not investigated in these studies. Thus a clear role for acute infection in the aetiology 
of pre-eclampsia has not yet been established.  
The pre-eclampsia study described in the next Chapter sought to address these issues 
by examining, in addition to UTI, the effects of acute RTI, maternal antibiotic 
prescriptions (a proxy for acute infection) and their timing and frequency in 
pregnancy, on the risk of developing pre-eclampsia, with optimal adjustment for 
confounding. Studying two different infectious processes at different sites, in 
addition to reducing the problem of bias associated with any one particular infection, 
allowed assessment of whether any effect of acute infection on the risk of pre-
eclampsia may be generic, and not specific to one type of infection. 
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Chapter 6  Methods - Acute maternal infection and pre-eclampsia 
This chapter describes the methods of a matched case-control study of acute maternal 
infection and pre-eclampsia using data from the GPRD. Primiparous women aged at 
least 13 years and registered with a participating practice between January 1987 and 
October 2007 were eligible for inclusion. All cases of pre-eclampsia and a random 
sample of pregnant women without pre-eclampsia (controls) were selected. Cases 
were individually matched with up to ten controls on practice, calendar year of 
delivery and gestational age. ORs and 95% CIs for pre-eclampsia were estimated 
comparing women exposed and unexposed to acute infection using multivariable 
conditional logistic regression. 
6.1 Study hypothesis and objectives 
The hypothesis was that acute infections in pregnancy may lead to an increased risk 
of pre-eclampsia. 
The primary objective was to: 
 Measure the effects of i) acute UTI, ii) acute systemic RTI, and iii) antibiotic 
prescriptions in pregnancy (a proxy for acute infection) on the risk of pre-
eclampsia. 
Secondary objectives were to: 
 Describe the occurrence of acute episodes of infection in each of the three 
pregnancy trimesters and assess the effect of the timing of infection on pre-
eclampsia risk. 
 Measure the effect of increasing numbers of episodes of acute infection on the 
risk of pre-eclampsia to establish whether there may be a dose-response 
relationship. 
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6.2 Description of the data source 
6.2.1 The General Practice Research Database 
The study used data from the Full Feature (pre-GOLD) version of the GPRD. The 
GPRD, founded in January 1987, is one of the world’s largest and best established 
research databases of population-based electronic primary care data. At the time of 
this study the database held anonymised longitudinal patient records for over ten 
million patients registered to over 600 UK general practices. More than 98% of the 
UK population are registered with a general practitioner (GP) and practices 
contributing to the database are representative of practices throughout the UK in 
terms of their size, geographical distribution and the age and sex distribution of 
patients.140  
Data are prospectively recorded at the patient level by each contributing practice and 
include medical diagnoses, prescribed medicines, hospital referrals, test results, 
lifestyle and demographic information, and additional clinical details on a variety of 
situations relating to patient care, including antenatal and postnatal care. Data 
recording guidelines to practices stipulate the recording of all significant clinical 
events in a patient’s medical history, including a summary of events which occurred 
prior to a patient’s registration with the practice, or prior to the practice contributing 
to the GPRD.141  
In addition to being a rich data source, the GPRD has high data validity. A recent 
systematic review of validation studies of GPRD diagnoses estimated a median 
positive predictive value of 89% for recorded diagnoses.142 Data are subject to 
ongoing evaluation, verification and validation procedures to ensure they are 
research-quality.143 At the patient level, individual patients with non-contiguous or 
poorly recorded data are identified as unacceptable for use in research and excluded. 
At practice level, each practice contributing to the GPRD is assigned an “up-to-
Standard” (UTS) date indicating when data recording by the practice adhered to 
specific quality measures based on an assessment of the completeness, continuity and 
plausibility of the data.144 Thus, data recorded by a practice from the UTS date are 
deemed high quality and fit for use in research.  
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6.2.2 Data structure and key elements 
Data on the defined study population were provided in multiple sets of text format 
files which could be linked using a unique patient identifier. Practice-level data were 
also provided, which could be linked to these patient-level data using a unique 
practice identifier. 
The patient file contained basic demographic information including gender, year of 
birth, details of registration with the practice, and, for approximately half the 
patients, an Index of Multiple Deprivation (IMD) score based on the postcode of the 
patient. The practice file included the UTS date and last data collection date for each 
contributing practice, and an IMD score based on the practice postcode.  
Clinical files comprised dated records of medical events, including clinical signs, 
symptoms and diagnoses, and feedback on diagnostic, therapeutic and surgical 
procedures. Test files included details of requests and results of diagnostic tests, and 
referral files documented patient referrals to secondary care and other services. 
Therapy files contained details of each drug prescription issued by the GP and the 
date of issue. The type and date of each patient consultation with their GP were 
provided in consultation files. 
Additional information relating to current and past pregnancies, including the 
number of births or miscarriages, expected delivery date, and the weeks’ gestation 
related to an antenatal booking, were recorded in the maternity file.  
For the majority of patients, additional data were available on blood pressure 
readings, smoking, and/or anthropometric measures.  
6.2.2.1 Coding systems 
Clinical entries in the Full Feature GPRD were coded using the Oxford Medical 
Information System (OXMIS) and Read coding system which allowed linkage of 
codes to the corresponding medical terms provided in a look-up file. Prescription 
drugs were coded using the Multilex Product coding system which provides detailed 
information on the drug, dose and route of administration. The corresponding drug 
names, drug substances and British National Formulary (BNF) codes and chapter 
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headings could be referenced by linking the Multilex product code to the products 
look-up file.  
GPRD Medical and Product dictionary browsers (version 0.3.7, Copyright © 2004) 
were also provided; these were used to build sets of medical and product codes to 
define specific events, diseases and drug treatments (see section 6.7.2). 
6.3 Study design 
A matched case-control study design was used to examine the association between 
acute maternal infections and pre-eclampsia. Cases (patients with pre-eclampsia) 
were individually matched with controls (patients who had completed a pregnancy 
without pre-eclampsia) on GP practice, calendar time of delivery, and gestational age 
defined as the duration of pregnancy starting from the first day of the woman’s last 
menstrual period (LMP) before delivery. Further comment on the choice of these 
matching variables, the rationale for using a matched design and details of the 
matching procedure are provided in section 6.5 
6.4 Participants 
Participants were derived from a source population of all female patients registered 
with practices meeting GPRD quality standards during the study period: from 1st 
January 1987 to 31st October 2007. 
Each participant’s period of UTS observation (and hence, UTS data) was identified 
as follows: the UTS start date was defined as the later of the practice UTS date and 
the patient’s registration date with the practice. Thus a patient who registered in 1987 
at a practice which became UTS at the start of January 1990 had UTS data from 1st 
January 1990. The UTS end date was defined as the earlier of the date the patient 
transferred out of the practice, their date of death, or the practice’s last data 
collection date (up to 31st October 2007).  
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6.4.1 Outcome 
The outcome of the study was pre-eclampsia, defined as a clinical diagnosis of pre-
eclampsia, eclampsia or the severe pre-eclampsia variant HELLP syndrome 
(haemolysis, elevated liver enzymes, low platelets).  
For the identification of potential cases when requesting data from the GPRD, a set 
of Read/OXMIS codes was compiled (see Table 6.1) following the strategy outlined 
in section 6.7.2.1, below.  
Because pre-eclampsia develops in the later stages of pregnancy, a patient must have 
completed a pregnancy to have had the opportunity to become a case. Therefore, 
only patients who had a recorded completed pregnancy in their primary care record 
were potentially eligible for inclusion in the study. Hence, for the identification of 
potential controls, an “end-of-pregnancy” code set was compiled of more than two 
thousand Read/OXMIS codes indicating that a patient had delivered, e.g. “birth 
details”, or was in the final stages of pregnancy, e.g. “antenatal 37 week 
examination”. Codes indicating early pregnancy loss due to miscarriage or 
termination (which could occur at any time prior to 24 weeks’ gestation and most 
often in the first trimester) were not included since such pregnancies were likely to 
end before a woman had reached the required gestational age to be at risk of 
developing clinical signs of pre-eclampsia. Thus, for the purpose of this study, a 
completed pregnancy was defined as one ending (or soon to end) in a live birth or 
stillbirth. 
Data were obtained from the GPRD on the following potential cases and controls, 
drawn from the source population on the basis of these pre-defined medical code 
sets: 
Potential cases (n=3362): all patients with a medical code for pre-eclampsia, 
eclampsia or HELLP syndrome in UTS data; 
Potential controls (n=93909): a random sample of patients with i) an end-of-
pregnancy code in UTS data, and ii) no medical codes for pre-eclampsia, eclampsia, 
HELLP syndrome, or history of pre-eclampsia.  
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Table 6.1 Pre-eclampsia medical codes. 
Medical code Medical term 
READ  
L124300 Mild or unspecified pre-eclampsia - not delivered 
L126600 Eclampsia in labour 
L126z00 Eclampsia NOS 
L127.00 Pre-eclampsia or eclampsia with pre-existing hypertension 
L127400 Pre-eclampsia or eclampsia with hypertension + p/n complication 
L125200 Severe pre-eclampsia - delivered with postnatal complication 
L124600 Pre-eclampsia, unspecified 
L125100 Severe pre-eclampsia – delivered 
L124.00 Mild or unspecified pre-eclampsia 
L124.12 Toxaemia NOS 
L126.00 Eclampsia 
L126300 Eclampsia - not delivered 
L127100 Pre-eclampsia or eclampsia with hypertension - delivered 
L129.00 Moderate pre-eclampsia 
L124000 Mild or unspecified pre-eclampsia unspecified 
L125z00 Severe pre-eclampsia NOS 
L126500 Eclampsia in pregnancy 
L124z00 Mild or unspecified pre-eclampsia NOS 
L126000 Eclampsia unspecified 
L125.00 Severe pre-eclampsia 
L126400 Eclampsia with postnatal complication 
L127000 Pre-eclampsia or eclampsia with hypertension unspecified 
L125000 Severe pre-eclampsia unspecified 
L124100 Mild or unspecified pre-eclampsia – delivered 
L124200 Mild or unspecified pre-eclampsia - delivered with p/n complication 
L125400 Severe pre-eclampsia with postnatal complication 
L126100 Eclampsia – delivered 
L127300 Pre-eclampsia or eclampsia with hypertension - not delivered 
L124.11 Mild pre-eclampsia 
L124400 Mild or unspecified pre-eclampsia with p/n complication 
L124500 Mild pre-eclampsia 
L125300 Severe pre-eclampsia - not delivered 
L12A.00 HELLP - Syndrome haemolysis, elevated liver enzyme low platelets 
L12B.00 Proteinuric hypertension of pregnancy 
L126200 Eclampsia - delivered with postnatal complication 
L127200 Pre-eclampsia or eclampsia with hypertension - delivered+p/n complication 
L127z00 Pre-eclampsia or eclampsia + pre-existing hypertension NOS 
Lyu1.00 [X] Oedema,proteinuria+hypertension in pregnancy,childbirth,puerperium 
Q000.11 Fetus affected by maternal toxaemia 
OXMIS  
7623 Toxaemia pregnancy affecting foetus/newborn 
6371PP Eclampsia post-partum 
7960TM Toxaemia 
6370A Toxaemia pre-eclamptic 
6370 Pregnancy pre-eclampsia 
6371 Pregnancy eclampsia 
6379 Toxaemia pregnancy 
NOS=not otherwise specified; p/n=postnatal; the prefix [X] is used for codes introduced with the migration to ICD10 in April 
1995.  
89 
 
6.4.2 Eligibility criteria 
Pre-eclampsia is more common in primiparous than in multiparous pregnancies145,146 
and therefore a large proportion of potential cases (included on the basis of 
developing pre-eclampsia) would have been in their first completed pregnancy. 
Parity may also be associated with the risk of acquiring acute infections in 
pregnancy, and was thus considered a potential confounder. Once data on potential 
cases and controls had been obtained, the study population was restricted further to 
patients on the basis of their first recorded completed pregnancy (to reduce the scope 
for confounding by parity). The methods used to identify participants’ first recorded 
completed pregnancies and to estimate the timing (start and end dates) of each 
pregnancy are reported in Chapter 7.  
Patients aged 13 years or older at the end of their first recorded completed pregnancy 
within the UTS period were potentially eligible for inclusion in the study.  
6.4.2.1 Case definition 
Cases were defined as patients with a first-ever clinical diagnosis of pre-eclampsia (a 
Read/OXMIS code for pre-eclampsia, eclampsia or HELLP syndrome listed in Table 
6.1) in their first recorded completed pregnancy.  
While the onset of pre-eclampsia typically occurs during the third trimester of 
pregnancy, clinical signs of the disease can manifest from as early as 20 weeks’ 
gestation up to 4 weeks postpartum147, as illustrated in Figure 6.1.  
Thus, to determine whether a patient’s first-ever pre-eclampsia record corresponded 
to their first recorded completed pregnancy (and not to a previous unrecorded or 
subsequent pregnancy), a time period was pre-specified within which the pre-
eclampsia record had to occur relative to the estimated date of delivery (EDD) of the 
first completed pregnancy (see Chapter 7 for details on how the EDD was derived). 
As illustrated in Figure 6.2, this time period started 28 weeks before the EDD and 
extended up to 15 weeks after the EDD. The choice of 28 weeks pre-EDD allowed 
for i) a first completed pregnancy of up to 42 weeks’ gestation (starting from the first 
day of the woman’s LMP before delivery), ii) a delay of up to six weeks in recording 
the delivery, and iii) an earliest pre-eclampsia diagnosis corresponding to this first 
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completed pregnancy at 20 weeks’ gestation. The choice of 15 weeks post-EDD 
allowed for i) an earliest subsequent pregnancy starting one week after delivery (of 
the first completed pregnancy), and ii) an earliest pre-eclampsia diagnosis 
corresponding to this subsequent pregnancy at 20 weeks’ gestation. Thus, cases 
whose earliest pre-eclampsia record was more than 28 weeks prior to the EDD or 
more than 15 weeks after the EDD were not included in the study, as it was assumed 
that their pre-eclampsia episode corresponded to an earlier (unrecorded) completed 
pregnancy or to a subsequent pregnancy. 
 
Figure 6.1 Pictorial representation of the timing of pre-eclampsia. 
LMP=Last menstrual period 
Pre-eclampsia is usually diagnosed in the presence of gestational hypertension 
associated with proteinuria. Thus for cases, additional data were extracted on 
hypertension diagnoses, blood pressure readings, the prescription of blood pressure 
lowering medication, and the presence of proteinuria. However, a pre-eclampsia 
diagnosis may be established in the absence of proteinuria by the presence of new 
onset hypertension in association with any of the following severe features: 
thrombocytopenia, impaired liver function, renal insufficiency, pulmonary oedema, 
or visual or cerebral disturbances.148 Furthermore, given that a substantial proportion 
of women were likely to have received shared antenatal care, data on hypertension or 
proteinuria during pregnancy may have been incomplete (the absence of these 
conditions documented in patient records did not preclude the presence of pre-
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eclampsia). For these reasons, data on hypertension and proteinuria did not form part 
of the case definition of pre-eclampsia and were used for descriptive purposes only.  
Gestational hypertension was defined as one or more of the following during 
pregnancy: 
 Read or OXMIS code for hypertension; 
 Prescription for antihypertensive medication defined as any product under 
BNF chapter 2.21 (thiazides and related diuretics), 2.4 (beta-adrenoceptor 
blocking drugs), 2.5 (hypertension and heart failure) or 2.6.2 (calcium-
channel blockers), and of 2.2.4 (potassium-sparing diuretics with other 
diuretics) any product which included "thiazide" as a drug substance; 
 Blood pressure reading of at least 140 mm Hg (systolic) or at least 90 mm Hg 
(diastolic) on at least two occasions. 
A record of either of the following during pregnancy was taken as evidence for 
proteinuria: 
 Read or OXMIS code for proteinuria; 
 Positive test result indicating more than a “trace” of protein in the urine. 
6.4.2.2 Control definition 
Controls were defined as patients with a first recorded completed pregnancy and with 
no clinical diagnosis of pre-eclampsia or history of pre-eclampsia recorded anywhere 
in their medical data. This ensured controls had no pre-eclampsia in their first 
recorded completed pregnancy, and no history of pre-eclampsia possibly relating to 
an earlier (unrecorded) pregnancy. 
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Figure 6.2 Linking the pre-eclampsia episode to the first completed pregnancy episode. 
LMP=last menstrual period 
6.4.2.3 Exclusions 
The following four exclusion criteria were applied to cases and controls: 
1. Uncertain timing of delivery 
Patients with either of the following were excluded: 
i. Delivery record on an invalid date (1st January 2500), which may represent 
a default date for a past delivery (see section 6.7.1);  
ii. Earliest delivery record on the same date as a new-patient or well-patient 
health visit, which may represent a past delivery retrospectively recorded 
with the wrong date.  
2. Evidence of an earlier (unrecorded) completed pregnancy  
Patients were excluded if their records indicated that they had completed an earlier 
pregnancy prior to their first recorded completed pregnancy. This was to help ensure 
that cases and controls were primiparous at the time of selection into the study, thus 
further reducing the possibility of confounding by parity. Evidence of an earlier 
completed pregnancy was defined as any of the following records at least six weeks 
before the EDD of the first recorded completed pregnancy, thus allowing for a delay 
of up to six weeks in recording the latter: 
93 
 
i. Postnatal record (indicating that a patient had given birth without 
specifying the timing postpartum), e.g. a Read code for “Postpartum 
depression”; 
ii. “History of” delivery record, e.g. a Read code for “History of postpartum 
haemorrhage”; 
iii. Parity status of one or more births recorded in the Maternity file.  
Records (of i, ii or iii) in the six weeks immediately preceding the EDD were not 
used as evidence of a previous pregnancy as they were considered more likely to 
correspond to the first recorded completed pregnancy whose outcome may have been 
recorded late. 
3. New onset hypertension in pregnancy persisted after delivery 
To strengthen the validity of the case definition of pre-eclampsia, patients with no 
evidence of pre-existing hypertension (no Read/OXMIS codes for hypertension or 
antihypertensive drug prescription records before pregnancy) but whose hypertension 
did not resolve following delivery (an antihypertensive drug prescription record six 
to 12 months after delivery) were excluded. This criterion helped to distinguish 
between true cases of pre-eclampsia and patients with essential or secondary 
hypertension which became clinically apparent during pregnancy. 
4. Part of the gestational period was outside the UTS observation period 
To ensure that the recording of diagnoses and events throughout the entire 
gestational period was research quality, patients whose pregnancies began prior to 
the UTS start date were excluded. Details of how each patient’s estimated pregnancy 
start date was derived are provided in Chapter 7. 
In addition, two case-only exclusion criteria were applied: 
1. Uncertain timing of pre-eclampsia 
Cases with either of the following were excluded: 
i. Pre-eclampsia record on an invalid date (1st January 2500), which may 
represent a default date for a past pre-eclampsia episode; 
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ii. Earliest pre-eclampsia record on the same date as a new-patient or well-
patient health visit, which may represent a past episode of pre-eclampsia 
retrospectively recorded with the wrong date.  
2. Evidence of an earlier (unrecorded) pre-eclampsia episode  
Cases whose records indicated an earlier pre-eclampsia episode (and hence an earlier 
unrecorded completed pregnancy) prior to the first recorded pre-eclampsia episode, 
e.g. a Read code for “History of pre-eclampsia”, were excluded. This criterion helped 
to ensure that cases were primiparous at the point of selection.  
6.4.3 Statistical power 
Power calculations were derived using methods outlined by Dupont (1988) for 
matched case-control studies.149 The statistical power of a matched case-control 
study can be increased by selecting more than one control per case.150 Although any 
additional gain in power is generally considered to be minimal if the case-control 
ratio exceeds 1:4, increasing this ratio may be desirable if the prevalence of exposure 
among controls is expected to be less than 0.15,151 or if analyses are to be stratified 
by other factors (potential confounders other than the matching variables).150 Both of 
these circumstances applied in this study. In addition, the number of controls 
identified as eligible for matching greatly exceeded the number of cases (by more 
than twenty-fold): thus, increasing the control-per-case ratio beyond four posed no 
additional cost or effort in data collection. For these reasons, the decision was taken 
to select up to ten controls per case.  
The power of the study to detect an OR for exposure to an acute maternal infection 
(UTI, RTI or antibiotic prescription during the gestational period) of at least 1.3 was 
estimated for a range of exposure prevalences among controls. Based on the number 
of pre-eclampsia cases identified as eligible for matching (n=1535), and allowing a 
case-control ratio of 1:10, the study had more than 90% power (at 5% significance) 
to detect the following: 
 OR of 1.5 or more if the prevalence of an acute maternal infection among 
controls (p0) was 5%;  
 OR of 1.4 or more if p0 was 10%; 
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 OR of 1.3 or more if p0 was 15%.  
6.5 Case-control matching 
Matching in a case-control study refers to the procedure whereby one or more 
controls are selected for each case on the basis of similarity with respect to certain 
characteristics other than the exposure(s) being investigated. The rationale for 
matching is to make adjustment for confounding in the analysis more efficient.150 
Without matching, such adjustment may result in multiple strata with sparse data. 
Balancing the distribution of matching variables across strata results in gains in 
precision and hence more stable effect estimates (ORs) with smaller standard errors 
and thus narrower CIs. However, matching will only increase efficiency if the 
matching variables are associated with both the disease and exposure and are not on 
the causal pathway linking the two. Thus, only potential confounders of the pre-
eclampsia and infection association were considered as candidate variables for 
matching in this study. 
6.5.1 Matching procedure 
With input from a statistician, an algorithm was developed to carry out a one-to-
many individual matching of cases to controls. Three matching criteria were chosen 
on the basis that each was thought to be associated with both the risk of being 
diagnosed with pre-eclampsia and the risk of being diagnosed with (or treated for) 
acute infection, and were thus potential confounders: i) GP practice; ii) calendar time 
of delivery (allowing an absolute difference of up to 12 months between the case-
control estimated delivery dates); and iii) gestational age. Matching on practice 
allowed for variability in recording and prescribing habits between practices, while at 
the same time providing some adjustment for unmeasured socioeconomic factors. 
Matching on delivery date within one year ensured that case and control pregnancies 
within matched sets were contemporaneous. Matching on gestational age ensured 
that the exposure period for cases and their matched controls was of a similar 
duration, hence allowing for a similar opportunity for infection. 
The following steps were taken to perform the matching: 
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i. All potential case-control matches were identified on the basis of GP 
practice; 
ii. Matches were excluded when case and control delivery dates were more 
than an absolute difference of 12 months apart; 
iii. Matches were excluded when the control had a shorter pregnancy than the 
case. When a control had a longer pregnancy than the case, this was 
curtailed to match the case’s gestational age at pre-eclampsia diagnosis, as 
outlined in section 6.6 below; 
iv. Of the remaining matches, up to ten controls per case were selected at 
random without replacement. 
The process generated matched sets, each comprising a single case and up to ten 
controls. Since cases and their matched controls were similar on these matching 
variables, their difference with respect to the outcome (pre-eclampsia) had to be 
attributable to other factors.  
6.6 Exposures  
In order to ascertain exposure to acute infections during pregnancy, it was first 
necessary to estimate the timing of each pregnancy. Full details of the methods used 
to date pregnancies in this study are provided in Chapter 7. 
The exposure period for each participant began on the estimated pregnancy start date 
(see Chapter 7, section 7.2.2 for details of how this date was derived) and ended at 
the index date. The index date was defined as follows: for cases, it was the earlier of 
the date of the pre-eclampsia diagnosis and the EDD; for controls it was the date they 
reached the same gestational age as their matched case at the case’s index date. 
Figure 6.3 illustrates the exposure period for a hypothetical case and matched 
control. 
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Figure 6.3 The exposure period for a hypothetical case and matched control: from the start of 
pregnancy to the index date. 
Data were extracted on three exposures of interest over the exposure period:  
- acute UTI (manifest as asymptomatic bacteriuria, cystitis, or pyelonephritis); 
- acute RTI (excluding non-specific or minor upper respiratory infections and 
symptoms such as sore throat); 
- antibiotic drug prescriptions.  
The Read/OXMIS codes and terms used to define acute UTI and RTI are listed in 
Appendix G-Tables G.1 and G.2. A preliminary list of antibiotic drug codes was 
compiled based on pre-defined headings within chapter 5.1 “Antibacterial drugs” of 
the BNF (see Table 6.2, below). Additional searches were conducted at the drug 
substance level to identify any relevant products not found in the preliminary search 
for which the BNF codes were missing. More than two thousand product codes for 
antibiotic drugs were identified and included in the final code set. 
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Table 6.2 British National Formulary (BNF) codes and headings for antibiotics. 
BNF code BNF chapter heading 
5.1.1 Penicillins 
5.1.1.1 Benzylpenicillin & phenoxymethylpenicillin 
5.1.1.2 Penicillinase-resistant penicillins 
5.1.1.3 Broad-spectrum penicillins 
5.1.1.4 Antipseudomonal penicillins 
5.1.1.5 Mecillinams 
5.1.2 Cephalosporins and other beta-lactams 
5.1.3 Tetracyclines 
5.1.4 Aminoglycosides 
5.1.5 Macrolides 
5.1.6 Clindamycin 
5.1.7 Some other antibacterials 
5.1.8 Sulphonamides & trimethoprim 
5.1.11 Metronidazole and tinidazole 
5.1.12 Quinolones 
5.1.13 Urinary-tract infections 
 
6.6.1 Quantifying and categorising exposure 
When a patient had more than one record of UTI, RTI or antibiotic prescription, a 
minimum of 29 days between successive records of the same type was required for 
these to be considered distinct episodes of infection, rather than repeat consultations 
for the same infection.  
Binary variables were created for each exposure of interest, indicating “exposed” 
versus “not exposed” at any time during the exposure period and during each of the 
three trimesters.  
To investigate the effect of the timing of infection over the exposure period, 
categorical variables were created for each exposure, each with four levels 
representing the most proximate exposure to the index date:  
i. no exposure (the reference category); 
ii. trimester one only;   
iii. trimester two (+/- trimester one);  
iv. trimester three (+/- trimester one or two).  
Thus, a patient diagnosed with an acute UTI in the first trimester and who 
experienced a second episode in the third trimester was assigned to exposure level iv.  
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To measure the effect of increasing episodes of infection, categorical variables were 
created for each exposure, each with three levels:  
i. no episodes (the reference category); 
ii. one episode;  
iii. more than one episode.  
6.6.2 Potential confounders 
In addition to maternal age and the matching variables practice, calendar year of 
delivery and gestational age at index date, detailed code sets and algorithms were 
developed for extracting information on established or potential confounders of each 
pre-eclampsia-infection association of interest: 
- Read/OXMIS codes for pre-existing comorbidities: renal disease, diabetes, 
hypertension, and asthma; 
- Multilex product codes for insulin and for anti-diabetic, anti-hypertensive and 
anti-asthmatic drugs (used as evidence of pre-existing diabetes, hypertension 
and asthma in the absence of medical codes for these conditions); 
- Read/OXMIS codes for multifetal gestation and previous early pregnancy 
loss; 
- Lifestyle factors: pre-pregnancy BMI and maternal smoking (a known 
protective factor).  
To address the possibility that infections may be more likely to be recorded among 
women who consult with their GP more frequently, data were extracted on the 
number of consultations and duration of follow-up each woman had prior to 
pregnancy. This allowed comparison of cases’ and controls’ pre-pregnancy 
consultation behaviour. 
6.6.2.1 Estimating pre-pregnancy BMI 
Data on pre-pregnancy BMI were derived from height and weight records or taken 
directly from BMI records (where available). Once all records of BMI, weight and 
height had been extracted, data were checked for outliers. Records which fell within 
the following pre-specified ranges of plausible values were retained:  
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- weight: 25.4-222 kilograms (kg);  
- height: 1.3-2.3 meters (m);  
- BMI (both recorded and derived measures): 15-50 kg/m2. 
When a patient had multiple records of height or weight on same day, the difference 
between the minimum and maximum values were generated; if the difference was ≤5 
cm (height) or ≤2 kg (weight) the average of these values were taken, if the 
difference exceeded 5 cm or 2 kg the records were dropped.  
Given that height is likely to be relatively stable beyond adolescence, the record 
closest to conception (either pre- or post-conception) was selected. Because an 
individual’s weight can fluctuate over time, the most proximate record either pre-
conception or up to eight weeks post-conception was selected as the best estimate of 
pre-pregnancy weight or BMI. Weight or BMI records more than eight weeks after 
conception may reflect gestational weight gain and were thus not used to estimate 
pre-pregnancy BMI.  
While some patients had no information on BMI, others had both recorded and 
derived estimates. In such cases, the estimate closest to conception was selected. A 
categorical variable for pre-pregnancy BMI was thus generated according to standard 
categories for adults, with an additional category for “unknown”:  
i. Underweight (<18.5 kg/m2) 
ii. Normal (18.5-24.9 kg/m2) 
iii. Overweight (25.0-29.9 kg/m2)  
iv. Obese (≥30 kg/m2)  
v. Unknown  
6.6.2.2 Estimating maternal smoking status 
Data on maternal smoking were limited (>80% of cases and controls had no smoking 
status recorded during pregnancy), thus the decision was taken to supplement this 
with information on smoking status prior to conception. Because an individual’s 
smoking status can change over time, the closest record prior to conception was 
selected as the best estimate of a patient’s smoking status at the time of conception. 
When a patient had multiple records during pregnancy, possibly indicating more than 
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one status (current smoker, ex-smoker or non-smoker), “current” took precedence 
over “ex”, and both of these superseded “non”. Hence, two smoking variables were 
generated indicting smoking status before and during pregnancy, from which patients 
were assigned to one of the following categories: 
1. Non-smoker (status “non” during pregnancy) 
2. Ex-smoker (status “ex” during pregnancy) 
3. Current smoker (status “current” during pregnancy) 
4. Unknown-non (status “unknown” during pregnancy and “non” pre-
pregnancy) 
5. Unknown-ex (status “unknown” during pregnancy and “ex” pre-pregnancy) 
6. Unknown-current (status “unknown” during pregnancy and “current” pre-
pregnancy) 
7. Unknown (status “unknown” both during and pre-pregnancy) 
To assess whether information on smoking status pre-pregnancy could be used as a 
proxy for smoking status during pregnancy (when the latter was unknown), ORs for 
pre-eclampsia were calculated and compared for each smoking category relative to 
non-smokers (category 1). The rationale was that if, for example, women who 
smoked before pregnancy (according to their most proximate record prior to 
conception) continued to smoke during pregnancy, the ORs for categories 3 and 6 
(relative to 1) would be similar. The similar effect estimates derived for categories 3 
and 6, for categories 2 and 5, and the close to null value for category 4 (as shown in 
Appendix H-Table H.1) indicated that this was a reasonable assumption. Thus, these 
seven smoking categories were combined to generate a single variable that best 
captured maternal smoking status: 
i. Non-smoker (status is “non” during pregnancy or status is “unknown” during 
pregnancy and “non” pre-pregnancy) 
ii. Ex-smoker (status is “ex” during pregnancy or status is “unknown” during 
pregnancy and “ex” pre-pregnancy)  
iii. Current smoker (status is “current” during pregnancy or status is “unknown” 
during pregnancy and “current” pre-pregnancy) 
iv. Unknown (status is “unknown” both during and pre-pregnancy)  
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6.7 Data management  
Despite the quality checks applied to GPRD data before they are made available for 
research, some additional checks, data cleaning and coding were necessary, as 
outlined below. 
6.7.1 Extracting and cleaning data 
Data were extracted on demographic characteristics (year of birth, practice, SES); 
medical codes used to identify cases and controls, exposures and potential 
confounders; prescription drug codes; and patient registration details. Key data fields 
were checked for missing values and outliers. Missing or incomplete dates were 
recorded in the GPRD as 1st January 2500. Records with this default date were thus 
assumed to represent past events or diagnoses for which the precise timing was 
uncertain.  
Information on the day and month of birth were not provided. Therefore, each 
patient’s date of birth was estimated as 1st July of their year of birth, thus allowing a 
maximum error margin of six months for age.  
6.7.2 Creating code sets 
In order to identify individuals with records of a particular disease, medical event or 
prescribed drugs to treat a condition, it was necessary to compile sets of codes 
defining each disease, event and drug treatment of interest. The procedure was 
iterative, involving the initial identification of all potentially relevant codes through 
searches of the GPRD dictionaries. The codes were then independently reviewed by 
two clinicians and final versions of each code set were agreed.  
6.7.2.1 Medical code sets  
The GPRD Medical dictionary browser was used to build sets of medical codes. The 
dictionary includes the GPRD assigned medical code for the type of event, the Read 
or OXMIS code for the event and a description of the medical term. Potential Read 
and OXMIS terms were identified using a two-stage search strategy. First, a list was 
compiled of key terms describing the event or disease. Using the wild card (*), these 
terms (or term stems) were used to search the GPRD dictionary. For example, 
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searching for *pre-eclam* identified terms including “Pre-eclampsia”, “Severe pre-
eclampsia with postnatal complication” and “Pre-eclampsia or eclampsia with 
hypertension”. Read codes group and define diseases and other clinical events within 
a hierarchical structure, with top level codes for broad disease categories branching 
into more specific codes. Therefore, stage two involved identifying relevant top level 
Read codes and including the lower level codes.  
The final sets of Read and OXMIS codes defining the study outcome (pre-eclampsia) 
and two exposures of interest (acute UTI and RTI) are listed in Table 6.1 and 
Appendix G-Tables G.1-G.2, respectively.  
6.7.2.2 Product code sets 
The GPRD Product dictionary browser was used to build sets of product codes. The 
dictionary includes the Multilex product code for the prescription, the product name, 
the composite drug substances and (where available) the corresponding BNF code 
and chapter heading. All prescription records had a Multilex code which could be 
referenced in the product dictionary. However, some Multilex codes had no 
corresponding BNF code if, for example, the drug was no longer licensed. Thus, to 
ensure all relevant products were included in a code set, a two-stage search strategy 
was implemented. First, all relevant BNF chapter headings were identified (Table 
6.2) and the dictionary was searched for all products under these headings. Second, a 
list of all drug substances within the products identified in stage one was reviewed 
and additional searches were conducted at the drug substance level to identify any 
relevant products missed in the first stage.  
6.8 Statistical analysis  
Data analyses were conducted using Stata, release 12 (StataCorp., College Station, 
Texas).  
6.8.1 Descriptive analyses 
Characteristics of study participants including demographic and lifestyle factors, pre-
existing morbidities, pregnancy characteristics, and the timing and number of acute 
infection episodes over the exposure period were summarised for cases and controls 
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separately. Proportions were calculated for categorical variables. For continuous 
variables, means (with standard deviations) or, where data were skewed, medians 
(with IQRs) were calculated.  
For cases, the severity of pre-eclampsia was determined according to the 
Read/OXMIS codes for pre-eclampsia which made up a single episode, defined as all 
successively recorded codes within 28 days apart (as for infection episodes, section 
6.6.1). When an episode comprised multiple codes indicating varying degrees of 
severity (ranging from non-specific to mild/moderate or severe pre-eclampsia, 
through to eclampsia or HELLP syndrome), the decision was taken to classify the 
case according to the most severe indication given the potential for the syndrome to 
develop. For example, where an episode contained a non-specific code and a code for 
severe pre-eclampsia, the case was classified as severe. 
6.8.2 Primary analysis 
To account for the individual matching carried out at the design stage, conditional 
logistic regression was used to estimate ORs and 95% CIs for pre-eclampsia 
comparing pregnant women exposed and not exposed to each exposure of interest: 
acute UTI, RTI or antibiotic prescriptions.  
The primary analysis assessed the effect of each exposure of interest occurring at any 
time during the exposure period. First, univariable analyses were conducted to 
estimate crude effects for all explanatory variables, including the exposures of 
interest. Potential confounding factors (outlined in section 6.6.2) found to be 
independently associated with pre-eclampsia in univariable analyses (determined by 
a p-value ≤0.2) were subsequently assessed in more complex, multivariable models. 
Maternal age (controlled for in five-year age groups: <20, 20-24, 25-29, 30-34, 35-
39, and ≥40) and pre-existing renal disease were included in all multivariable models 
a priori. The remaining potential confounders were each added to models in 
succession based on their strength of association with pre-eclampsia (in decreasing 
order), and were retained if they made an appreciable difference to the exposure of 
interest OR (determined by ≥10% change in either direction) and/or the likelihood 
ratio test indicated an improved model fit with their inclusion, or (in borderline 
cases) if their inclusion did not markedly compromise the precision of the exposure 
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effect. Variables excluded at earlier stages of the modelling process were later re-
introduced to assess whether the presence of other factors altered their effect on the 
infection-pre-eclampsia association of interest.  
6.8.3 Secondary analyses 
Using the same methods as for the primary analysis and the categorical exposure 
variables described in section 6.6.1, the effects of infection occurring at different 
stages of pregnancy and of increasing episodes of infection over the exposure period 
were examined for each exposure of interest. To assess whether the timing of 
infection may be important, adjusted ORs and 95% CIs for pre-eclampsia were 
estimated comparing women exposed (according to the most proximate episode to 
the index date) versus women not exposed at any time during the exposure period. 
To assess whether there may be a dose-response effect of infection on pre-eclampsia 
risk, adjusted ORs and 95% CIs for pre-eclampsia were estimated for women with a 
single episode of infection, and for women with more than one episode, relative to 
women not exposed at any time during the exposure period.  
6.8.4 Sensitivity analyses 
Misclassification of UTI due to proteinuria 
It was recognised that bias may have arisen due to possible misdiagnosis of UTI 
among patients with pre-eclampsia due to the identification of proteinuria. To 
address this possibility, a sensitivity analysis was done assessing the effects of early 
exposure to UTI or antibiotics in the first two trimesters only versus no exposure (to 
UTI or antibiotics) at any time during the exposure period, among a subset of the 
study population: cases who developed pre-eclampsia in the third trimester and their 
matched controls. The rationale was that these third trimester pre-eclampsia cases 
were unlikely to have had proteinuria detected during the first two trimesters, thus 
minimising the potential for such differential misclassification of exposure. 
Incident versus past or prevalent infections 
An inflated incidence rate of acute events, such as UTIs or RTIs, has been 
demonstrated in the period following registration with a practice, resolving to 
baseline over approximately six months.152 In order to ensure that the infections 
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observed throughout the exposure period were incident and did not represent 
diagnoses for past infections retrospectively recorded within the first few months 
after a patient joined a practice, a sensitivity analysis was done excluding patients 
with less than six months UTS follow-up prior to their estimated pregnancy start 
date.  
Pre-eclampsia diagnoses before year 2000 
To address the possibility that pre-eclampsia diagnoses made in earlier years may 
have been less exact, analyses were restricted to pregnancies in the year 2000 
onwards following publication of the first recommended consensus definition of pre-
eclampsia.153  
Timing and severity of pre-eclampsia 
Pre-eclampsia is usually defined as “early-onset” when clinical manifestations occur 
before 34 weeks’ gestation, and “late-onset” when occurring at or after 34 weeks’ 
gestation.154 To assess whether the effect of acute infection differed according to the 
timing of pre-eclampsia onset or the severity of the syndrome, separate analyses were 
performed for cases with early-onset pre-eclampsia (<34 weeks’ gestation) and late-
onset pre-eclampsia (≥34 weeks’ gestation), and for cases with documented severe 
pre-eclampsia, eclampsia or HELLP syndrome. 
Additional sensitivity analyses were performed, excluding the following:  
 Patients aged less than 18 years as they may differ from older women with 
respect to their pregnancy outcomes and underlying risk profile;  
 Patients with pre-existing hypertension, to reduce the possibility of 
misdiagnosis of pre-eclampsia;  
 Controls with new onset hypertension during pregnancy which resolved in the 
6-12 months after delivery (as determined by an absence of antihypertensive 
prescription records during this period), as these controls may have had pre-
eclampsia even in the absence of a clinical diagnosis;  
 Assisted reproductive technology (ART) pregnancies, defined as in vitro 
fertilization with or without intracytoplasmic sperm injection, and related 
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techniques including gamete intrafallopian transfer and embryo transfer, 
which may have a higher risk of developing pre-eclampsia. 
6.9 Ethics approval 
Ethics approval for the study was obtained from the Independent Scientific Advisory 
Committee (ISAC) (protocol 07_094) and the London School of Hygiene and 
Tropical Medicine Ethics Committee (application number 5283). 
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Chapter 7  Dating pregnancies in the GPRD 
This chapter outlines the methods used to estimate the timing of pregnancies for 
participants included in the case-control study of pre-eclampsia (described previously 
in Chapter 6). It was crucial to establish when participants’ pregnancies started and 
ended in this study, as this represented the exposure period of interest during which 
acute infections were identified.  
Pregnancy is measured in trimesters from the first day of a woman’s LMP (two 
weeks before conception) and normally lasting 37 to 42 weeks to delivery. While 
data pertaining to pregnancy are included in the GPRD, the timing of conception (or 
first day of the LMP) is rarely recorded. In addition, not all completed pregnancies 
have a timely, or indeed any, delivery record in the general practice data. The 
absence of such details on the precise timing of pregnancies in the GPRD presented a 
major challenge for the pre-eclampsia study, which relied on the ability to ascertain 
exposure to infections during the gestational period. Hence, development of a 
strategy to identify the start and end dates of pregnancy in GPRD patients was 
required. 
7.1 Previous work to identify pregnancies in EHR databases 
Previous approaches to identify pregnancies and classify gestational periods in the 
GPRD and in other EHR databases in the absence of LMP or conception data are 
outlined below.155–158 While providing a useful basis on which to build a new 
strategy (described in section 7.2 below), each approach was limited in its ability to 
reliably estimate the timing of the start of pregnancy. Thus none were considered 
suitable for application in the pre-eclampsia study.  
The earlier of two algorithms for identifying pregnancies in the GPRD, developed by 
Hardy et al,155 used a “pregnancy-indicator” approach. This involved mapping early 
pregnancy markers (e.g. an antenatal visit, positive pregnancy test, or any pregnancy-
related diagnosis or procedure) to pregnancy outcomes (e.g. birth, spontaneous 
abortion), allowing up to 280 days (40 weeks) between pregnancy markers and 
outcomes. The authors subsequently estimated the first pregnancy trimester as the 70 
day period after the earliest pregnancy marker, allowing for the fact that the first 
109 
 
documentation of pregnancy (the earliest pregnancy marker) was likely to be several 
days/weeks after conception.156  
A simpler approach to identify pregnancies in a Health Maintenance Organisation 
automated database was taken by Andrade et al,157 whose “delivery date” algorithm 
involved counting back 270 days from the delivery date to estimate the timing of 
conception; hence the algorithm assumed all pregnancies were of equal duration 
(lasting 270 days from conception to delivery). The period between 181 and 270 
days before delivery was considered a proxy for the first pregnancy trimester.  
Despite their different approaches, both algorithms were similarly limited in their 
application: the pregnancy-indicator algorithm156 excluded women whose first 
recorded antenatal visit was less than seven months before delivery (among whom 
were women who began antenatal care late and/or some who delivered prematurely), 
and the delivery date algorithm157 excluded women with documented conditions 
associated with preterm birth. While the purpose of these exclusions was to reduce 
misclassification of first trimester exposures among women with shorter gestations 
or late entry into antenatal care, these exclusions also undermined the utility of the 
algorithms, particularly for studies such as the case-control study carried out for this 
thesis (described in Chapter 6), whose outcome of interest (pre-eclampsia) is 
associated with shorter gestations97 and possibly also later antenatal care. A study 
comparing the performance of the two algorithms in identifying exposure to first 
trimester prescription medications found that Andrade et al’s delivery date algorithm 
resulted in greater sensitivity (90.0%) and specificity (99.3%) for identifying 
medication use than Hardy et al’s pregnancy-indicator algorithm (sensitivity: 56.4%, 
specificity 97.7%).159 However, almost all of these pregnancies were among women 
who delivered at term; as expected, the sensitivity of the delivery date algorithm was 
markedly diminished for preterm deliveries (65.8%).  
A more recent paper by Devine et al reported on the development of a computer-
based algorithm for identifying pregnancies in the GPRD.158 In contrast to the 
previous approaches described above which attempted to identify the start of 
pregnancy by counting back a fixed number of days from the pregnancy outcome, 
this method used a number of rules, allowing a variable number of days between the 
earliest pregnancy marker and the outcome, thus improving the identification of 
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pregnancies with outcomes other than full-term birth. The rationale was that 
pregnancies ending in stillbirth or live preterm delivery span a range of gestational 
ages (from as early as 24 weeks) and can appear to overlap with other pregnancies 
(and hence go undetected) when a fixed-day approach is used.  
Despite the clear advantage of Devine et al’s variable-day approach, it too was 
limited in its ability to estimate the precise timing of the start of pregnancy, as the 
earliest indication of pregnancy in a patient’s records (e.g. “patient pregnant”) is not 
a good proxy for the pregnancy start date as it would invariably be late. Notably, 
neither of the two GPRD-based algorithms155,158 fully exploited information from 
individual pregnancy records that reported gestational age (e.g. “pregnancy 
prolonged – 41 weeks”) or the time period postpartum (“Maternal postnatal 6 week 
exam”), to inform the timing of conception or delivery.  
7.2 A new approach to dating pregnancies in the GPRD 
Drawing from the previous approaches described above, and from discussions with 
researchers at the University of Nottingham and University College London who had 
undertaken pregnancy-related studies using EHRs, a new algorithm was developed 
for use in the pre-eclampsia study to estimate as accurately as possible the start and 
end dates of each participant’s first recorded completed pregnancy. The algorithm is 
described in detail in sections 7.2.1 and 7.2.2 below. In brief, it involved extracting 
and using in a hierarchy all available general practice-recorded information on the 
timing of pregnancy from: 
 antenatal records (medical codes indicating the weeks’ gestation related to an 
antenatal booking); 
 delivery records (medical codes indicating gestational age at delivery or the 
number of days or weeks postpartum);  
 records indicating the expected date of delivery and/or the estimated date of 
conception (EDC) (when available).  
Given that each woman must have completed a pregnancy in order to be considered 
eligible for the pre-eclampsia study, the process began with estimating the date of 
delivery (see section 7.2.1) corresponding to their first recorded completed 
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pregnancy. Subsequently, the pregnancy start date was determined (see section 7.2.2) 
based on gestational age and thus defined as the date of the first day of the woman’s 
LMP before delivery. A common convention was used to estimate the timing of 
trimesters: first trimester (first day of the LMP to 13 weeks), second (weeks 14 to 
26), and third (week 27 to delivery).  
7.2.1 Estimating the date of delivery  
As described in Chapter 6 (section 6.4.1), an “end-of-pregnancy” code set was 
compiled of Read/OXMIS codes which represented a completed pregnancy (i.e. 
codes specifying the birth outcome or mode of delivery, or indicating that the woman 
was close to term), using the strategy outlined in section 6.7.2.1. This “end-of-
pregnancy” code set was used to estimate the date of delivery of case and control 
pregnancies, as follows.  
First, each code was assigned to one of the following mutually exclusive categories:  
1. Birth outcome, e.g. “Caesarean section”; 
2. Very late pregnancy: likely to be one to two days before delivery, e.g. 
“Premature rupture of membranes”; 
3. Very early postnatal: up to one week after delivery, e.g. “Repair of 
episiotomy”; 
4. Early postnatal: one to six weeks after delivery, e.g. “Postnatal – tenth day 
visit”; 
5. Late pregnancy: up to six weeks before delivery, e.g. “Cephalic version”; 
6. Other postnatal: any other postnatal code indicating a patient had given birth, 
but where the timing postpartum was uncertain e.g. “Postnatal depression”. 
Category 1-4 codes were combined to form a single set of delivery codes and extra 
information within these codes (when available) was used to derive the EDD, as 
outlined below. Category 5 codes were considered to be proxy delivery codes and 
hence were also used to determine the EDD. While category 6 codes indicated that a 
patient had given birth, they did not specify the time period postpartum, and hence 
could not be used to determine the EDD. However, any such codes recorded more 
than six weeks before the EDD were subsequently used as evidence of an earlier 
completed pregnancy, an exclusion criterion, as outlined in Chapter 6, section 
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6.4.2.3. Hence, only codes in categories 1-5 were used to estimate the date of 
delivery of participants’ first completed pregnancies (see Appendix G-Table G.3).  
Using these category 1-5 codes, the following steps were taken to derive the EDD, as 
illustrated in Figure 7.1: 
 Step 1. Identifying patients’ earliest delivery records 
Clinical, referral and maternity files of each potential case and control were searched 
for delivery codes (categories 1-4), and those recorded within ten years of the 
patient’s year of birth (records which were likely to relate to the patient’s own birth 
rather than her infant’s birth) were excluded. Each patient’s earliest delivery record 
(or records, if more than one on the same day) was selected.  
The next step depended on whether the patient had at least one delivery record or no 
delivery records, as outlined below. 
Step 2.i. Estimating the date of delivery for patients with a delivery code 
For patients with at least one delivery record identified in Step 1, additional data 
were extracted on: 
a. Late pregnancy (category 5) codes corresponding to an earlier pregnancy 
within the study period. This was to identify earlier completed pregnancies 
that had no corresponding delivery records. These codes were recorded more 
than 24 weeks prior to the patient’s earliest delivery record, as illustrated in 
Figure 7.2. The choice of 24 weeks was based on the minimum gestation of a 
completed pregnancy (lasting 24 weeks from the first day of LMP), thus 
allowing a minimum of 24 weeks between two successive deliveries. When a 
patient had more than one late pregnancy code, codes recorded within six 
weeks of each other were assumed to correspond to the same pregnancy; 
b. Information on the number of days or weeks postpartum within the earliest 
delivery record(s);  
c. Late pregnancy (category 5) codes corresponding to the same pregnancy as 
the earliest delivery record (codes recorded less than 24 weeks prior to the 
earliest delivery record), also shown in Figure 7.2.  
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Figure 7.1 Deriving the estimated date of delivery (EDD) of participants’ first recorded 
completed pregnancies.
Initial sample of 
pregnant women
STEP 1
Identify earliest delivery records
≥ 1 delivery record 
(category 1-4 code)?
Yes
STEP 2.i
Derive EDD for patients with a delivery 
record
≥ 1 late pregnancy record 
(category 5 code) for an 
earlier pregnancy?
Yes
EDD=date of latest 
late pregnancy record 
for earliest pregnancy 
plus no. days to full 
term
No
Information on 
days/weeks 
postpartum within 
delivery records?
Yes
EDD=date of earliest delivery 
record minus no. days 
postpartum
No
≥ 1 late pregnancy record (category 5 
code) for first recorded completed 
pregnancy?
Yes
EDD=earlier of i) date of latest late pregnancy record 
plus no. days to latest post-term delivery (42 weeks' 
gestation); and ii) date of earliest delivery record 
No
EDD=date of earliest 
delivery record
No 
STEP 2.ii
Derive EDD for patients with no delivery 
records
≥ 1 late pregnancy 
record (category 5 
code)?
Yes
EDD=date of latest 
late pregnancy record 
for earliest pregnancy 
plus no. days to full 
term
No 
Excluded from 
study
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Using all available information on a, b, and c and the following hierarchy of rules 
(summarised in Figure 7.1), a single best estimate of the date of delivery 
corresponding to a patient’s first recorded completed pregnancy was derived:  
 For patients with a (a late pregnancy record corresponding to an earlier 
pregnancy), the date of the latest a record corresponding to the earliest 
pregnancy was used to estimate the date of delivery, by adding on the appropriate 
number of weeks to full term (at 40 weeks’ gestation), e.g. for a record of 
“Antenatal 36 week exam”, four weeks were added to arrive at the EDD. 
 For patients with b (information on days/weeks postpartum), and not a, the date 
of the earliest delivery record was adjusted by counting back the specified 
number of days, e.g. for a record of “Postnatal tenth day visit”, ten days were 
subtracted to arrive at the EDD. 
 For patients with c only (a late pregnancy record corresponding to the same 
pregnancy as the earliest delivery record), the date of the latest c record was 
identified and adjusted by adding on the appropriate number of weeks to post-
term at 42 weeks (allowing for a latest possible delivery at 42 weeks), e.g. for a 
record of “Antenatal 41 week exam”, one week was added. The earlier of this 
adjusted date and the date of the earliest delivery record was then selected as the 
EDD. Figure 7.3 illustrates this process using two hypothetical completed 
pregnancies, A (post-term) and B (preterm).  
 For patients with no a, b or c records, the date of the earliest delivery record was 
selected as the EDD. 
Step 2.ii. Estimating the date of delivery for patients without a delivery code 
Clinical, referral and maternity files of patients with no delivery records identified 
in Step 1 were searched for late pregnancy records (category 5 codes). As for Step 
2.i, successive records within six weeks of each other were assumed to correspond to 
the same pregnancy. The date of the latest late pregnancy record corresponding to 
the earliest pregnancy was selected. The date of delivery was then estimated by 
adding on the appropriate number of weeks to full term (e.g. for a record of 
“Antenatal 39 week exam”, one week was added to arrive at the EDD).  
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Figure 7.2 Mapping late pregnancy records onto pregnancy episodes. 
a When an earlier completed pregnancy was identified on the basis of a late pregnancy record, that pregnancy was used in the 
study (see Section 7.2.1, Step 2.i). 
After completing Steps 1-2.ii, all patients with a delivery record or a late pregnancy 
record were assigned an EDD for their first recorded completed pregnancy. 
Appendix I-Figures I.1 and I.2 illustrate the participant flow through this process for 
all potential cases and controls. Patients with no delivery or late pregnancy records, 
for whom it was not possible to estimate the date of delivery, were not eligible for 
the study (as described previously in Chapter 6, section 6.4.1).  
The frequency distribution of codes used to estimate the date of delivery of study 
participants’ first completed pregnancies is shown in Appendix G-Table G.3. 
7.2.2 Estimating the pregnancy start date 
Once each participant had been assigned an EDD corresponding to their first 
recorded completed pregnancy, the following steps were taken to estimate the 
pregnancy start date (the date of the first day of the woman’s LMP before delivery), 
as illustrated in Figure 7.4. 
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Figure 7.3 Deriving the estimated date of delivery (EDD) for patients with both a delivery 
record and a late pregnancy record corresponding to their first recorded completed pregnancy. 
LMP=last menstrual period 
The figure illustrates two hypothetical scenarios: A, a post-term pregnancy with delivery at 42 weeks; 
and B, a preterm pregnancy with delivery at 38 weeks. In both scenarios, the latest late pregnancy 
record is identified and an adjusted late pregnancy date is calculated by adding on the appropriate 
number of weeks to the latest possible delivery (at 42 weeks). However, in A, the adjusted date is 
earlier than the earliest delivery record, hence the former is selected as the EDD, whereas in B, the 
adjusted date is later than the earliest delivery record, hence the latter date is selected as the EDD.  
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Step 3. Extracting information on the timing of the start of pregnancy 
Clinical, referral and maternity records of patients with an EDD were searched for 
the following: 
d. Read/OXMIS antenatal codes with information on gestational age (e.g. 
“Antenatal ultrasound scan at 22 weeks”), or a recorded estimate of weeks’ 
gestation related to an antenatal booking in the maternity file. 
e. Read/OXMIS code for “Estimated date of conception” (EDC) or “Expected 
date of delivery”, calculated manually by GPs or automatically by practice 
software as two weeks after the first day of the LMP (EDC) and 40 weeks 
after the first day of the LMP (expected date of delivery); 
f. Read/OXMIS delivery codes providing information on gestational age at 
birth, e.g. “Baby premature 36 weeks”.  
Estimates of the pregnancy start date (i.e. the date of the first day of the LMP before 
delivery) were derived from each of these records, as described in Step 4, below. 
This resulted in multiple LMP estimates for some patients, sometimes relating to 
more than one pregnancy. LMP estimates corresponding to a patient’s first recorded 
completed pregnancy were determined by allowing a minimum gestation of 24 
weeks and a maximum gestation of 42 weeks between the LMP date and EDD. All 
remaining LMP estimates which did not correspond to a patient’s first recorded 
completed pregnancy were excluded.  
Step 4. Obtaining a best estimate of the pregnancy start date  
Using all available information on d, e, and f (extracted in Step 3) and the following 
hierarchy of rules (summarised in Figure 7.4), a single best estimate of the pregnancy 
start date for each patient’s first recorded completed pregnancy was derived:  
 For patients with d (antenatal records indicating gestational age), the pregnancy 
start date was estimated by subtracting from the date of the antenatal record the 
specified number of weeks’ gestation, e.g. subtracting 16 weeks from the date 
corresponding to a record of “Antenatal 16 weeks exam”. If a patient had more 
than one “weeks’ gestation” record corresponding to their first recorded 
completed pregnancy, the record specifying the longest weeks’ gestation was 
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used to derive the pregnancy start date. The rationale was that estimates of 
gestational age from an antenatal examination or scan are likely to be more 
reliable than a patient’s recall of their LMP, and the later the scan, the more 
reliable the estimate of weeks’ gestation.  
 For patients with e (EDC or “expected date of delivery”) and not d, the 
pregnancy start date (based on gestational age) was estimated by subtracting 40 
weeks from the expected date of delivery or two weeks from the EDC. If a 
patient had more than one EDC or “expected date of delivery” record 
corresponding to their first recorded completed pregnancy, the record yielding 
the latest LMP estimate was used to derive the pregnancy start date. The 
rationale was that the latest estimate was least likely to correspond to an earlier 
pregnancy (ending in miscarriage, for example). 
 For patients with f only (information on gestational age at delivery), the 
pregnancy start date was estimated by subtracting from the date of the delivery 
record the specified number of weeks’ gestation. When a delivery code indicated 
a range of gestational ages, for example, “Baby extremely premature 28-32 
weeks” the mid-point (30 weeks) was used. If a patient had more than one record 
of gestational age at birth corresponding to their first recorded completed 
pregnancy, the earliest record was used to derive the pregnancy start date. The 
rationale was that the earliest record was most likely to represent the timing of 
delivery, with later records possibly reflecting some delay in recording.  
 For patients with no d, e or f records, the pregnancy start date was estimated by 
subtracting 40 weeks from the EDD. 
After completing Steps 3 and 4, each patient was assigned an estimated pregnancy 
start date corresponding to their first recorded completed pregnancy. Appendix I-
Figures I.3 and I.4 illustrate the participant flow through this process for potential 
cases and controls with an EDD. 
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Figure 7.4 Estimating the pregnancy start date of participants’ first completed pregnancies. 
All women with an 
estimated date of 
delivery (EDD)
STEP 3
Extract information on timing of start of pregnancy
STEP 4
Obtain a best estimate of the pregnancy start date
≥ 1 antenatal record of 
weeks' gestation?
Yes
Pregnancy start date=date 
of antenatal record with 
longest weeks' gestation 
minus no. weeks' gestation
No
≥  1 record of "Estimated 
date of conception" or 
"Expected delivery date"?
Yes
Pregnancy start date="Estimated date of 
conception" minus 2 weeks or "Expected 
delivery date" minus 40 weeks
No
≥ 1 delivery record with 
information on gestational age at 
delivery?
Yes
Pregnancy start date=date of 
earliest delivery record minus no. 
weeks' gestation
No
Pregnancy start 
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7.3 Conclusion 
This Chapter has described the development of a new approach for dating 
pregnancies in the GPRD, and its application in the pre-eclampsia study described in 
Chapter 6. Descriptive data pertaining to the identified pregnancies are presented in 
the next Chapter among the wider findings of the analysis of acute maternal infection 
and pre-eclampsia. 
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Chapter 8  Results – Acute maternal infection and pre-eclampsia 
This chapter reports on the findings of the matched case-control study described in 
Chapter 6, which assessed the effects of three exposures during pregnancy: antibiotic 
prescriptions (a proxy for acute infection), UTI and RTI, on the risk of pre-
eclampsia. The first two sections describe the selection of cases and controls and 
summarise their demographic, clinical and pregnancy-related characteristics. The 
next three sections present the findings: the primary analysis, which assessed the 
effect of each exposure occurring at any time during pregnancy (prior to the index 
date); secondary analyses which explored the timing and number of episodes of each 
exposure; and a range of sensitivity analyses (outlined in Chapter 6). The chapter 
concludes with a summary of the main findings and discussion of the strengths and 
potential limitations of the study. 
8.1 Identifying eligible cases and controls  
Participants were drawn from a base population of all female patients registered with 
practices contributing UTS data to the GPRD during all or part of the study period 
from 1st January 1987 to 31st October 2007 inclusive.  
Data were obtained on all women with a clinical diagnosis of pre-eclampsia during 
this period (n=3362 potential cases) and a large random sample of women who had a 
completed pregnancy recorded during this period and no diagnosis of pre-eclampsia 
ever recorded in their data (n=93909 potential controls).  
After applying the eligibility, exclusion and matching criteria, as outlined in Chapter 
6 (sections 6.4.2 and 6.5.1), 1533 cases (women who developed pre-eclampsia in 
their first recorded completed pregnancy) and 14236 controls (women with a first 
recorded completed pregnancy and no record of pre-eclampsia) were included in the 
primary analysis. The identification of these women is illustrated in participant flow 
diagrams Figure 8.1 and Figure 8.2. The most common reason for not being eligible 
for inclusion in the study was uncertainty about the timing of delivery. 
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Figure 8.1 Participant flow – Cases. 
*a record indicating the patient had delivered (e.g. birth details) or was soon to deliver (e.g. antenatal 37 week examination) 
†UTS = up-to-standard (i.e. data meeting GPRD quality standards) 
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Figure 8.2 Participant flow – Controls. 
*a record indicating the patient had delivered (e.g. birth details) or was soon to deliver (e.g. antenatal 37 week examination) 
†UTS = up-to-standard (i.e. data meeting GPRD quality standards) 
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8.2 Descriptive data 
8.2.1 Patient and pregnancy characteristics 
Using the algorithm developed for dating pregnancies described in Chapter 7, 
estimates of gestational age at delivery were derived, ranging from 24.1 to 42.0 
weeks, starting from the first day of a woman’s LMP before delivery. The median 
gestational age at delivery was 40.0 weeks for both cases and controls (IQR 38.1-
40.0 weeks for cases, 40.0-40.0 weeks for controls). More than half of cases and 
controls had no information in antenatal or delivery records indicating the likely 
timing of the LMP; for these women, the date of the first day of the LMP was 
assumed to occur 40 weeks prior to the EDD. However, among the 667 (43.5%) 
cases and 5278 (37.1%) controls for whom the estimated date of the first day of the 
LMP was derived from antenatal or delivery records, the median gestational age at 
delivery was 37.4 weeks (IQR 34.1-39.6) and 40.3 weeks (IQR 39.3-41.1), 
respectively.  
Table 8.1 summarizes the risk profile, demographic and additional pregnancy 
characteristics of cases and controls. Cases and controls were of similar age at 
delivery (median 28.3 years for cases; 28.2 years for controls) and shared similar 
consultation behaviour before pregnancy (median 11 consultations over a median 
registration period of approximately 2.5 years). Cases were significantly more likely 
than controls to have a multifetal pregnancy (1.6% versus 0.9%, p=0.003), a history 
of hypertension (10.5% versus 6.2%, p<0.001) or diabetes (1.8% versus 1.2%, 
p=0.024). Pre-existing renal disease was uncommon, present in less than 0.3% of 
participants’ records. Approximately one fifth of cases and controls had a record of 
early pregnancy loss prior to their first recorded completed pregnancy. 
Among participants for whom data were available on pre-pregnancy BMI and/or 
smoking status, cases were significantly more likely to be overweight (OR 1.49, 95% 
CI 1.27-1.74) or obese (OR 2.16, 95% CI 1.79-2.60) before pregnancy (p 
trend<0.001), and less likely to smoke during pregnancy (OR 0.66, 95% CI 0.57-
0.77), compared to controls.  
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Participants who were exposed to RTI in pregnancy were more likely to have pre-
existing asthma (29.5%) than those not exposed to RTI (17.1%) (p<0.001), and were 
more likely to smoke (28.6%) than those not exposed (22.5%) (p<0.001).  
Table 8.1 Characteristics of study participants. 
Characteristic n (%) Cases  
(N=1533) 
Controls 
(N=14236) 
ORa (95% CI) 
Maternal age at delivery (years)    
<20 132 (8.6) 1470 (10.3) 1.00 
20-24 340 (22.2) 2846 (20.0) 1.34 (1.08-1.66) 
25-29 478 (31.2) 4492 (31.6) 1.21 (0.98-1.48) 
30-34 406 (26.5) 3803 (26.7) 1.21 (0.98-1.49) 
35-39 146 (9.5) 1348 (9.5) 1.23 (0.95-1.58) 
40+ 31 (2.0) 277 (2.0) 1.25 (0.82-1.91) 
median, IQR 28.3, 23.9-32.3 28.2, 23.9-32.1  
Pre-pregnancy BMI (kg/m2)     
<18.5 (underweight)  26 (1.7) 526 (3.7) 0.53 (0.36-0.80) 
18.5-25 (normal)  620 (40.4) 6618 (46.5) 1.00 
25-30 (overweight)  272 (17.7) 1959 (13.8) 1.49 (1.27-1.74) 
30+ (obese)  192 (12.5) 946 (6.7) 2.16 (1.79-2.60) 
unknown 423 (27.6) 4187 (29.4) b 
median, IQR 24.1, 21.6-27.9 22.7, 20.7-25.6  
Smoking status in pregnancy     
non-smoker 834 (54.4) 6680 (46.9) 1.00 
ex-smoker 166 (10.8) 1476 (10.4) 0.90 (0.75-1.08) 
current smoker 283 (18.5) 3311 (23.3) 0.66 (0.57-0.77) 
unknown 250 (16.3) 2769 (19.5) b 
Practice level socioeconomic statusc     
IMD score [median, IQR] 16.2, 8.7-30.1 16.3, 8.4-30.2  
Patient level socioeconomic status    
IMD score [median, IQR]  14.3, 8.4-25.7 14.8, 8.3-26.4  
unknown 744 (48.5) 6734 (47.3)  
Pre-existing hypertension  161 (10.5) 875 (6.2) 1.82 (1.52-2.18) 
Pre-existing renal disease  4 (0.3) 25 (0.2) 1.55 (0.54-4.45) 
Pre-existing diabetes  28 (1.8) 166 (1.2) 1.60 (1.06-2.41) 
Pre-existing asthma 291 (19.0) 2509 (17.6) 1.10 (0.96-1.26) 
Previous miscarriage or termination  298 (19.4) 2869 (20.2) 0.96 (0.84-1.09) 
Multiple pregnancy  25 (1.6) 121 (0.9) 1.95 (1.26-3.02) 
ART pregnancy 11 (0.7) 84 (0.6) 1.24 (0.65-2.35) 
Consultations with GP pre-pregnancy 
[median, IQR] 
11, 4-27 11, 4-24  
UTS follow-up pre-pregnancy (years) 
[median, IQR] 
2.4, 0.9-5.1 2.5, 1.1-5.3  
Abbreviations: IQR=interquartile range; BMI=body mass index; IMD=Index of Multiple Deprivation score based on practice 
post-code (practice level socioeconomic status) or patient post-code (patient level socioeconomic status): the higher the score, 
the greater the deprivation; UTS=up-to-standard (i.e. data meeting GPRD quality standards); ART=assisted reproductive 
technology  
aORs adjusted for matched design 
bindividuals with missing data not included in OR estimates 
cmatching variable 
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The characteristics of matched study participants were similar to those who were 
eligible for matching; the latter, which included cases and controls with no match 
and additional controls not selected at random during the matching procedure, are 
described in Appendix J-Table J.1 for comparison. 
8.2.2 Timing and severity of pre-eclampsia 
Based on the estimated start and end dates of pregnancy (see Chapter 7 for details of 
how these were derived), the median gestational age of cases at pre-eclampsia 
diagnosis was 38.1 weeks (IQR 34.9-39.9 weeks). The majority of cases (79.5%) 
were late-onset, defined as an earliest pre-eclampsia diagnosis at 34 weeks’ gestation 
or more; just 16 cases (1%) had a pre-eclampsia diagnosis before 20 weeks.  
The majority of pre-eclampsia diagnoses were non-specific regarding severity 
(47.3%) or indicated mild to moderate disease (32.0%); the remaining 20.7% 
specified severe pre-eclampsia, eclampsia or HELLP syndrome (see Figure 8.3 
below).  
While more than half of cases (57.7%) had a record of hypertension in pregnancy, 
fewer (12.9%) had documented proteinuria, and just 166 cases (10.8%) had records 
of both conditions.  
 
Figure 8.3 Classification of cases (N=1533) by severity or subtype. 
32%
12%
7%
2%
47%
Mild-moderate
Severe
Eclampsia
HELLP
Unspecified
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8.2.3 Exposure to acute infections in pregnancy 
During their first completed pregnancy, 528 (34.4%) cases and 4110 (28.9%) 
controls were prescribed an antibiotic drug, 182 (11.9%) cases and 1376 (9.7%) 
controls had one or more recorded UTI, and 77 (5.0%) cases and 781 (5.5%) controls 
had one or more recorded RTI. In each pregnancy trimester, cases were exposed 
more frequently than controls to antibiotic prescriptions and to UTI, whereas the 
frequency of RTI was similar among cases and controls (see Table 8.2). 
Table 8.2 Frequency of maternal infections and antibiotic prescriptions.  
Exposure during pregnancya n (%) Cases (N=1533) Controls (N=14236) 
Antibiotic prescription   
First trimester 221 (14.4) 1684 (11.8) 
Second trimester 238 (15.5) 1952 (13.7) 
Third trimester 203 (13.2) 1520 (10.7) 
Any time in pregnancy 528 (34.4) 4110 (28.9) 
Urinary tract infection    
First trimester 64 (4.2) 463 (3.3) 
Second trimester 81 (5.3) 606 (4.3) 
Third trimester 57 (3.7) 487 (3.4) 
Any time in pregnancy 182 (11.9) 1376 (9.7) 
Respiratory tract infection   
First trimester 31 (2.0) 293 (2.1) 
Second trimester 29 (1.9) 307 (2.2) 
Third trimester 24 (1.6) 218 (1.5) 
Any time in pregnancy 77 (5.0) 781 (5.5) 
Note some women had more than one exposure in the same (or in another) trimester. 
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this 
is the date they reached the same gestational age as their matched case at the case’s index date). 
While the majority of exposed cases and controls experienced just a single episode of 
infection or antibiotic treatment during pregnancy, a few had more than one episode 
(range 1 to 6 episodes for antibiotics; 1 to 4 episodes for both UTI and RTI). The 
frequency distribution of the number of exposure episodes among cases and controls 
is shown in Table 8.3. Overall, 706 episodes of antibiotic treatment, 208 UTIs and 85 
RTIs during pregnancy were recorded among cases during pregnancy; 5543 
antibiotic treatment episodes, 1628 UTIs and 832 RTIs were recorded among 
controls.  
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Table 8.3 Frequency distribution of the number of episodes of maternal infection or antibiotic 
treatment. 
Exposure during pregnancya n (%) Cases (N=1533) Controls (N=14236) 
Antibiotic prescription   
No episodes 1005 (65.6) 10126 (71.1) 
1 episode 389 (25.4) 3026 (21.3) 
2 episodes 109 (7.1) 804 (5.7) 
≥3 episodes 130 (2.0) 280 (2.0) 
Urinary tract infection    
No episodes 1351 (88.1) 12860 (90.3) 
1 episode 158 (10.3) 1168 (8.2) 
2 episodes 23 (1.5) 167 (1.2) 
≥3 episodes 1 (0.1) 41 (0.3) 
Respiratory tract infection   
No episodes 1456 (95.0) 13455 (94.5) 
1 episode 70 (4.6) 734 (5.2) 
2 episodes 6 (0.4) 44 (0.3) 
≥3 episodes 1 (0.1) 3 (0.0) 
Note some women had more than one exposure. 
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this 
is the date they reached the same gestational age as their matched case at the case’s index date). 
The distribution of the timing of exposure episodes over the three trimesters by 
cases-control status is presented in Table 8.4; as shown, episodes were spread fairly 
evenly across the trimesters for both cases and controls.  
Table 8.4 Frequency distribution of the timing of episodes of maternal infection and antibiotic 
treatment. 
Exposure during pregnancya No. (%) exposure episodes 
First trimester Second 
trimester 
Third 
trimester 
Overall in 
pregnancy 
Antibiotic prescription     
Cases (n exposed=528) 230 (32.6) 257 (36.4) 219 (31.0) 706 (100) 
Controls (n exposed=4110) 1812 (32.7) 2102 (37.9) 1629 (29.4) 5543 (100) 
Urinary tract infection     
Cases (n exposed=182) 64 (30.8) 85 (40.9) 59 (28.4) 208 (100) 
Controls (n exposed=1376) 481 (29.6) 638 (39.2) 509 (31.3) 1628 (100) 
Respiratory tract infection     
Cases (n exposed=77) 31 (36.5) 30 (35.3) 24 (28.2) 85 (100) 
Controls (n exposed=781) 299 (35.9) 311 (37.4) 222 (26.7) 832 (100) 
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this 
is the date they reached the same gestational age as their matched case at the at the case’s index date) 
Almost 90% of participants with a record of UTI or RTI in pregnancy also had an 
antibiotic prescription (89.3% of cases, 88.5% of controls), whereas less than half of 
participants with an antibiotic prescription during pregnancy had a record of UTI or 
RTI (42.8% of cases, 44.3% of controls). 
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8.3 Primary analysis 
The primary analysis assessed the effects of antibiotic drug prescriptions, UTI and 
RTI, occurring at any time during pregnancy prior to the index date, on the risk of 
pre-eclampsia. Crude and adjusted ORs for the association between pre-eclampsia 
and each of these three primary exposures of interest are summarized in Table 8.5.  
8.3.1 Univariable analyses 
A crude positive association with pre-eclampsia was observed for both antibiotic 
prescriptions (crude OR 1.29, 95% CI 1.15-1.44) and UTI in pregnancy (crude OR 
1.23, 95% CI 1.04-1.46). However, no such crude effect was observed for RTI (crude 
OR 0.91, 95% CI 0.71-1.15). 
Table 8.5 The association between maternal infection and pre-eclampsia: crude and adjusted 
odds ratios for matched cases and controls. 
Exposure in 
pregnancya 
Cases 
N=1533 
n (%) 
Controls 
N=14236  
n (%) 
Matched crude OR 
(95% CI) 
Matched adjustedb 
OR (95% CI) 
Antibiotic 
prescription 
528 (34.4) 4110 (28.9) 1.29 (1.15-1.44) 1.28 (1.14-1.44) 
Urinary tract 
infection 
182 (11.9) 1376 (9.7) 1.23 (1.04-1.46) 1.22 (1.03-1.45) 
Respiratory tract 
infection 
77 (5.0) 781 (5.5) 0.91 (0.71-1.15) 0.91 (0.72-1.16) 
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this 
is the date they reached the same gestational age as their matched case at the case’s index date). 
bORs adjusted for maternal age; pre-gestational hypertension, diabetes and renal disease; and multifetal gestation. In addition, 
ORs for UTI and RTI are mutually adjusted for each other. 
8.3.2 Multivariable analyses 
Antibiotic prescriptions (adjusted OR 1.28, 95% CI 1.14-1.44) and UTI (adjusted OR 
1.22, 95% 1.03-1.45) in pregnancy were associated with an increased risk of pre-
eclampsia after controlling for maternal age; pre-gestational conditions - renal 
disease, diabetes and hypertension; multifetal gestation; and RTI in pregnancy (when 
assessing UTI only). There was no evidence for confounding by previous early 
pregnancy loss. 
Consistent with the crude analysis, no association was observed between RTI and 
pre-eclampsia after adjustment for UTI in pregnancy; maternal age; pre-gestational 
renal disease, diabetes and hypertension; and multifetal gestation (adjusted OR 0.91, 
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95% CI 0.72-1.16). The inclusion of pre-existing asthma to the model did not alter 
the RTI effect estimate. 
8.3.2.1 Further adjustment for pre-pregnancy BMI and smoking 
As described previously in section 8.2.1, data on BMI (a well-established risk factor 
for pre-eclampsia) and smoking (a putative protective factor), were incomplete. 
Thus, the primary analysis was repeated among individuals for whom these data 
were available (1048 cases and 7216 matched controls), allowing for the additional 
adjustment. Table 8.6 presents the findings from both the crude and adjusted 
analyses. As shown, further adjustment for pre-pregnancy BMI and maternal 
smoking made no material difference to the effect estimates for UTI (adjusted OR 
1.24, 95% CI 1.01-1.53), RTI (adjusted OR 0.90, 95% CI 0.66-1.23) or antibiotic 
prescriptions (adjusted OR 1.21, 95% CI 1.05-1.40).  
Table 8.6 The association between maternal infection and pre-eclampsia: crude and adjusted 
odds ratios for matched cases (n=1048) and controls (n=7216) with data on BMI and smoking. 
Exposure in pregnancya Matched crude OR (95% CI) Matched adjustedb OR (95% CI) 
Antibiotic prescription 1.23 (1.06-1.42) 1.21 (1.05-1.40) 
Urinary tract infection 1.24 (1.01-1.52) 1.24 (1.01-1.53) 
Respiratory tract infection 0.92 (0.68-1.25) 0.90 (0.66-1.23) 
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this 
is the date they reached the same gestational age as their matched case at the case’s index date). 
bORs adjusted for maternal age; pre-gestational hypertension, diabetes and renal disease; multifetal gestation, pre-pregnancy 
BMI and maternal smoking. In addition, ORs for UTI and RTI are mutually adjusted for each other.  
8.4 Secondary analyses  
Secondary analyses were performed to assess the effects of the timing of infection 
and the number of infection episodes throughout the gestational period.  
Adjusted ORs and 95% CIs for pre-eclampsia associated with infection occurring at 
different stages of pregnancy are presented in Table 8.7. Antibiotic prescriptions in 
all three trimesters were associated with a significantly increased risk of pre-
eclampsia. A small but significant trend of increased risk of pre-eclampsia was 
observed with increasing proximity of antibiotic prescription to delivery (p 
trend<0.001). No effect was observed for RTI at any time during pregnancy. There 
was no evidence to suggest a difference in the effect of UTI according to the timing 
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of UTI onset. Thus, the timing of infection did not appear to play an important role in 
the development of pre-eclampsia.  
Table 8.7 The effect of infections at different stages of pregnancy on the risk of pre-eclampsia. 
Latest onset of exposure during 
pregnancy  
n (%) 
Cases (N=1533) Controls 
(N=14236) 
ORa (95% CI) 
Antibiotic prescription    
Unexposed 1005 10126 1.00 
First trimester 136 1039 1.31 (1.08-1.58) 
Second trimester 189 1551 1.23 (1.04-1.45) 
Third trimester 203 1520  1.33 (1.13-1.57) 
Test for trend p<0.001 1.10 (1.05-1.16)b 
Urinary tract infection     
Unexposed 1351  12860 1.00 
First trimester 49 363  1.24 (0.91-1.68) 
Second trimester 76 526  1.36 (1.06-1.76) 
Third trimester 57 487  1.07 (0.80-1.42) 
Test for trend p=0.063 1.07 (1.00-1.16)b 
Respiratory tract infection    
Unexposed 1456 13455  1.00 
First trimester 25  270  0.85 (0.56-1.30) 
Second trimester 28  293  0.89 (0.60-1.32) 
Third trimester 24 218  1.02 (0.66-1.56) 
Test for trend p=0.644 0.97 (0.87-1.09)b 
aORs adjusted for maternal age; pre-gestational hypertension, diabetes and renal disease; and multifetal gestation. In addition, 
ORs for UTI and RTI are mutually adjusted for each other.  
bOR per unit increase in onset of exposure 
Table 8.8 presents adjusted ORs and 95% CIs for pre-eclampsia associated with a 
single episode of infection, and more than one episode, during pregnancy. While a 
small but significant trend of increased pre-eclampsia risk with increasing episodes 
of antibiotic treatment (p trend<0.001) and UTI (p trend=0.044) was detected, the 
OR point estimates for increasing episodes of antibiotic treatment, UTI or RTI did 
not suggest a dose-response association with pre-eclampsia. 
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Table 8.8 The effect of increasing episodes of maternal infection on the risk of pre-eclampsia. 
Dose of exposure during pregnancy  
n (%) 
Cases (N=1533) Controls 
(N=14236) 
ORa (95% CI) 
Antibiotic prescription    
No episodes 1005  10126  1.00 
1 episode 389 3026 1.29 (1.13-1.46) 
≥2 episodes 139 1084 1.28 (1.05-1.55) 
Test for trend p<0.001 1.18 (1.08-1.28)b 
Urinary tract infection     
No episodes 1351 12860 1.00 
1 episode 158 1168 1.25 (1.04-1.50) 
≥2 episodes 24 208 1.08 (0.70-1.66) 
Test for trend p=0.044 1.15 (1.00-1.33)b 
Respiratory tract infection    
No episodes 1456 13455 1.00 
1 episode 70 734 0.89 (0.69-1.14) 
≥2 episodes 7 47 1.29 (0.58-2.89) 
Test for trend p=0.609 0.94 (0.76-1.18)b 
aORs adjusted for maternal age; pre-gestational hypertension, diabetes and renal disease; and multifetal gestation. In addition, 
ORs for UTI and RTI are mutually adjusted for each other.  
bOR per unit increase in dose of exposure  
8.5 Sensitivity analyses 
A number of sensitivity analyses were performed as outlined in Chapter 6, section 
6.8.4. The results of these analyses are described below and summarised in Table 8.9 
and Table 8.10.  
To address the possibility that the detection of proteinuria among cases may have 
been misdiagnosed by the GP as a UTI (hence leading to differential 
misclassification of UTI), the primary analysis was repeated after confining the 
exposure window for UTI and antibiotic prescriptions to the first two trimesters only 
and excluding cases (n=41) with very early onset pre-eclampsia prior to the third 
trimester (and their matched controls). The findings were virtually identical to the 
primary analysis: adjusted OR for antibiotics 1.26, 95% CI 1.11-1.43 and for UTI 
1.22, 1.01-1.49. 
Consistent with the primary analysis, an increased risk was observed for both early-
onset (n=315) and late-onset pre-eclampsia (n=1218) associated with maternal 
antibiotics prescriptions and UTI, with no evidence for a clear difference between 
these two subgroups (Table 8.9). Restricting the analysis to documented severe cases 
of pre-eclampsia, eclampsia or HELLP syndrome (n=317) yielded findings 
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consistent with the primary analysis: adjusted OR for antibiotics 1.29, 95% CI 1.00-
1.67, UTI 1.66, 1.16-2.39 and RTI 1.24, 0.76-2.02. 
Table 8.9 Adjusted odds ratios for early-onset (<34 weeks’ gestation) and late-onset (≥34 weeks’ 
gestation) pre-eclampsia. 
 Matched adjustedb OR (95% CI) 
Exposure in pregnancya Early-onset pre-eclampsia 
(n=315 cases)  
Late-onset pre-eclampsia 
(n=1218 cases) 
Antibiotic prescription 1.54 (1.19-2.00) 1.22 (1.07-1.39) 
Urinary tract infection 1.39 (0.94-2.06) 1.19 (0.99-1.44) 
Respiratory tract infection 1.46 (0.88-2.42) 0.81 (0.61-1.07) 
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this 
is the date they reached the same gestational age as their matched case at the case’s index date). 
bORs adjusted for maternal age; pre-gestational hypertension, diabetes, renal disease; and multifetal gestation. In addition, ORs 
for UTI and RTI are mutually adjusted for each other. 
Additional sensitivity analyses were conducted, as outlined in Chapter 6, excluding 
the following participants/pregnancies (excluded matched sets, n): 
 cases and controls with less than six months UTS follow-up prior to the start 
of pregnancy (n=236); 
 pregnancies which began prior to publication of the first recommended 
consensus definition of pre-eclampsia in 2000 (n=887); 
 cases and controls aged <18 years at delivery (n=44); 
 cases and controls with pre-existing hypertension (n=162); 
 controls with new onset hypertension in pregnancy which resolved 6-12 
months after delivery (n=0). The 292 controls who met this exclusion criterion 
did not result in a loss of matched sets as all cases still had at least one 
remaining matched control; 
 ART pregnancies (n=11). 
Each of these analyses yielded estimates similar to those obtained in the primary 
analysis (see Table 8.10). 
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Table 8.10 Results of sensitivity analyses by exclusion criteria. 
  Matched adjusteda OR (95% CI) for pre-eclampsia 
 No. cases 
included 
Antibiotic 
prescriptionb 
UTIb RTIb 
Primary analysis 1533 1.28 (1.14-1.44) 1.22 (1.03-1.45) 0.91 (0.72-1.16) 
 
Sensitivity analyses 
    
1. Excluding women with less than 6 months UTS data prior to 
conception 
1297 1.27 (1.12-1.44) 1.25 (1.04-1.50) 0.88 (0.67-1.16) 
2. Excluding pregnancies before year 2000 646 1.38 (1.16-1.66) 1.26 (0.97-1.65) 1.12 (0.76-1.64) 
3. Excluding women aged <18 years  1489 1.28 (1.13-1.44) 1.20 (1.01-1.42) 0.90 (0.70-1.16) 
4. Excluding women with pre-existing hypertension 1371 1.34 (1.18-1.51) 1.31 (1.09-1.57) 0.96 (0.75-1.23) 
5. Excluding controls with new onset hypertension in pregnancy 
which resolved 6-12 months after delivery 
1533 1.29 (1.15-1.44) 1.24 (1.04-1.46) 0.91 (0.72-1.17) 
6. Excluding ART pregnancies 1522 1.28 (1.14-1.44) 1.21 (1.02-1.44) 0.91 (0.71-1.16) 
Abbreviations: UTS=up-to-standard (i.e. data meeting GPRD quality standards). ART=assisted reproductive technology  
aORs adjusted for maternal age; pre-gestational hypertension (except for analysis 4), diabetes and renal disease; and multifetal gestation. In addition, ORs for UTI and RTI are mutually adjusted for each other. 
bany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this is the date they reached the same gestational age as their matched case at the case’s index 
date). 
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8.6 Discussion 
8.6.1 Summary of main findings 
The findings of this study suggest that women who acquire UTI during pregnancy, 
and women prescribed antibiotics during pregnancy (a likely proxy for acute 
infection) are at a higher risk of pre-eclampsia. The increased risk of pre-eclampsia 
developing in the third trimester following UTI or antibiotic prescriptions in the first 
two trimesters (before the likely detection of proteinuria among these third trimester 
cases) supports the notion that acute infections in pregnancy may play a role in the 
pathogenesis of pre-eclampsia. However, this study found no evidence for an 
increased risk of pre-eclampsia among women who acquire RTI during pregnancy.  
The absence of an association with RTI is intriguing and warrants further 
investigation, although it does not preclude the possibility of a generic effect of acute 
infection on pre-eclampsia risk. The adjusted analyses suggest this finding is unlikely 
to be explained by the higher prevalence of maternal smoking (known to be 
associated with protection against pre-eclampsia) among women with RTI. While the 
finding may reflect the absence of a true RTI effect, it may also at least partly be due 
to incomplete ascertainment of RTI consultations. The definition of RTI used in this 
study excluded all non-specific RTI diagnoses (e.g. “Acute respiratory infection” or 
“Respiratory tract infection”) as it was unclear whether these were minor upper RTIs 
or more severe lower RTIs. While the exclusion of non-specific diagnoses increased 
the likelihood that the infections captured in the study were the more severe RTIs 
sufficient to produce systemic effects, the ascertainment of severe RTIs may have 
been incomplete, hence some individuals classified as unexposed to RTI may in fact 
have had a severe episode. It is likely that any such non-differential misclassification 
of RTI would lead to an underestimate of effect due to cases and controls being more 
homogeneous on exposure.  
Neither the timing nor the number of episodes of UTI, RTI or antibiotic prescriptions 
during pregnancy appeared to play an important role in the development of pre-
eclampsia.  
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8.6.2 Study strengths 
A major strength of the study is the use of a population-based cohort of women from 
which all cases of pre-eclampsia in a first completed pregnancy and a random sample 
of primiparous controls without pre-eclampsia were selected. The nested case-control 
design avoided the common problem of selection bias inherent in many case-control 
studies, particularly those in which the base population giving rise to the cases is less 
clearly defined. Matching on practice allowed for variability in recording and 
prescribing habits between practices, and helped ensure that cases and controls were 
comparable on a range of socio-economic and environmental indicators. The 
additional criterion of allowing no more than 12 months between case and control 
delivery dates ensured pregnancies within matched sets were contemporaneous. 
Another strength of this study is that data were available on a substantial number of 
well-known risk factors for pre-eclampsia, some of which, most notably renal disease 
and diabetes, were not accounted for in previous studies of UTI and pre-
eclampsia102,127,131. The associations with UTI and antibiotic prescriptions persisted 
even after adjustment for maternal age; pre-existing renal disease, diabetes and 
hypertension; and multifetal gestation. The possibility of residual confounding 
cannot be excluded, if disease risk factors were not recorded for some women; for 
example, the low prevalence of pre-existing renal disease among cases (0.3%) and 
controls (0.2%) suggests ascertainment of renal disease may be limited to the more 
severe end of the disease spectrum. However, this is unlikely to have been a major 
concern since it is the more severe disease (stages 3-5) which predisposes to pre-
eclampsia, rather than mild renal disease.160 Missing information on maternal 
smoking and pre-pregnancy BMI limited the ability of this study to assess the effects 
of these risk factors in the complete study population. Nevertheless, additional 
adjustment for BMI and smoking made no material difference to the findings. The 
similar pre-pregnancy consultation behaviour of cases and controls suggests the 
findings are unlikely to be explained by possible increased ascertainment of infection 
among cases due to differential health-seeking behaviour.  
The study population comprised women with a first documented completed 
pregnancy in their primary care record, defined as a medical code indicating a live 
birth, stillbirth, or that the woman was soon to deliver (e.g. “antenatal 37 week 
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examination”). Pregnancies resulting in early pregnancy loss (miscarriage or 
termination) were not included, as these were not considered to be completed 
pregnancies. A completed pregnancy record was an eligibility criterion in the study 
for two reasons: first, it ensured that all women had the opportunity to develop pre-
eclampsia (typically occurring after 20 weeks’ gestation), which enabled the 
selection of an appropriate control group; second, it allowed the timing of each 
woman’s pregnancy to be estimated, this being essential for defining the exposure 
period for acute infection and for matching cases and controls on gestational age at 
the index date. Selecting women at a less well-defined stage of pregnancy, for 
example, on the basis of a miscarriage record, which could occur at any time prior to 
24 weeks’ gestation and most often in the first trimester, would have been 
problematic: most of these women were unlikely to have reached the required 
gestational age to be at risk of developing pre-eclampsia. The further criterion that 
the completed pregnancy must be the first in the primary care record, coupled with 
the exclusion of women with evidence of an earlier (unrecorded) completed 
pregnancy, helped ensure that the large majority of included pregnancies were 
primiparous, thus reducing the scope for confounding by parity. A further advantage 
of this approach is that it reduced the potential for confounding by change in 
paternity or by inter-pregnancy interval among multiparous women.161  
While there is no universal agreement on the definition of pre-eclampsia,98 a 
diagnosis has major consequences for a pregnant woman and is unlikely to be 
recorded speculatively. In 2000, the National High Blood Pressure Education 
Program Working Group developed diagnostic criteria for pre-eclampsia,162 
recommended in the American College of Obstetricians and Gynecologists practice 
guidelines for diagnosing pre-eclampsia153. To improve the validity of the case 
definition used in this study, women whose new onset hypertension in pregnancy did 
not resolve following delivery were excluded from the primary analysis, in keeping 
with this consensus definition. While the possibility of misclassification of pre-
eclampsia cannot be ruled out, this criterion helped to distinguish cases of pre-
eclampsia from women with essential or secondary hypertension which became 
clinically apparent during pregnancy. Furthermore, the sensitivity analysis which 
restricted to pregnancies (and hence pre-eclampsia diagnoses) in the year 2000 
onwards made no material difference to the findings. 
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8.6.3 Potential limitations of the study 
In the absence of systematically recorded information on the precise timing of 
pregnancy in the GPRD, information from antenatal, perinatal and postnatal records 
was used to estimate the date of delivery, the start of pregnancy, and the timing of 
trimesters for all primiparous pregnancies. Any imprecision in the pregnancy dates 
may have resulted in some misclassification of exposure; for example, if the 
estimated LMP date was late, some infections or antibiotic prescriptions occurring 
early in pregnancy might have been missed, whereas if the estimated LMP date was 
early, some pre-pregnancy infections/antibiotics may have been incorrectly assigned 
to the first trimester. Although the timing may have been inexact, the same methods 
were used for dating case and control pregnancies, so any such imprecision is likely 
to have been non-differential. The date of diagnosis of infection or antibiotic 
prescription was used rather than the date of onset of infection (the latter being 
unknown). However, the majority of patients, even with upper RTIs, attend their GP 
within three days of onset.163 This small degree of imprecision in the timing of onset 
of infection is unlikely to have materially affected the results.  
It was recognized that not all infections would lead to a GP consultation, so some 
episodes may not have been recorded. However, such infections are more likely to be 
minor or asymptomatic; those severe enough to induce systemic inflammation are 
more likely to result in a consultation and be detected. It is possible that the observed 
associations with maternal UTI and antibiotic prescriptions may partly be attributed 
to increased ascertainment of infections among women considered to be at high-risk 
for pre-eclampsia. However, the study only included primiparous women and hence 
may have been less prone to this particular source of bias since those at highest risk 
(i.e. women with a history of pre-eclampsia) were not included. Furthermore, the 
study also investigated the effect of acute RTI; the null effect observed for RTI 
suggests that such ascertainment bias is unlikely. 
Possible misclassification of UTI among women with pre-eclampsia due to detection 
of protein in the urine was also considered to be a potential source of bias. This was 
addressed in a sensitivity analysis restricted to cases with pre-eclampsia in the third 
trimester (and their matched controls), and infections occurring in the first two 
trimesters (likely to precede the onset of proteinuria). The resulting effect estimates 
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for both UTI and antibiotic prescriptions were virtually identical to those obtained in 
the primary analysis, suggesting that any such bias was minimal and further 
strengthening the study findings. 
More than half of women in the study with an antibiotic prescription in pregnancy 
had no urinary or respiratory indication, a finding which has previously been noted in 
primary care data.164 While some antibiotics might have been prescribed 
prophylactically against recurrent infections, this is likely to have been a small 
minority: the majority would have been given for acute infections such as UTI, 
which is particularly common in pregnancy132. Nevertheless, it is possible (albeit 
unlikely) that the finding of an antibiotic effect may reflect an association with the 
drugs themselves rather than an association with acute infection, the main indication 
for their use. 
Finally, the relatively few individuals with more than one episode of infection (or 
antibiotic prescriptions) during pregnancy limited the power of the study to reliably 
examine a dose-effect. 
8.6.4 Conclusion 
This study has shown that acute maternal UTI and antibiotic drug prescriptions in 
pregnancy (a likely proxy for infection), though not RTI in pregnancy, are associated 
with an increased risk of pre-eclampsia. While the underlying mechanism of this 
association could not be ascertained in this study, the findings support the notion that 
acute infections during pregnancy may contribute to the development of pre-
eclampsia. A discussion of how the study findings compare with those from previous 
studies of pre-eclampsia and acute maternal infection is presented in the next chapter 
(Chapter 9, section 9.2). 
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Chapter 9  Discussion 
This project has sought to establish a clearer role for acute inflammation and 
infection in vascular disease, by undertaking two large observational studies using 
EHRs. The first, a SCSS study reported in Chapters 3-4 (see also Appendix A) used 
Medicaid data to examine the risk of vascular events following invasive dental 
treatment.31 The second, a matched case-control study (Chapters 6-8 and Appendix 
B) used GPRD data to investigate acute maternal infection as a possible trigger for 
pre-eclampsia.32 This chapter summarises the key findings of these studies in the 
context of what previous studies of these associations have shown, considers possible 
mechanisms for the effects observed, and highlights some of the strengths and 
limitations of using EHRs to address these research questions. Finally, some areas 
for future research and implications for clinical practice are recommended.  
9.1 Invasive dental treatment and vascular events 
9.1.1 What was already known  
A link between periodontal disease and CVD is well-established and treating 
periodontal disease is widely thought to bring long-term vascular benefits by 
reducing the burden of infection.30 However, intervention studies of intensive 
periodontal therapy, including a randomized controlled trial comparing the intensive 
treatment with standard community-based care, have demonstrated that intensive 
periodontal therapy gives rise to an acute inflammatory response followed by 
transiently impaired flow-mediated dilatation and elevated markers of inflammation 
and endothelial activation in the week after therapy.47–49 This suggests that invasive 
dental treatment may trigger a short-term increase in risk of vascular events, although 
prior to the dental study, no studies of any such acute effect arising from dental 
treatment had been reported.  
9.1.2 What the dental study adds 
The SCCS dental study (described in Chapters 3-4) has shown a 1.5-fold increased 
rate of vascular events associated with invasive dental treatment in the preceding 
four weeks, which gradually resolved over the subsequent 20 weeks. Similar effects 
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were observed for ischaemic stroke and MI separately, though with poorer precision 
(due to the fewer cases in these subsets) and not reaching statistical significance. The 
case-only approach used in this study made within-person comparisons, thus no 
comparison group was needed. This markedly reduced the scope for confounding to 
which a more conventional cohort design would have been susceptible, particularly 
when addressing a question of this nature as baseline characteristics related to 
vascular risk are likely to differ substantially between treated and untreated 
individuals. Furthermore, all analyses were age-adjusted using 5-year (and 
subsequently 2-year) age groups, hence the effects seen are very unlikely to be 
explained by increasing age. 
The mechanisms through which invasive dental treatment may influence vascular 
event risk in the short term could not be reliably ascertained in this study (a 
limitation of the data source, see section 9.3.2.3 below). As discussed previously in 
Chapter 4, it is possible that non-inflammatory mechanisms might explain at least 
part of the effect observed; for example, acute stress, discontinuation of antiplatelet 
drugs or use of NSAIDs coinciding with the invasive dental treatment may all 
potentially trigger a vascular event. Nevertheless, the transient increased risk of 
vascular events observed in the first few weeks after the treatment is consistent with 
the short-lived inflammatory response observed after periodontal therapy, and 
confirms previous findings of a similar effect associated with other acute 
inflammatory exposures.16,17,21 The dental study findings are thus compatible with an 
acute inflammatory response and associated short-term change in endothelial 
function after dental treatment mediating this increase in vascular risk.  
Three recent cohort studies57–59 (described in Chapter 2, section 2.3.1) have since 
been published which assessed the effect of invasive dental treatment on vascular 
risk up to several years after treatment. These studies reported a reduction in risk of 
vascular events associated with invasive dental treatment57,58 or no treatment effect59 
over the longer-term; however, they did not investigate any acute effect of dental 
treatment on vascular risk.  
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9.2 Pre-eclampsia and acute maternal infection 
9.2.1 What was already known  
Previous research on acute infections during pregnancy and pre-eclampsia has 
yielded mixed findings. UTI, the most frequently studied acute maternal infection, 
has been shown to be associated with a 1.3- to 4.8-fold increased odds of pre-
eclampsia in some studies,114,115,117,119–126,130,131 and no association in 
others112,113,116,118,127–129. Two cohort studies of hospitalised pneumonia during 
pregnancy have reported a significant positive association with pre-
eclampsia/eclampsia although no association with mild pre-eclampsia.137,138 
However, studies of acute Chlamydia pneumoniae infection and cytomegalovirus 
infection (as determined by the presence of IgM antibodies) found no association 
with pre-eclampsia.106,110,133–135,139 The effects of other acute infections on the risk of 
pre-eclampsia are unknown.  
9.2.2 What the pre-eclampsia study adds 
The case-control study of pre-eclampsia (described in Chapters 6-8) has 
demonstrated a greater than 1.2-fold increased odds of pre-eclampsia associated with 
both maternal antibiotic prescriptions and UTI in pregnancy, independent of maternal 
age, multifetal gestation and pre-gestational conditions (hypertension, renal disease 
and diabetes). None of the earlier studies referred to above assessed the role of 
antibiotic prescriptions as a proxy for acute infection. Contrary to the two previous 
studies which found an increased risk of pre-eclampsia associated with maternal 
pneumonia, no association was observed between pre-eclampsia and acute RTI 
during pregnancy in this study. One explanation for this finding is that the definition 
of RTI used in the pre-eclampsia study encompassed a wider range of infections than 
pneumonia, some of which would have been less severe. The null effect of RTI is 
nevertheless consistent with previous studies showing no association with acute 
Chlamydia pneumoniae infection, a common cause of both upper and lower RTI165. 
As discussed previously in Chapter 8, the pre-eclampsia study has a number of 
advantages over the earlier studies, including: 
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 more complete adjustment for confounding (particularly renal disease and 
diabetes, which were not accounted for in most earlier studies of pre-eclampsia 
and UTI); 
 the ability to establish clearly the temporal sequence between infection and pre-
eclampsia onset (due to the data being prospectively recorded, see section 
9.3.1.2, below);  
 the assessment of more than one infection (RTI in addition to UTI); since both of 
these infections were susceptible to similar ascertainment bias (i.e. possible 
increased ascertainment of infections among cases), the finding of a positive 
association with UTI but no effect of RTI suggests that such ascertainment bias 
was unlikely.  
Although it was not possible to establish the mechanism by which acute infections 
such as UTI may be associated with pre-eclampsia in this study (again, a limitation 
of the data source, discussed below in 9.3.2.3), various hypotheses have been 
proposed which implicate inflammation (a key feature of pre-eclampsia) as a 
mediating factor. For example, it has been suggested that acute infections may play a 
direct role in initiating pre-eclampsia by increasing the risk of acute uteroplacental 
atherosis166 which may result in increased systemic inflammation and endothelial 
dysfunction preceding the clinical onset of disease. Acute infections may also 
contribute to the progression of pre-eclampsia by triggering the release of 
inflammatory cytokines into maternal circulation, hence amplifying the already 
increased level of inflammation in the pregnant women and altering vascular 
endothelial function.167 Thus, there may be more than one mechanism through which 
acute infections, among other factors, may increase the risk of pre-eclampsia 
developing. 
9.3 Strengths and limitations of electronic health data 
EHRs are increasingly being used in epidemiological research, particularly in 
observational studies. Two of the most commonly used sources of EHRs for research 
are primary care and administrative claims databases, such as the GPRD and the 
Medicaid database used for this project. A clear advantage of using EHRs for 
research is that the data are pre-collected and readily available, and hence provide 
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unparalleled gains in efficiency over studies which involve more costly and time-
consuming traditional methods of participant recruitment and data collection. 
However, the quality of EHR-based research crucially depends on the validity and 
completeness of the data. A discussion of the methodological strengths and 
limitations of the dental and pre-eclampsia studies has been reported in the results 
chapters of the thesis (Chapters 4 and 8). This section considers more specifically the 
strengths and potential limitations of the databases used to address the study 
questions. 
9.3.1 Strengths 
The Medicaid database and the GPRD have previously been described in Chapter 3 
(section 3.2.1) and Chapter 6 (section 6.2.1), respectively. The databases share a 
number of key strengths as outlined below:  
9.3.1.1 Large sample size 
One of the main strengths of the databases for use in research is their size which 
allows for the study of rare outcomes and/or exposures with reduced concerns about 
loss of statistical power. The Medicaid database used for the dental study comprised 
data on more than nine million individuals. The ability to include such a large 
number of cases (more than 20,000) arising from this base population was of 
particular importance in the dental study given the relatively low frequency of 
exposure to invasive dental treatment. The pre-eclampsia study was able to include 
data on more than 1500 cases and 14000 controls, and was thus one of the largest 
studies to date assessing the role of acute infection in pre-eclampsia. Despite these 
large sample sizes, the dental study had limited power to examine stroke and MI 
separately, and the pre-eclampsia study was limited in its ability to reliably assess a 
dose-effect with increasing episodes of infection.  
9.3.1.2 Prospectively collected data  
A further common advantage of the GPRD and Medicaid databases is that data are 
collected routinely and prospectively. Medicaid captures all medical care provided to 
beneficiaries including dental care, which allowed the occurrence of invasive dental 
procedures to be linked with hospital diagnoses of vascular events and hence the 
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question of whether such procedures increase vascular risk could be addressed. The 
GRPD comprises a comprehensive record of patients’ medical profiles, including 
details pertaining to pregnancy and its outcome, and thus presented a suitable data 
source for addressing the question of whether infections acquired during pregnancy 
pose an increased risk of pre-eclampsia. Because data are prospectively recorded, 
data on exposure to invasive dental procedures (Medicaid) and to infections and 
antibiotic prescriptions (GPRD) were not subject to recall bias (when the presence of 
disease influences the reporting of exposure) or observer bias (when knowledge of 
participants’ disease status influences the ascertainment or recording of exposure). 
9.3.1.3 Generalisability  
A key strength of the GPRD is that it is broadly representative of the UK 
population.143 The ability to select all cases of pre-eclampsia and a random sample of 
controls from the same well-defined population minimized the scope for selection 
bias in the pre-eclampsia study and ensured the results were generalisable. By 
contrast to the GPRD, the population served by Medicaid cannot be considered 
broadly representative of the overall US population given that eligibility is income-
related and hence the majority of beneficiaries come from lower socioeconomic 
groups.61 Nevertheless, the relative effect of invasive dental treatment on vascular 
event risk is unlikely to be different in low-income patients as compared with higher-
income individuals. 
9.3.1.4 Routine data quality checks  
Both the GPRD and the Medicaid database are subject to ongoing internal quality 
assessments to ensure the research data are high-quality. In the GPRD, assessment is 
undertaken at the patient level (excluding patients with inconsistent or incomplete 
data in key areas including age, sex and registration details) and at practice level 
(ensuring, for example, that recording of patient referrals or prescriptions issued 
reach specified thresholds). The practice UTS date, based on the latter, indicates 
when the practice met quality standards and hence the point from which the data 
were deemed fit for research. In Medicaid, improper coding is flagged to recommend 
actions for improving data quality to the carrier or data processor. 
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9.3.2 Potential limitations 
In addition to the strengths described above, some potential limitations of the 
databases need also be considered.  
9.3.2.1 Validity of diagnoses  
One of the most important concerns with using EHRs for epidemiological research is 
the validity of the data, particularly regarding clinical diagnoses. While EHRs 
provide a number of advantages for research as discussed above, it is important to 
consider the accuracy of clinical entries in the EHR for the study of a particular 
disease, given that the primary reason for data collection is for clinical use rather 
than for research. A large number of validation studies have assessed the validity of 
recording in the GPRD across a range of diagnoses and reassuringly, estimates of 
validity have consistently been high.142,168 Similarly, the validity of hospital 
discharge diagnoses in Medicaid has been extensively examined with studies 
estimating positive predictive value of more than 90% for stroke and MI.75,76 
9.3.2.2 Timing of events  
For some events, the precise timing can be difficult to discern from the EHR. In 
Medicaid, the date of admission to hospital for a vascular event (as indicated by the 
primary discharge diagnosis) was used rather than the date of onset, the latter being 
unknown. However, for acute severe events such as ischaemic stroke and MI which 
often result in immediate hospitalisation, the admission date is likely to be a 
reasonable proxy. It is also possible that a few individuals may have experienced 
their event during their hospital stay (hence after the admission date) although this is 
unlikely as the primary discharge diagnosis (principal diagnosis) should reflect the 
main reason for the admission. Any small imprecision in the timing of the events is 
unlikely to have caused notable bias in the dental study.  
As described in Chapter 7, a major challenge for the pre-eclampsia study was the 
need to develop an algorithm to estimate the likely start and end dates of 
participants’ pregnancies in order to identify the relevant “risk” period for exposure 
to acute infection. The algorithm has not been validated, hence it was not possible to 
establish the degree of imprecision in the pregnancy dates. The main consequence of 
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any such imprecision for this study is possible misclassification of exposure early in 
pregnancy, although this is likely to be non-differential (as discussed in Chapter 8, 
section 8.6.3). Systematic recording of both the LMP and delivery dates in the GPRD 
would have reduced the scope for exposure misclassification and hence would be of 
great benefit to future studies of pregnancy in the GPRD.  
9.3.2.3 Missing or incomplete data  
Clinical outcomes 
The Medicaid database comprises details of all health care provided to beneficiaries. 
Data are based on paid and adjudicated administrative claims for reimbursement of 
medical services and include information on diagnosed conditions and services 
performed. Hence the data should represent a virtually complete record of care 
received, though not of care needed (and not received) or undiagnosed conditions, 
neither of which were a particular concern for the dental study.  
Although practices contributing to the GPRD are required to document all significant 
clinical events and diagnoses including referrals to specialists and hospital 
admissions, the recording of outcomes may be incomplete. However, any such 
under-ascertainment is likely to apply to the more minor medical events rather than 
significant events such as pre-eclampsia or infections severe enough to cause 
systemic effects (see Chapter 8, section 8.6.3). Hence this issue was not especially 
concerning in the pre-eclampsia study.  
Lifestyle and anthropometrics 
Both databases include some demographic data, such as year of birth, gender and (for 
Medicaid only) ethnicity. However, data on lifestyle and anthropometric factors 
(SES, smoking, alcohol use, body weight and height), which are often important 
confounding factors in many studies, are not readily available in Medicaid and may 
be incomplete or unavailable for some patients in the GPRD. The absence of such 
data was less of an issue for the dental study due to the case series design which 
implicitly controlled for between-person differences by making within-person 
comparisons. In the pre-eclampsia study, missing information on maternal smoking 
and pre-pregnancy BMI, two well-established risk factors for pre-eclampsia, 
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precluded the assessment of their effects in the complete study population. 
Nevertheless, their effects were assessed among the majority of women (who had 
available BMI and smoking data). 
Prescription drugs 
Prescriptions issued in primary care are computer-generated by the GP and so are 
automatically recorded in the GPRD. The therapy files therefore contain a complete 
record of prescriptions issued by the GP. However, prescriptions issued in secondary 
care are not accounted for in the GPRD. While this raises the question of possible 
incomplete ascertainment of antibiotic prescriptions in the pre-eclampsia study if 
some women were prescribed antibiotics in hospital antenatal clinics, it is likely that 
the majority of women would be referred to their GP for prescriptions due to cost. 
Furthermore, any such under-ascertainment of antibiotics is likely to have been more 
common among cases since women with high-risk pregnancies are more likely to be 
seen in hospital, hence resulting in an underestimation of the antibiotic effect.  
In Medicaid, drug data relate to prescriptions which have been dispensed by the 
pharmacist rather than issued by the physician. Nevertheless, uncertainty remains as 
to whether the medicine was actually taken. Hence, it was not possible to ascertain 
patient compliance in either the GPRD or Medicaid. Any such under-ascertainment 
of drug use due to lack of compliance may have implications for studies examining 
drug effects. However, this was not a concern in the pre-eclampsia study given that 
antibiotic prescriptions (an exposure of interest) served as a proxy for acute infection 
independent of whether the drugs themselves were actually taken by the patient.  
Finally, neither database capture non-prescription (over-the-counter) medicines. This 
was not an issue for the pre-eclampsia study as antibiotics are only available with 
prescription in the UK. Although drug effects were not assessed directly in the dental 
study, the possibility of residual confounding due to incomplete ascertainment of 
non-prescription aspirin or other NSAIDs was recognised (as discussed earlier in 
Chapter 4, section 4.6.3). 
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Data on underlying mechanisms 
While the Medicaid database provided sufficient information to examine whether an 
association between invasive dental procedures and vascular events exists, it did not 
allow for an investigation of the implied mechanism. A potential pathogenic pathway 
underlying the effect observed may be the raised levels of CRP and other markers of 
systemic inflammation and endothelial dysfunction exhibited by patients who 
undergo invasive dental treatment. However such data on inflammatory biomarkers 
and endothelial function were lacking in Medicaid.  
Similarly, the mechanisms by which UTI (and possibly other acute infections) might 
increase the risk of pre-eclampsia could not be reliably ascertained in the pre-
eclampsia study. As discussed in Chapter 6, pre-eclampsia is a heterogeneous 
syndrome, and the mechanisms underlying the pathology may vary according to the 
specific clinical phenotype.169 However, data on pre-eclampsia phenotypes were 
lacking in the GPRD (for example pre-eclampsia in association with a small-for-
gestational-age infant or placental observations indicating atherosis) which limited 
the ability of the study to reliably assess whether acute infection may be implicated 
in different phenotypes. Nevertheless, development of an algorithm to date 
pregnancies in the pre-eclampsia study (described in Chapter 7) enabled the 
gestational age of cases at pre-eclampsia diagnosis to be estimated. Hence stratified 
analyses were undertaken among early-onset cases (thought to be placental-mediated 
and associated with placental insufficiency and fetal growth restriction) versus late-
onset cases (linked to maternal factors such as BMI and thought to be associated with 
less severe outcomes)170 to assess the role of acute infection in each of these 
subtypes. These analyses indicated no evidence for a difference in effect between the 
two groups (see Chapter 8, section 8.5).  
9.4 Further areas for research 
The studies presented in this thesis have shown that the risk of vascular outcomes 
may be increased in the short term following acute inflammatory exposures. 
However, further research is required to elucidate the underlying mechanisms of 
these associations.  
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The dental study assessed the effect of a broad range of invasive dental treatments, 
the majority of which were extractions. This work could be extended in further 
studies with larger sample sizes to examine the effects of different types of invasive 
dental treatment (for example periodontal therapy versus extractions with non-
infectious causes such as trauma) on the short-term risk of vascular events. In 
addition, the effects of other medical procedures (outside the realm of dental 
treatment) that are likely to be associated with short-term inflammation could be 
investigated. Such studies may give further insight into specific situations and time 
periods of increased vascular risk and possibly identify particular groups of 
individuals who may benefit most from preventative interventions during short-term 
high-risk periods. 
An important, related area for future research is the identification of interventions 
that may be effective in reducing vascular risk over the short term after inflammatory 
procedures. Among the possible candidate drugs for prophylactic use during transient 
periods of increased vascular risk are statins and antiplatelet agents, both widely used 
to reduce vascular risk over the longer term among high-risk individuals. However, 
to date there is limited evidence supporting the usefulness of such short-term 
prophylactic therapy. Studies assessing the effect of statin use during the 
perioperative period have yielded inconclusive findings.171 A recent randomised 
placebo controlled trial of patients undergoing noncardiac surgery found no evidence 
for a protective effect of either aspirin or clonidine administered 
perioperatively.172,173 Thus further studies are required to assess the benefit of 
administering such treatments during short-term periods of increased risk after 
invasive dental treatment and other inflammatory exposures.  
The pre-eclampsia study carried out for this thesis investigated the effect of antibiotic 
prescriptions in pregnancy as a proxy for acute infection on pre-eclampsia risk. A 
different though related question which warrants addressing in future studies is 
whether treating acute maternal infections such as UTI with antibiotics may reduce 
the risk of pre-eclampsia developing. While such a study may feasibly be undertaken 
using EHRs, it may be prone to confounding by indication whereby differences in 
the underlying risk profile of pregnant women who do and do not receive antibiotic 
treatment for infection may be related to the risk of pre-eclampsia. Hence measures 
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to deal with this, for example using a propensity score approach, would need 
consideration. Furthermore, the uncertainty of compliance may complicate the 
interpretation of the findings of such a study. An additional issue is that the majority 
of symptomatic maternal UTIs are likely to be treated. A randomised controlled trial 
to evaluate the effect of screening for and treating bacteriuria among pregnant 
women would overcome these issues and provide the strongest evidence for an effect 
of screening and antibiotic administration on pre-eclampsia risk.  
It has been suggested that particular clinical phenotypes of pre-eclampsia may differ 
in their underlying pathology.169 Hence, an additional area which warrants 
investigating is whether acute infections such as UTI may be implicated in different 
pre-eclampsia phenotypes. The timing of onset and other clinical features pertaining 
to a particular pre-eclampsia phenotype could be established in a hospital setting. 
However, a very large multi-centre study would be required to accrue enough women 
with each phenotype in order to reliably assess the effect of infection on a specific 
phenotype. Future research in this area may further our understanding of the 
pathogeneses of this complex maternal syndrome and possibly identify groups of 
women at particularly high risk for whom preventative measures may be of particular 
benefit. 
9.5 Implications for clinical practice 
The recognition that individuals might have a transiently increased risk of vascular 
outcomes after acute inflammatory exposures such as invasive dental treatment and 
maternal UTI could have important implications for clinical practice.  
The dental study findings presented in this thesis raise important questions relating to 
the management of patients undergoing invasive dental treatment or other 
inflammatory procedures, particularly of those individuals at high risk. For example, 
it is uncertain whether such procedures warrant routine pre-treatment cardiovascular 
risk evaluation, or whether patients should delay or even avoid such procedures at 
times of increased vascular risk. Confirmation of these findings in future studies 
would be useful for such decisions in clinical practice.  
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Furthermore, as discussed in section 9.4 above, the value of prophylactic 
interventions such as therapy with statins or antiplatelet medicines in transient 
periods of increased vascular risk is uncertain. Thus more research is needed before 
targeting specific therapies to individuals not already on such treatment regimens 
during short-term high-risk periods. However, the recommendation for patients to 
continue taking antiplatelet drugs or other cardioprotective medicines before and 
after invasive dental treatment when possible (among high-risk individuals already 
receiving these preventative medicines) seems reasonable on the basis of the dental 
study findings. The use of prophylactic antibiotics may also be prudent among high-
risk individuals who undergo planned invasive dental treatment, in particular those 
with underlying periodontal disease or other dental infection (hence already at 
increased levels of inflammation). 
Our incomplete understanding of the pathophysiology of pre-eclampsia has been a 
barrier to efforts to prevent and treat the syndrome. With the exception of a modest 
but significant protective effect of low-dose aspirin administered early in pregnancy 
in women at high risk of pre-eclampsia,174 preventative interventions to date have 
been largely unsuccessful. If the association observed in the pre-eclampsia study 
between pre-eclampsia and acute UTI is in fact causal, this could have important 
implications for antenatal care programs, including the screening for and prompt 
treatment of asymptomatic bacteriuria (in addition to symptomatic UTI) in early 
pregnancy, which could have the potential to reduce the risk of pre-eclampsia. There 
may also be a role for prophylactic administration of low-dose antibiotics among 
women deemed at especially high risk of developing pre-eclampsia. However, such a 
strategy is less likely to be viable due to the potential threat of antibiotic drug 
resistance to public health. Crucially, the benefit of any such preventative 
interventions would require confirmation in a randomised trial setting and would 
need to outweigh any potential associated risks.  
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9.6 Overall conclusions  
This thesis has reported on two large EHR-based observational studies which, using 
different study designs and data sources, have shown that vascular risk may be 
elevated in the short term following acute inflammatory exposures. The results of 
both studies are consistent with previous research on the effect of acute 
infection/inflammation on vascular outcomes, with the exception of the null effect 
observed of acute RTI on pre-eclampsia. The SCCS dental study has identified 
invasive dental treatment as a novel potential acute inflammatory trigger for vascular 
events. While the exact mechanisms for the associations observed in these studies 
remain uncertain, the findings lend support to the increasing body of evidence that 
acute inflammation may confer a transient increase in vascular risk. 
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Invasive Dental Treatment and Risk for Vascular Events
A Self-Controlled Case Series
Caroline Minassian, MSc; Francesco D’Aiuto, PhD; Aroon D. Hingorani, PhD; and Liam Smeeth, PhD
Background: Treatment of periodontal disease may reduce cardio-
vascular risk in the longer term, but studies have suggested a link
among dental procedures, acute inflammation, and endothelial dys-
function. However, whether such acute inflammatory effects trans-
late into a short-lived increased risk for vascular events is not
known.
Objective: To investigate whether invasive dental treatment tran-
siently increases the risk for vascular events.
Design: Self-controlled case series.
Setting: Data came from the U.S. Medicaid claims database.
Patients: All persons exposed to invasive dental treatment with a
primary hospital discharge diagnosis of ischemic stroke (n 650) or
myocardial infarction (n 525) from 2002 to 2006.
Measurements: The incidence of ischemic stroke and myocardial
infarction in periods immediately after invasive dental treatment
was compared with the incidence in all other observed time peri-
ods. Incidence ratios and 95% CIs were calculated.
Results: The rate of vascular events significantly increased in the
first 4 weeks after invasive dental treatment (incidence ratio, 1.50
[95% CI, 1.09 to 2.06]) and gradually returned to the baseline rate
within 6 months. The positive association remained after exclusion
of persons with diabetes, hypertension, or coronary artery disease
or persons with prescriptions for antiplatelet or salicylate drugs
before treatment.
Limitations: Power to examine the effects of invasive dental
treatment on stroke and myocardial infarction separately was
limited because of the low frequency of invasive dental pro-
cedures. Lack of information about use of over-the-counter
drugs limited the ability to assess confounding by possible with-
holding of antiplatelet or salicylate drugs before invasive dental
treatment or by the use of nonsteroidal anti-inflammatory drugs
after treatment.
Conclusion: Invasive dental treatment may be associated with a
transient increase in the risk for vascular events. However, the
absolute risks are minimal, and the long-term benefits on vascular
health will probably outweigh the short-lived adverse effects.
Primary Funding Source: Wellcome Trust.
Ann Intern Med. 2010;153:499-506. www.annals.org
For author affiliations, see end of text.
There is considerable interest in the role of inflammatorymechanisms in the occurrence of cardiovascular events.
Local inflammation—the process by which the body re-
sponds to injury or infection—plays an important role in
the pathogenesis of the atherosclerotic lesion (1). More-
over, long-term, low-grade chronic systemic inflammation
has been linked to adverse cardiovascular outcomes (2).
Acute inflammation after surgery (3), or bacterial infection
(4), has also been associated with a short-term increase in
the risk for vascular events, with endothelial dysfunction
representing a possible common pathway through which
several risk factors, including inflammation, may influence
the atherogenic process (5, 6).
Epidemiologic data implicate exposure to low-grade
dental infection—particularly periodontitis (a common
chronic infection of the oral cavity caused by bacteria)—in
the cause of cardiovascular disease. Such infections have
been found to be associated with elevated levels of
C-reactive protein and other inflammatory biomarkers (7),
endothelial dysfunction (8), atherosclerosis, and an in-
creased risk for stroke and myocardial infarction (9).
Recent studies have shown that intensive periodontal treat-
ment leads to transiently impaired, flow-mediated dilata-
tion (a measure of endothelial function) and increased
markers of inflammation and endothelial activation in the
week after treatment followed by a longer-term improve-
ment relative to baseline (10, 11). The more invasive the
dental treatment (12), the more marked the changes.
Ischemic stroke and myocardial infarction share a
common pathophysiologic process: arterial thrombosis oc-
curring in a background of atherosclerosis. We have previ-
ously established that infections cause a transient increased
risk for both myocardial infarction and stroke (6). If the
likelihood of a vascular event is associated with variations
in the underlying inflammatory state and endothelial func-
tion, then invasive dental treatment sufficient to produce
an inflammatory response may transiently increase the risk
for vascular events—namely myocardial infarction and
stroke—despite providing longer term vascular benefits
due to reducing the infectious burden. To test this hypoth-
esis of a transient increased risk, we examined the incidence
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of ischemic stroke and myocardial infarction after invasive
dental treatment by using Medicaid claims data from the
United States and the self-controlled case series method.
METHODS
Medicaid Database
Medicaid is a federally funded, state-administered
health care program for persons without private insurance
coverage. It is used by approximately 13% of U.S. citizens
and provides inpatient, outpatient, drug treatment, and
long-term care. The Medicaid claims database contains
pooled data from 9 geographically dispersed states, includ-
ing medical and dental records and details of interventional
treatment, prescription drug claims, and enrollment. The
data have high levels of completeness and validity (13).
Eligibility is income-related and evaluated monthly. All in-
formation obtained from the database is anonymous.
Case Series Method
We examined the risk for vascular events after expo-
sure to invasive dental procedures. Persons who have had
invasive dental treatment may differ from those who have
not in ways that can be difficult to measure and control
for. Some of these differences may also be associated with
the future risk for vascular events, which makes a conven-
tional cohort design a less reliable source of information on
this association. Therefore, we used the self-controlled case
series method (14), which relies on within-person compar-
isons in a sample of persons, all of whom had an outcome
of interest. The main advantage of this method is that
inference is within a person; hence, fixed confounders
(those that do not vary with time during the observation
period) are implicitly controlled for. We derived incidence
ratios of events occurring during predefined risk periods
after an exposure, relative to all other observed time peri-
ods for each person. Our null hypothesis was that rates of
vascular events remain constant from day to day and are
not affected by exposure to invasive dental treatment. The
Figure illustrates this method and the time intervals used.
A key assumption underlying the case series method is
that events are independent within a person. This does not
hold for vascular events because the occurrence of an isch-
emic stroke or myocardial infarction increases the proba-
bility of subsequent events. In the case in which this as-
sumption fails, a reasonable strategy is to restrict the
analysis to first events, provided that these are not common
(14, 15). We therefore chose not to look at recurrent
events and instead used the first event in the study period
to assess the effect of invasive dental treatment on vascular
events. Our approach is reasonable because both ischemic
stroke and myocardial infarction are relatively uncommon
conditions.
Participants
Participants were derived from a population of 9 901 464
persons for whom data were available in the Medicaid data-
base from January 2002 to December 2006. This comprised
approximately 28 million person-years of observation. All in-
cident cases of ischemic stroke or myocardial infarction occur-
ring during this period were identified from primary discharge
diagnoses that were coded by using the International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM), classification system.
Candidates were those who had a first hospitalization
record for ischemic stroke or myocardial infarction at least
24 weeks after their enrollment period began. This ensured
a minimum of 24 weeks of observation before each out-
come, thus allowing participants’ exposure status to be as-
certained throughout this period. Restricting to the first
event record avoided the problem of repeated coding of a
single event within the database. Because participants who
were eligible had at least 24 weeks of continuous observa-
tion before their first event record, we could be confident
that their first event record was not a repeated record for an
earlier event. We excluded persons if they were younger
than 20 years at the time of their first hospitalization
record for stroke or myocardial infarction because the cause
of the event could have differed from that of older persons.
Because eligibility for Medicaid health care is ascertained
on a monthly basis, gaps were often found in a person’s
enrollment. Events or procedures occurring during such
gaps are unlikely to be recorded in the database. This could
lead to misclassification of exposure status. To avoid this,
we identified each person’s maximum period of continuous
enrollment and restricted the person’s follow-up to this pe-
riod. Persons whose stroke or myocardial infarction occurred
outside this period were subsequently excluded from the rele-
vant analyses.
All candidates not excluded for these reasons were
eligible for the study. However, in a case series analysis,
persons not exposed during their observation period do not
contribute to the estimates of association between exposure
and outcome. The primary analysis was therefore restricted
Context
Chronic inflammatory states, such as periodontal disease,
are increasingly believed to play a role in the cause of
cardiovascular disease.
Contribution
Using data from a large administrative database, research-
ers found that adults who underwent discrete invasive
dental procedures have an increased risk for myocardial
infarction or stroke in the 4 weeks immediately after the
procedure, but not at later times.
Implication
Acute dental inflammation may transiently increase cardio-
vascular disease risk.
—The Editors
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to eligible persons who had both an event and invasive
dental treatment during their continuous enrollment
period.
Exposure
Data were extracted on claims for invasive dental pro-
cedures. Dental procedures are recorded in Medicaid by
using the Current Dental Terminology coding system
(16). We defined invasive dental procedures as those that
may feasibly result in bacteremia and induce an inflamma-
tory response. These included periodontal therapy and
other invasive dental surgery, such as simple or compli-
cated tooth extractions, also known to be associated with
bacteremia (17, 18) and raised markers of inflammation
(19). Some persons had several records of procedures,
sometimes within a few days of one another. We defined
procedures recorded at least 1 week apart as repeated pro-
cedures, and we excluded, for each person, all procedure
records occurring within 1 week of a previous record, as-
suming these to be repeated records of the same treatment
program. When addressing repeated procedures, we as-
sumed the risk to be the same after each procedure, thus
not allowing for a dose effect. Appendix Table 1 (available
at www.annals.org) describes all of the invasive dental pro-
cedures found in the study participants’ records.
Outcome Measures
The accuracy of hospital discharge diagnostic codes for
stroke and myocardial infarction classifications in adminis-
trative claims databases has been examined and validated
(20, 21). On the basis of the criteria by Tirschwell and
Longstreth (20), we defined ischemic stroke as any one of
the following ICD-9-CM primary discharge diagnostic
codes on inpatient admission records: 433.x1 (in which “x”
can vary to specify a specific arterial distribution), 434 (ex-
cluding 434.x0), and 436. If any traumatic brain injury
(ICD-9-CM codes 800 to 804 or 850 to 854) was re-
corded for the same hospitalization, the stroke was ex-
cluded. We defined myocardial infarction, according to
criteria used by Kiyota and coworkers (21), as an ICD-
9-CM primary discharge diagnostic code of 410.x1 and a
hospital length of stay lasting from 3 to 180 days. If the
patient died during hospitalization, the length of stay could
be less than 3 days.
For descriptive purposes and sensitivity analyses, we
identified persons with a diagnosis of diabetes, hyperten-
sion, coronary artery disease, or rheumatoid arthritis on
inpatient admission or outpatient claim records before
their invasive dental treatment. We defined each condition
according to the following ICD-9-CM diagnostic codes:
diabetes (code 250), hypertension (codes 401 to 405), cor-
onary artery disease (codes 410 to 414 and 429.2), and
rheumatoid arthritis (code 714).
Statistical Analysis
The exposed period started 1 day after an invasive
dental procedure and extended up to 24 weeks later. It was
subdivided into 1 to 4, 5 to 8, 9 to 12, 13 to 16, and 17 to
24 weeks because we assumed the risk to be similar during
the last 8 weeks. All other observation time was considered
the baseline (unexposed) period. Persons who were exposed
to at least 1 invasive dental procedure were included in the
primary analysis. For persons who had more than 1 proce-
dure during the observation period, each procedure was
followed by a 24-week exposed period. Our decision to
start the exposed period 1 day after a procedure is based on
current evidence that the host response and vascular func-
tion are affected at their maximum 24 hours after invasive
dental treatment (10–12). We used a 24-week exposed
period on the basis of previous work, which suggested any
increased risk would have returned to baseline by 24 weeks
(6, 22), and thus we would be able to fully describe the
resolution of any increased risk. In the case of overlapping
risk periods, we adopted a simple convention: later proce-
dures take precedence over earlier ones (14).
Analyses were done for vascular events overall and sep-
arately by event type (ischemic stroke or myocardial infarc-
tion). We estimated incidence ratios and 95% CIs for
events occurring within each stratum of the exposed period
compared with baseline by using conditional Poisson re-
Figure. Pictorial representation of the case series method.
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Start of continuous enrollment
End of continuous enrollment or death
Vascular event
Vascular event
Start of study period End of study period
Four possible scenarios for the timing of vascular events and invasive
dental procedures (each representing a single participant) are shown.
A. Participant is followed for the duration of the study period, has two
24-week risk periods (each after an invasive dental procedure), and has a
vascular event during the second risk period. B. Participant is followed
for part of the study period and has 1 dental procedure followed by a
vascular event at baseline. C. Participant is followed from the start of the
study period, has a vascular event at baseline before a dental procedure,
and dies before the end of the study period. D. Participant is followed for
most of the study period, has 2 dental procedures, and has a vascular
event during the first risk period. All participants included in a particular
analysis had at least 1 exposure and at least 1 vascular event. Each risk
period began the day after a procedure, lasted 24 weeks (not drawn to
scale relative to length of baseline periods), and was divided into the
following intervals: 1 to 4, 5 to 8, 9 to 12, 13 to 16, and 17 to 24 weeks.
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gression. We adjusted for age in 5-year age groups (for
example, 20 to 24 years, 25 to 29 years, and 30 to 34
years). Each person’s observation was split into successive
intervals determined by changes in age group and exposure
status, thus allowing persons to contribute to different age
groups over time. In a case series analysis, persons not
exposed at any time during follow-up do not contribute to
the estimates of the association between exposure and out-
come. However, including these unexposed persons can
help control for confounding by age because they contrib-
ute information on the age-specific incidence of the out-
come of interest. We did a sensitivity analysis including
unexposed cases to check that the estimates did not vary.
The validity of the case series method rests on the
assumption that the probability of exposure is not affected
by the occurrence of an outcome event. This may not hold
true if the event of interest increases the mortality rate (as is
the case for ischemic stroke or myocardial infarction);
therefore, we conducted a sensitivity analysis excluding
persons who died during their hospital stay for the vascular
event or whose enrollment ended within 1 month of their
event (possibly indicating death). Although fixed covariates
are implicitly controlled for in a case series analysis, we
recognized that there may be potential for confounding by
possible withholding of antiplatelet or salicylate medica-
tions before invasive dental treatment among high-risk per-
sons receiving such drug regimens. We therefore did a sen-
sitivity analysis restricted to patients who had no recorded
use of antiplatelet or salicylate agents before invasive dental
treatment. The rationale for this is that among such pa-
tients, cessation of drug therapy at the time of dental treat-
ment is unlikely to occur. Thus, any observed increased
risk for a vascular event after the dental therapy is unlikely
to be attributable to cessation of antiplatelet or salicylate
therapy. To address the possibility that the use of nonste-
roidal anti-inflammatory drugs (NSAIDs) after invasive
dental procedures for pain control may confound the asso-
ciation observed, we did an additional sensitivity analysis
excluding persons with a recorded diagnosis of rheumatoid
arthritis at any time before invasive dental treatment (who
were probably taking NSAIDs) or with an NSAID pre-
scription around the time of their dental treatment (4
weeks before to 4 weeks after treatment). Similarly, the
potential for confounding by the development of diabetes,
hypertension, or coronary artery disease in the period lead-
ing up to invasive dental treatment was addressed in sen-
sitivity analyses excluding patients with these conditions
newly diagnosed within the year before dental treatment.
To eliminate the possibility that our convention (al-
lowing later procedures to take precedence over earlier ones
if the risk periods overlapped) might contribute to an ob-
served effect in earlier time frames, we did additional sen-
sitivity analyses by excluding persons with overlapping risk
periods and persons with repeated procedures. Finally,
given that most dental procedures included in our anal-
yses were extractions, we repeated our analyses, restrict-
ing to only these homogeneous exposures. Data were
analyzed by using Stata software, version 10 (StataCorp,
College Station, Texas). The Appendix (available at www.
annals.org) provides further details of our analysis.
Role of the Funding Source
A Wellcome Trust Senior Fellowship grant and a se-
nior fellowship from the British Heart Foundation funded
this study. The funding sources had no role in the design,
conduct, and reporting of the study or in the decision to
submit this manuscript for publication.
RESULTS
A total of 32 060 persons were identified from the
Medicaid database with a hospitalization for ischemic
stroke (n  17 741) or myocardial infarction (n 
14 783); 11 691 were excluded for 1 of the following rea-
sons: Less than 24 weeks of observation had passed before
their first event record (n  10 822); they were younger
than 20 years at the time of their first event (n  104); or
the first event occurred outside the continuous enrollment
period (n  765). Among the remaining 20 369 eligible
persons, the median age at the time of diagnosis was 67.3
years (interquartile range [IQR], 56.5 to 79.6 years),
34.3% were men, the mean observation period was 3.4
years, and 7.7% died during their hospital stay. Among
eligible persons with ischemic stroke (n  11 284), the
median age at the time of diagnosis was 68.8 years (IQR,
57.5 to 80.4 years), 31.4% were men, the mean observa-
tion period was 3.4 years, and 5.6% died during their
hospital stay. Among eligible persons with myocardial in-
farction (n  9484), the median age at the time of diag-
nosis was 65.2 years (IQR, 55.3 to 78.4 years), 37.7% were
men, the mean observation period was 3.3 years, and
10.3% died during their hospital stay.
Only cases that had been exposed to an invasive dental
procedure at least once during follow-up were included in
the primary analysis of vascular events, overall and by event
type. Table 1 provides demographic details of these per-
sons. The identification of the 1152 persons included in
the primary analysis of vascular events is illustrated in Ap-
pendix Figure 1 (available at www.annals.org). The mean
duration of total observation for patients with vascular
events was 4.2 years (4.2 years for patients with ischemic
stroke and 4.1 years for patients with myocardial infarc-
tion). During the observation period, 1152 (5.7%) eligible
persons with a vascular event (629 with ischemic stroke
only, 504 with myocardial infarction only, and 19 with
both) had 1 or more invasive dental procedures; 861
(74.7%) of whom had a single exposure period, 281
(24.4%) had 2 to 4 exposure periods, and 10 (0.9%) had 5
or more exposure periods. Of these 1152 exposed persons,
4.1% died during their hospital stay (2.6% of those first
hospitalized for ischemic stroke and 5.7% of those first
hospitalized for myocardial infarction). The median num-
ber of days between adjacent procedures was 56.5 days
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(IQR, 21 to 245 days). A total of 89% of all invasive dental
procedures included in the primary analysis were extrac-
tions, and more than 95% of persons had at least 1 extrac-
tion (Appendix Table 1). Table 2 shows the number of
exposed persons who had an ischemic stroke or myocardial
infarction and the age-adjusted incidence ratios after inva-
sive dental treatment.
The rate of vascular events (n  1152) significantly
increased in the first 4 weeks after invasive dental treatment
compared with the baseline (unexposed) period (incidence
ratio, 1.50 [95% CI, 1.09 to 2.06]) and decreased thereaf-
ter. No events occurred on the same day as an invasive
dental procedure. Examining stroke and myocardial infarc-
tion separately yielded similar findings, although these
were not statistically significant. The rate of myocardial
infarction (n  525) was higher in the first 4 weeks after
an invasive dental treatment compared with baseline (inci-
dence ratio, 1.56 [CI, 0.98 to 2.47]) and seemed to de-
crease over 24 weeks. For ischemic stroke (n  650), a
slightly elevated risk was seen during the first 4 weeks after
an invasive dental treatment (incidence ratio, 1.39 [CI,
0.89 to 2.15]), although this was less marked and the pat-
tern of resolution was less clear. Repeating the analyses to
include unexposed cases did not materially alter the esti-
mates of the effect of invasive dental procedures on isch-
emic stroke or myocardial infarction.
We conducted further sensitivity analyses: restricting
to persons whose enrollment continued for at least 1
month after their vascular event and hence did not die
immediately or shortly after stroke or myocardial infarc-
tion; excluding persons with overlapping risk periods; ex-
cluding persons with repeated procedures; excluding per-
sons probably taking NSAIDs around the time of dental
treatment (those with a rheumatoid arthritis diagnosis at
any time before treatment or an NSAID prescription 4
weeks before or after treatment); restricting our exposure to
extractions; and restricting to persons who were healthy, as
defined by an absence of diabetes, hypertension, or coro-
nary artery disease diagnoses at any time before invasive
dental treatment. To assess whether any observed effect
could be attributable to persons stopping antiplatelet or
salicylate therapy before their dental treatment, we did an
analysis restricted to persons with no antiplatelet or salicy-
late drug prescriptions at any time before their dental treat-
ment. Among this group, stopping therapy was unlikely to
be an issue. Finally, to assess whether the development of
diabetes, hypertension, or coronary artery disease might
confound the observed association between invasive
dental treatment and vascular events, we excluded per-
sons with these conditions newly diagnosed within 1
year before their dental treatment. These analyses made
no material difference to our findings, and if anything,
they yielded a marginally stronger effect 1 to 4 weeks
after dental treatment. Table 3 summarizes the results
of the sensitivity analyses.
DISCUSSION
Our study has shown that invasive dental procedures
may be associated with a transient increase in the risk for
stroke and myocardial infarction in the first 4 weeks after
treatment. These findings provide further evidence to sup-
port the link between acute inflammation and the risk for
vascular events.
In studies investigating the risk for vascular events af-
ter inflammatory exposures, the potential for confounding
is great because persons who have invasive dental treatment
may differ from those who do not in ways that are difficult
to control for. The major strength of our study is the use of
a case series analysis in which within-person comparisons
are done, thereby overcoming the problem of potential
confounding associated with the influence of risk factors,
which may vary among persons. Confounding would occur
only if intraperson risk factors for vascular events that
change with time are also associated with the timing of
invasive dental treatment. In addition, to produce the ef-
fect observed, any such factors would need to have a large
Table 1. Characteristics of Study Participants
Characteristic Patients
With
Vascular
Events
(n  1152)*
Patients
With
Ischemic
Stroke
(n  650)†
Patients
With
Myocardial
Infarction
(n  525)†
Men, n (%) 458 (39.8) 233 (35.9) 236 (45.0)
Women, n (%) 694 (60.2) 417 (64.2) 289 (55.1)
Ethnicity, n (%)
White 558 (48.4) 282 (43.4) 282 (53.7)
Black 463 (40.2) 303 (46.6) 171 (32.6)
Hispanic 17 (1.5) 9 (1.4) 8 (1.5)
Other 114 (9.9) 56 (8.6) 64 (12.2)
Age at first event, n (%)
20–29 y 24 (2.1) 21 (3.2) 3 (0.6)
30–39 y 74 (6.4) 41 (6.3) 33 (6.3)
40–49 y 258 (22.4) 117 (18.0) 147 (28.0)
50–59 y 282 (24.5) 156 (24.0) 138 (26.3)
60–69 y 228 (19.8) 139 (21.4) 93 (17.7)
70–79 y 167 (14.5) 100 (15.4) 67 (12.8)
80–89 y 111 (9.6) 72 (11.1) 40 (7.6)
90 y 8 (0.7) 4 (0.6) 4 (0.8)
Diabetes diagnosis at any time
before IDT, n (%)
474 (41.2) 269 (41.4) 214 (40.8)
Hypertension diagnosis at any
time before IDT, n (%)
809 (70.2) 463 (71.2) 366 (69.7)
Coronary artery disease
diagnosis at any time
before IDT, n (%)
470 (40.8) 211 (32.5) 278 (53.0)
IDT  invasive dental treatment.
* Persons included in the primary analysis of vascular events.
† Twenty-three patients had both an ischemic stroke and a myocardial infarction
during their observation period: 19 were included in each analysis (vascular events
overall and by event type), and 4 (2 from each analysis, by event type) were
excluded from the primary analysis of vascular events because their earlier event
met the exclusion criteria.
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acute effect and their time-dependent effect would need to
operate in a large proportion of included participants. Pos-
sible confounding by the development of diabetes, hyper-
tension, or coronary artery disease; the cessation of anti-
platelet or salicylate medications before invasive dental
treatment; or the use of NSAIDs after treatment for pain
control were addressed in sensitivity analyses that excluded
persons with these newly diagnosed conditions, those with
recorded use of antiplatelet or salicylate drugs before dental
treatment, and those probably taking NSAIDs around the
time of dental treatment. These exclusions made no ma-
terial difference to our findings. Nevertheless, we recog-
nize that our ascertainment of use of antiplatelet agents,
salicylates, or NSAIDs may be incomplete because some
patients probably received these agents both through
prescription and over the counter. Because the database
does not capture over-the-counter use, we cannot ex-
clude the possibility of residual confounding by differ-
ential use of these agents around the time of invasive
dental treatment. Further sensitivity analyses demon-
strated that our results were robust with regard to as-
sumptions underlying the within-person case series.
In our study, the exposed period starts 1 day after an
invasive dental procedure; hence, the day of a dental pro-
cedure contributes to the baseline period. This avoids the
problem of events occurring on the same day as a proce-
dure, which are a consequence of some other factors unre-
lated to the dental treatment included in our risk estimates.
Any bias occurring from this convention would lead to an
underestimate of effect. However, this is of no concern in
our study because no vascular events occurred on the same
day as a procedure.
A further strength of the study is that the Medicaid
database has high levels of completeness and validity (13).
It contains records of all medical care provided to eligible
persons, therefore eliminating the problems of recall or
interviewer bias in both exposure and outcome. Neverthe-
Table 2. Age-Adjusted Incidence Ratios of a First Vascular
Event in Risk Periods After Exposure to Invasive Dental
Treatment
Outcome and Risk Period Cases, n Age-Adjusted
Incidence Ratio
(95% CI)
Vascular event (n  1152)*
Risk period after procedure
1–4 wk 40 1.50 (1.09–2.06)
5–8 wk 29 1.11 (0.77–1.61)
9–12 wk 30 1.16 (0.81–1.68)
13–16 wk 25 0.96 (0.64–1.43)
17–24 wk 53 1.08 (0.82–1.43)
Baseline period† 975 1.00
Ischemic stroke (n  650)
Risk period after procedure
1–4 wk 21 1.39 (0.89–2.15)
5–8 wk 14 0.94 (0.55–1.60)
9–12 wk 18 1.21 (0.76–1.95)
13–16 wk 11 0.73 (0.40–1.32)
17–24 wk 33 1.18 (0.83–1.69)
Baseline period† 553 1.00
Myocardial infarction (n  525)
Risk period after procedure
1–4 wk 19 1.56 (0.98–2.47)
5–8 wk 16 1.35 (0.82–2.23)
9–12 wk 13 1.12 (0.64–1.95)
13–16 wk 14 1.20 (0.70–2.05)
17–24 wk 20 0.90 (0.57–1.42)
Baseline period† 443 1.00
* Vascular events are 639 ischemic strokes (55.5%) and 513 myocardial infarc-
tions (44.5%).
† Baseline period is all observation time except for the 24-wk period after an
invasive dental procedure.
Table 3. Results of Sensitivity Analyses
Analysis of Vascular Event Risk* Cases
Included in
Analysis, n
Age-Adjusted Incidence
Ratio (95% CI)†
Primary analysis
Vascular events‡ 1152 1.50 (1.09–2.06)
Sensitivity analyses, by exclusion criteria
Overlapping risk periods (204 excluded) 948 1.65 (1.17–2.33)
Several invasive dental procedures (291 excluded) 861 1.53 (1.04–2.25)
Procedures that were not extractions (135 excluded) 1017 1.58 (1.13–2.21)
Enrollment ending or death within 1 mo after vascular event (83 excluded) 1069 1.62 (1.17–2.24)
Antiplatelet or salicylate drug prescription record at any time before IDT (486 excluded) 666 2.23 (1.56–3.18)
NSAID prescription 4 wk before to 4 wk after IDT or rheumatoid arthritis diagnosis at any time before IDT (687 excluded) 465 1.84 (1.17–2.89)
Earliest record of diabetes within 12 mo before IDT (224 excluded) 928 1.46 (1.02–2.10)
Earliest record of hypertension within 12 mo before IDT (398 excluded) 754 1.64 (1.12–2.40)
Earliest record of coronary artery disease within 12 mo before IDT (239 excluded) 913 1.70 (1.21–2.40)
Diagnosis of diabetes, hypertension, or coronary artery disease at any time before IDT (924 excluded) 228 1.76 (0.92–3.36)
IDT  invasive dental treatment; NSAID  nonsteroidal anti-inflammatory drug.
* 1–4 wk after procedure compared with baseline. Baseline period is all observation time except for the 24-wk risk period after an invasive dental procedure.
† 1–4 wk after an invasive dental procedure.
‡ Vascular events are 639 ischemic strokes (55.5%) and 513 myocardial infarctions (44.5%).
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less, we cannot exclude the possibility of case ascertainment
bias, whereby patients with events may be more likely to be
designated as having an outcome in the first month after a
dental procedure than later. There is also some scope for
misclassification of exposure status. We cannot determine
who had dental coverage—only who made dental claims.
If some persons did not qualify for dental coverage yet had
undergone an invasive dental treatment (either self-funded
or covered by another insurer), this would not be captured
in the database. These persons would be misclassified as
unexposed, which could lead to an underestimate of effect.
This is unlikely to be a major problem in our study because
only those persons with an invasive dental procedure
record (and thus with dental coverage) contributed to the
analyses, and the chance of their dental coverage changing
during enrollment is probably small.
Our study was based on claims data, and a potential
weakness may relate to the skewed nature of the population
eligible for Medicaid. Eligibility is income-related, which
raises the question of generalizability of these findings to
other populations. Eligible groups include low-income
adults and their children and persons with certain disabil-
ities. Patients with diseases that put them at greater risk for
thrombotic events may be more likely to enter the Medic-
aid program to pay for needed care, including dental care.
However, this is more of a problem in descriptive studies
and less of a concern in an analytical study such as ours,
particularly because each person serves as his or her own
control. The relatively small study population is another
limitation. In a case series design, only persons exposed at
least once during follow-up contribute to the analyses.
Given that invasive dental procedure claims were fairly un-
common, a relatively small proportion of our initial study
sample contributed to the analyses. This resulted in a loss
of power, which unfortunately limited our ability to exam-
ine the effects of invasive dental treatment on stroke and
myocardial infarction separately. Nevertheless, the strin-
gent criteria used to define our exposure and outcomes and
the suitability of our statistical approach together make the
case for the validity of our findings.
Increasing evidence implicates low-grade dental infec-
tions, such as periodontitis, in the cause of systemic dis-
eases. Several epidemiologic studies have shown that peri-
odontal disease is associated with elevated markers of
inflammation (23–25) and increased cardiovascular disease
risk in the long term (9, 26, 27). Treatment of periodon-
titis may yield a positive influence on longer term cardio-
vascular disease risk by reducing the infectious burden
(28). Recent studies have found that intensive periodontal
therapy produces an acute systemic inflammatory response
1 week in duration and a transient impairment of endo-
thelial function followed by a subsequent improvement rel-
ative to baseline (10–12). Our findings of a small but sta-
tistically significant association between invasive dental
treatment and vascular event risk over the short term are
consistent with these earlier studies. Although we cannot
exclude the possibility that other mechanisms may be in-
volved, such as elevated stress due to pain arising from
invasive dental treatment, possible discontinuation of anti-
platelet or salicylate therapy before treatment, or the use of
NSAIDs after treatment, our findings lend support to the
hypothesis that inflammation may play an important role
in the occurrence of vascular events.
Although the mechanisms are uncertain, we conclude
that invasive dental treatment may be associated with a
transient increase in the risk for stroke and myocardial
infarction in adults. The short-lived adverse effects are nev-
ertheless likely to be outweighed by long-term benefits of
invasive dental treatment to vascular health.
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APPENDIX
The following provides a brief overview of the self-
controlled case series (SCCS) method and further details of its
application to our study on invasive dental treatment and risk for
vascular events. For readers interested in using the SCCS
method, the Web site run by the statistician who developed the
method (http://statistics.open.ac.uk/sccs/) provides a tutorial
(14) and files to download to implement the method in several
statistical software packages: Stata (StataCorp); SAS (SAS Insti-
tute, Cary, North Carolina); R (R Foundation for Statistical
Computing, Vienna, Austria); GLIM (Royal Statistical Society,
London, United Kingdom); and GenStat (VSN International,
Hemel Hempstead, United Kingdom).
Background and Description of SCCS Method
The SCCS method uses within-person comparisons in a
population of persons who had the outcome of interest to inves-
tigate the association between time-varying exposures and out-
come events. It is derived from a Poisson cohort model by con-
ditioning on the number of events and exposure history that a
person has during a predefined observation period: the time dur-
ing which, if an event occurred, the person would be sampled.
Although the method was originally developed to investigate as-
sociations between vaccination and acute adverse events (29, 30),
it has subsequently been applied in other settings (for example, to
investigate the risk for myocardial infarction and stroke [6] and
deep venous thrombosis and pulmonary embolism [22] after
acute infection) and has been extensively used in pharmacoepi-
demiology (31–34).
The SCCS method provides an alternative to the more es-
tablished cohort method for estimating the relative incidence of
an event (that is, the ratio of the rate of events in a defined period
after exposure to the rate of events in the absence of exposure).
Appendix Figure 2 illustrates this method. Only cases are
sampled—there is no comparison control group of persons.
Comparisons are within person. To take this into account, the
likelihood is conditional on an outcome event having occurred
during the observation period. Thus, the likelihood is based on
the probability density that a person’s event occurred when it did
in relation to exposure, given that the event occurred during the
observation period.
Advantages
The main advantage of the SCCS method is that inference is
within persons; hence, fixed or stable characteristics, such as ge-
netic factors, sex, socioeconomic status, and underlying health
status (individual characteristics that do not vary over the obser-
vation period) are implicitly controlled for. The method uses
only case patients, which reduces the cost and effort involved in
data collection and provides consistent estimates of the relative
incidence of events. In addition, it allows age or temporal varia-
tion in baseline incidence to be controlled for. It also often has
high statistical efficiency relative to the cohort method from
which it is derived.
Limitations and Assumptions
The SCCS method produces only estimates of relative inci-
dence and not absolute incidence. Hence, our study reports only
incidence ratios. The method also requires some variability in the
time or age at event: It would fail if all events occurred at the
same age (an unlikely scenario and not an issue in our study). In
addition, the validity of the method rests on some important
assumptions (35). First, the occurrence of an event does not
affect a person’s subsequent exposure; second, the occurrence of
an event does not alter the duration of the observation period;
and third, events are independent within a person. In the context
of our study, these assumptions are discussed in the section, Ad-
dressing the Assumptions Underlying the SCCS Method.
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Application of the SCCS Method to Our Study
To examine the risk for vascular events after exposure to inva-
sive dental procedures, we used the SCCS method because persons
who have had invasive dental treatment may differ from those who
have not in ways that can be difficult to measure and control for.
Some of these differences may also be associated with the future risk
for vascular events, which makes a conventional cohort design a less
reliable approach for examining this association.
Persons who had a vascular event and at least 1 invasive
dental procedure during their observation period were included
in the primary analysis. The observation period for each person
was the time during which, if a vascular event occurred, the
person would be sampled (that is, the continuous enrollment
period in Medicaid from January 2002 to December 2006).
Thus, each person was followed from the start of his or her
continuous enrollment period until he or she died or the contin-
uous enrollment period ended (whichever occurred first), regard-
less of when the vascular event occurred. We took into account
repeated invasive dental procedures during the observation pe-
riod, assuming the same level of risk after each procedure. By
using conditional Poisson regression, we derived incidence ratios
of vascular events occurring during predefined risk periods ex-
tending up to 24 weeks after an invasive dental procedure, rela-
tive to all other observed time periods. Our null hypothesis was
that rates of vascular events remain constant from day to day and
are not affected by exposure to invasive dental treatment.
Although fixed covariates are implicitly controlled for in a
case series analysis, there is still scope for confounding if intra-
person risk factors for vascular events that change with time are
also associated with the timing of invasive dental treatment. As
the baseline risk for vascular events varies with age (that is, the
risk in the absence of exposure to invasive dental treatment), we
split each person’s follow-up into successive intervals determined
by changes in age (by using 5-year groupings) and exposure sta-
tus. The time-varying effect of age was thus controlled for by
including the age group factor as a covariate in each model.
We recognized that there may be potential for confounding
by the development of diabetes, hypertension, or coronary artery
disease; possible withholding of antiplatelet or salicylate medica-
tion before invasive dental treatment; or the use of NSAIDs after
dental treatment for pain control. Therefore, we conducted sen-
sitivity analyses excluding persons with these conditions newly
diagnosed during the year before invasive dental treatment, those
with recorded use of antiplatelet or salicylate drugs before dental
treatment (who thus had the opportunity to withhold from their
medication), or those with a recorded diagnosis of rheumatoid
arthritis before dental treatment (who were probably taking
NSAIDs) or with an NSAID prescription around the time of
their dental treatment. These exclusions made no material differ-
ence to our findings or conclusions.
Addressing the Assumptions Underlying the SCCS Method
Assumption 1: The Occurrence of an Event Should Not Affect
the Probability of Subsequent Exposure. This is perhaps the most
restrictive assumption underlying the SCCS method (36). Other
than the vascular outcome itself being fatal (thus curtailing the
probability of exposure), we can think of no major factors likely
to alter exposure to invasive dental treatment after a vascular
event. To address the issue of fatal vascular events, we conducted
a sensitivity analysis excluding persons who died during their
hospital stay for their vascular event or whose enrollment ended
within a month of their event, possibly indicating death. Exclud-
ing all such possible deaths did not materially alter our findings
or conclusions. We found a marginally stronger effect in 1 to 4
weeks after invasive dental treatment.
Assumption 2: The Occurrence of the Event Should Not Censor
or Alter the Duration of the Observation Period. In a case series
study, each person’s observation period is usually determined by
using predefined calendar time boundaries, age limits, or both
and must be independent of the timing of the event. This as-
sumption may also be violated when the event of interest is likely
to increase the short-term death rate. Thus, the sensitivity anal-
yses described previously also addressed this assumption.
Assumption 3: Events Are Independent Within a Person. The
case series method requires that the occurrence of an event
should not affect the rate at which subsequent events may occur.
If this assumption fails, a reasonable strategy is to restrict the
analysis to first events, provided that these are not common (14,
15, 36). We restricted our analyses to the first event during the
observation period (that is, the first occurring during baseline or
a risk period). We did this because the recurrence times of events
under study (ischemic stroke and myocardial infarction) cannot
be assumed to be independent within persons. Occurrence of a
first stroke or myocardial infarction is known to increase the risk
for further strokes or myocardial infarctions. All events subse-
quent to the first in a person’s observation period were not in-
cluded in the analysis, yet each person was followed for the du-
ration of his or her continuous enrollment period. Thus, his or
her predefined observation period was preserved. Although ex-
cluding subsequent events could underestimate the absolute risk
for events, this is unlikely to have any material effect on the
relative risk (the outcome of our study). A similar approach was
taken in a study exploring the risk for myocardial infarction and
stroke after acute infection and vaccination (6). Appendix Table
2 shows the number of subsequent events excluded from each of
our analyses.
Overlapping Risk Periods
Some persons had several dental procedures during their
observation period. When 2 or more procedures occur within 24
weeks of each other, the risk periods for these procedures overlap.
A simple convention to address overlapping risk periods is that
later exposures take precedence over earlier ones (14). We used
this convention in our study; thus, when a person had 2 or more
dental procedures and a later procedure occurred at some point
during the risk period of an earlier procedure, a new 24-week risk
period started from that point. This means that the later proce-
dure takes precedence, although it does not replace the earlier
procedure. The earlier procedure is not ignored. Appendix Fig-
ure 3 illustrates our convention with 2 possible scenarios. First, if
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a person had a dental procedure followed by a vascular event 2
weeks later and then a second dental procedure 20 weeks after the
first, the vascular event would not be classified as occurring dur-
ing baseline; it would be classified as occurring in the risk period
corresponding to the first procedure (Appendix Figure 3, scenario
A). However, a vascular event occurring 2 weeks after the second
dental procedure would be classified as occurring during the risk
period of this second procedure rather than during the risk pe-
riod of the first (Appendix Figure 3, scenario B). This convention
reflects the actual exposure experience: In both scenarios, the
event occurred 2 weeks after exposure.
Appendix Table 1. Distribution of Invasive Dental Procedures Found in Study Participants’ Records
Dental
Procedure
Code*
Description Persons With >1 Procedure Record, n (%)
Patients With
Vascular
Events
(n  1152)†
Patients With
Ischemic Stroke
(n  650)
Patients With
Myocardial
Infarction
(n  525)
D7210 Surgical removal of erupted tooth requiring elevation of mucoperiosteal flap and
removal of bone, section of tooth, or both
847 (73.5) 499 (76.8) 364 (69.3)
D7250 Surgical removal of residual tooth roots (cutting procedure) 151 (13.1) 90 (13.8) 67 (12.8)
D7310 Alveoloplasty in conjunction with extractions (4 teeth or tooth spaces per
quadrant)
104 (9.0) 49 (7.5) 55 (10.5)
D7510 Incision and drainage of abscess (intraoral soft tissue) 25 (2.2) 15 (2.3) 11 (2.1)
D4341 Periodontal scaling and root planning (4 teeth per quadrant) 23 (2.0) 7 (1.1) 16 (3.0)
D7320 Alveoloplasty not in conjunction with extractions (4 tooth spaces per
quadrant)
16 (1.4) 9 (1.4) 8 (1.5)
D7240 Removal of impacted tooth (completely bony) 15 (1.3) 10 (1.5) 5 (1.0)
D7230 Removal of impacted tooth (partially bony) 13 (1.1) 8 (1.2) 6 (1.1)
D4211 Gingivectomy or gingivoplasty (1–3 contiguous teeth or bounded teeth spaces
per quadrant)
6 (0.5) 3 (0.5) 5 (1.0)
D7471 Removal of lateral exostosis (maxilla or mandible) 5 (0.4) 3 (0.5) 2 (0.4)
D4210 Gingivectomy or gingivoplasty (4 contiguous teeth or bounded teeth spaces
per quadrant)
4 (0.3) 1 (0.2) 3 (0.6)
D7241 Removal of impacted tooth (completely bony, with unusual surgical
complications)
4 (0.3) 3 (0.5) 1 (0.2)
D7999 Unspecified oral surgery procedure, by report 4 (0.3) 0 (0) 4 (0.8)
D7540 Removal of reaction-producing foreign bodies (musculoskeletal system) 3 (0.3) 3 (0.5) 0 (0)
D3410 Apicoectomy or periradicular surgery (anterior) 2 (0.2) 1 (0.2) 1 (0.2)
D7960 Frenulectomy (frenectomy or frenotomy) as a separate procedure 2 (0.2) 0 (0) 2 (0.4)
D7970 Excision of hyperplastic tissue (per arch) 2 (0.2) 0 (0) 2 (0.4)
D3421 Apicoectomy or periradicular surgery (bicuspid [first root]) 1 (0.1) 1 (0.2) 0 (0)
D4342 Periodontal scaling and root planning (1–3 teeth per quadrant) 1 (0.1) 1 (0.2) 0 (0)
D7290 Surgical repositioning of teeth 1 (0.1) 0 (0) 1 (0.2)
D7321 Alveoloplasty not in conjunction with extractions (1–3 teeth or tooth spaces per
quadrant)
1 (0.1) 0 (0) 1 (0.2)
D7410 Excision of benign lesion 1.25 cm 1 (0.1) 0 (0) 1 (0.2)
D7460 Removal of benign nonodontogenic cyst or tumor (lesion diameter 1.25 cm) 1 (0.1) 0 (0) 1 (0.2)
D7461 Removal of benign nonodontogenic cyst or tumor (lesion diameter 1.25 cm) 1 (0.1) 0 (0) 1 (0.2)
D7520 Incision and drainage of abscess (extraoral soft tissue) 1 (0.1) 1 (0.2) 0 (0)
D7550 Partial ostectomy or sequestrectomy for removal of nonvital bone 1 (0.1) 1 (0.2) 0 (0)
* From Current Dental Terminology (16).
† Persons included in the primary analysis of vascular events.
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Appendix Figure 1. Study flow diagram.
Initial sample (n = 32 060)
All persons with a hospitalization record for a vascular event from 1 January 2002 to 31 December 2006
Stroke only: 17 277
MI only: 14 319
Both: 464* 
Cases included in primary analysis (n = 1152)
Persons with an earliest recorded vascular event and exposure to invasive dental treatment during 
continuous enrollment period
Stroke only: 629
MI only: 504
Both: 19
Excluded (n = 10 822)
Less than 24 wk of continuous enrollment in Medicaid before earliest recorded 
hospitalization for vascular event
Stroke only: 5838
MI only: 4815
Both: 169
Candidates (n = 21 238)
Stroke only: 11 439
MI only: 9504
Both: 295 
Excluded (n = 104)
Age <20 y at time of earliest recorded vascular event
Stroke only: 92
MI only: 12
Both: 0
Candidates (n = 21 134)
Stroke only: 11 347
MI only: 9492
Both: 295 
Excluded (n = 765)
Earliest recorded vascular event occurs outside continuous enrollment period
Stroke only: 396
MI only: 360
Both: 9
Eligible cases (n = 20 369)
Stroke only: 10 951
MI only: 9132
Both: 286 
Excluded (n = 19 217)
Not exposed to invasive dental treatment during continuous enrollment period
Stroke only: 10 322
MI only: 8628
Both: 267
MI  myocardial infarction.
* Individuals who had both an ischemic stroke and an MI during the study period.
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Appendix Figure 2. Pictorial representation of the self-
controlled case series method.
Day of exposure Day of exposure
Baseline period
Risk period after exposure (e.g., an invasive dental procedure)
Start of observation End of observation
Time
A single participant who had 2 exposures during the observation period
is shown. The outcome event could occur at any time during the obser-
vation period.
Appendix Table 2. Cases With a Subsequent Event and
Number of Subsequent Events Excluded From Analysis
Outcome Cases
Included,
n
Cases With a
Subsequent
Event, n (%)
Subsequent
Events
Excluded
(Range), n
Vascular event* 1152 126 (10.9) 158 (2–5)
Ischemic stroke 650 73 (11.2) 93 (2–5)
Myocardial infarction 525 38 (7.2) 46 (2–3)
* Ischemic stroke or myocardial infarction.
Appendix Figure 3. Pictorial representation of overlapping risk periods.
Dental
procedure 1
Risk period corresponding to first procedure
Risk period corresponding to second procedure
Baseline
Scenario A
Start of observation
20 wk 24 wk
End of observation
Dental
procedure 2
Vascular event 2 wk
after procedure 1
Dental
procedure 1
Scenario B
Start of observation
20 wk 24 wk
End of observation
Dental
procedure 2
Vascular event 2 wk
after procedure 2
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Abstract
Background: Infection in pregnancy may be involved in the aetiology of pre-eclampsia. However, a clear association
between acute maternal infection and pre-eclampsia has not been established. We assessed whether acute urinary tract
infection, respiratory tract infection, and antibiotic drug prescriptions in pregnancy (a likely proxy for maternal infection) are
associated with an increased risk of pre-eclampsia.
Methods and Findings: We used a matched nested case-control design and data from the UK General Practice Research
Database to examine the association between maternal infection and pre-eclampsia. Primiparous women aged at least 13
years and registered with a participating practice between January 1987 and October 2007 were eligible for inclusion. We
selected all cases of pre-eclampsia and a random sample of primiparous women without pre-eclampsia (controls). Cases
(n = 1533) were individually matched with up to ten controls (n = 14236) on practice and year of delivery. We calculated
odds ratios and 95% confidence intervals for pre-eclampsia comparing women exposed and unexposed to infection using
multivariable conditional logistic regression. After adjusting for maternal age, pre-gestational hypertension, diabetes, renal
disease and multifetal gestation, the odds of pre-eclampsia were increased in women prescribed antibiotic drugs (adjusted
odds ratio 1.28;1.14–1.44) and in women with urinary tract infection (adjusted odds ratio 1.22;1.03–1.45). We found no
association with maternal respiratory tract infection (adjusted odds ratio 0.91;0.72–1.16). Further adjustment for maternal
smoking and pre-pregnancy body mass index made no difference to our findings.
Conclusions: Women who acquire a urinary infection during pregnancy, but not those who have a respiratory infection, are
at an increased risk of pre-eclampsia. Maternal antibiotic prescriptions are also associated with an increased risk. Further
research is required to elucidate the underlying mechanism of this association and to determine whether, among women
who acquire infections in pregnancy, prompt treatment or prophylaxis against infection might reduce the risk of pre-
eclampsia.
Citation:Minassian C, Thomas SL, Williams DJ, Campbell O, Smeeth L (2013) Acute Maternal Infection and Risk of Pre-Eclampsia: A Population-Based Case-Control
Study. PLoS ONE 8(9): e73047. doi:10.1371/journal.pone.0073047
Editor: Andrew Dewan, Yale School of Public Health, United States of America
Received April 4, 2013; Accepted July 16, 2013; Published September 3, 2013
Copyright:  2013 Minassian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by a Wellcome Trust Senior Research Fellowship in Clinical Science awarded to Professor LS (grant number 098504/Z/12/Z). Dr
DJW receives part of his funding from UCL/UCLH Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: caroline.minassian@lshtm.ac.uk
Introduction
Pre-eclampsia is a multi-system vascular syndrome of pregnancy
defined by the gestational onset of hypertension and proteinuria,
typically occurring after 20 weeks’ gestation. It is a major cause of
maternal and perinatal morbidity and mortality worldwide, its
incidence ranging between 2% and 8% in nulliparous women. [1]
Despite advances in knowledge, we still have a limited ability to
predict or prevent pre-eclampsia. While its aetiology is generally
considered to be multifactorial, involving both maternal and
placental contributions, [2] there is increasing evidence that
inflammation plays a central pathogenic role. [3] Impaired
vascular endothelial function, which can derive from inflamma-
tion, is evident among women prior to developing pre-eclampsia.
[4] Poor placental perfusion as a result of inadequate placentation
is a key inflammatory stimulus for many women with pre-
eclampsia. However, any factor that provokes the maternal
systemic inflammatory response, such as infection, may contribute
to the overall inflammatory burden and the development of pre-
eclampsia.
A growing body of evidence suggests that infection, a common
cause of inflammation and of endothelial dysfunction, may be
involved in the aetiology of pre-eclampsia. [5] An increased risk of
pre-eclampsia associated with maternal periodontal disease has
been well-documented.[6–8] Studies based on serological markers
of chronic infections have also yielded positive findings,[9–14]
although temporal associations in these studies are uncertain.
Acute maternal infections such as urinary tract infection (UTI)
may also play a role in pre-eclampsia, possibly by amplifying the
maternal systemic inflammatory response. A meta-analysis of
observational studies examining the relationship between maternal
infections and pre-eclampsia [5] reported a summary odds ratio
for pre-eclampsia of 1.57 (95% CI 1.45–1.70) in women with UTI
in pregnancy. However, there was marked heterogeneity between
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studies and results were inconsistent. Findings from two more
recent studies are conflicting: one, a large population-based cohort
study [15] reported an increased risk of pre-eclampsia among
women with maternal UTI, while a case-control study found no
association. [16] Factors such as the timing of infection in relation
to pre-eclampsia were not investigated in these studies, and the
findings may have been confounded by renal disease, or biased by
increased ascertainment of UTI in pregnancy, particularly among
women at risk of pre-eclampsia. Data on the effects of other acute
maternal infections are lacking. Thus a clear role for acute
infection in the aetiology of pre-eclampsia has not been
established.
The large sample size afforded by the UK General Practice
Research Database (GPRD) provided a unique opportunity to
address these issues. We assessed the gestational onset of UTI, as
well as respiratory tract infection (RTI), and maternal antibiotic
prescriptions (a likely proxy for infection). Examining the role of
antibiotic prescriptions and infections in different organ systems
would, if positive, suggest that the effect of acute infection on the
risk of pre-eclampsia is generic and not specific to one type of
infection.
Methods
The General Practice Research Database
The GPRD is an electronic UK population-based primary care
database. Established in January 1987, it holds anonymised
longitudinal patient records, routinely recorded as part of patients’
normal care, for over 10 million patients registered to over 600
general practices. More than 98% of the UK population are
registered with a general practitioner (GP) and practices contrib-
uting to the database are representative of practices throughout
the UK. [17] In addition to being a rich data source, the GPRD
has high data validity. [18] Each participating practice is assigned
an ‘‘up-to-standard’’ date indicating when data recording com-
plied with specific quality measures (based on an assessment of the
completeness, continuity and plausibility of data). Data are subject
to ongoing evaluation, verification and validation procedures to
ensure they are research-quality [19].
Ethics Statement
The electronic health records used for this study comprised data
from the Full Feature GPRD obtained under licence from the UK
Medicines and Healthcare Products Regulatory Agency. GPRD
data are used extensively for public health research, and the
GPRD has stringent procedures for maintaining confidentiality of
personal data. All data provided to researchers are anonymised to
ensure that individual patients cannot be identified. In addition,
patients have the right to opt out from the use of their anonymised
data. The use of these data for this study was approved by the
Independent Scientific Advisory Committee of the GPRD
(protocol 07_094) and by the London School of Hygiene and
Tropical Medicine Ethics Committee (application number 5283).
Study Design and Participants
We used a matched nested case-control study design to examine
the association between acute maternal infections and pre-
eclampsia. Participants were derived from a source population of
all female patients registered with a practice contributing to the
GPRD between 1st January 1987 and 31st October 2007 inclusive
and who had a pregnancy during this period.
Eligibility criteria. Because pre-eclampsia usually develops
in the later stages of pregnancy, a woman must have completed
her pregnancy to have the opportunity to become a case.
Therefore, only women with a documented completed pregnancy,
defined as an end-of-pregnancy record indicating the woman had
delivered a live birth or stillbirth (e.g. ‘‘birth details’’), or was soon
to deliver (e.g. ‘‘antenatal 37 week examination’’), were potential
candidates. Pregnancies resulting in miscarriage or termination
were not included since they were likely to end before a woman
had reached the required gestational age to be at risk of being
diagnosed with pre-eclampsia. As pre-eclampsia is much more
common in nulliparous women, [20] we restricted the study
population to women with a first documented completed
pregnancy during the study period.
Women aged at least 13 years at delivery and whose data
throughout the gestational period (from conception to delivery)
were within up-to-standard follow-up were eligible for inclusion.
The follow-up criterion helped ensure that diagnoses and events
pertaining to the pregnancy were captured. Clinical entries in the
data were coded using the Oxford Medical Information System
(OXMIS) and Read coding system. We selected as potential cases
all those with a clinical diagnosis of pre-eclampsia, defined as a
Read/OXMIS code for pre-eclampsia, eclampsia or the severe
pre-eclampsia variant HELLP syndrome (hemolysis, elevated liver
enzymes, low platelets), in their first documented completed
pregnancy. We selected as potential controls a random sample of
eligible women with no diagnosis of pre-eclampsia anywhere in
their medical data. This ensured controls had no pre-eclampsia in
their first documented completed pregnancy, and no history of
pre-eclampsia possibly relating to an earlier (unrecorded) preg-
nancy.
Exclusions. To help ensure cases and controls were primip-
arous, we excluded women with evidence for an earlier completed
pregnancy (e.g. a record of ‘‘previous caesarean section’’ before
their earliest delivery record). To distinguish cases of pre-eclampsia
from women with essential or secondary hypertension which
became clinically apparent during pregnancy, we excluded women
with no evidence of high blood pressure until pregnancy but whose
hypertension did not resolve six to 12 months post-delivery. The
identification of cases and controls for inclusion in the study is
illustrated in Figure 1.
Matching. Cases were matched with controls on GP practice
to allow for variability in recording and prescribing habits between
practices, and on year of delivery (an absolute difference of up to
12 months between cases’ and controls’ estimated delivery dates)
to ensure they were contemporaneous. All possible case-control
matches were identified and up to ten controls per case were
selected at random without replacement. Although any additional
gain in power is minimal if the case-control ratio exceeds 1:4, the
number of eligible controls exceeded the number of cases by more
than twenty-fold: thus, increasing the control-per-case ratio
beyond four posed no additional cost or effort in data collection.
Dating Pregnancies
In the absence of systematically recorded information on the
exact timing of pregnancy, we used information from antenatal
records indicating gestational age, delivery records indicating the
number of days or weeks postnatal, and recorded estimates of the
expected date of delivery and first day of a woman’s last menstrual
period (LMP) to obtain our best estimates of the start and end of
each woman’s completed pregnancy. We estimated the timing of
trimesters adopting a common convention: first trimester (first day
of LMP to 13 weeks), second (weeks 14 to 26), and third (week 27
to delivery).
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Exposures
The exposure period for each participant began on the first day
of LMP and ended at the index date, defined as the date of pre-
eclampsia diagnosis (for cases). For controls, the index date was the
date they reached the same gestational age as their matched case
at pre-eclampsia diagnosis. This was to ensure the duration of the
exposure period for cases and their matched controls was
comparable.
We extracted data on Read/OXMIS codes for acute UTIs
(manifest as asymptomatic bacteriuria, cystitis, or pyelenephritis)
and RTIs (excluding non-specific or minor upper RTIs and
symptoms such as sore throat), and on antibiotic drug prescriptions
over the exposure period. When a woman had more than one
record of infection or antibiotic prescription, a minimum of 29
days between records of the same type was required for these to be
considered distinct episodes of infection (rather than repeat records
for the same infection).
Potential confounders. Data on the following potential risk
factors were extracted: maternal age; pre-gestational renal disease,
diabetes, hypertension and asthma; multifetal gestation; pre-
pregnancy body mass index (BMI); maternal smoking (a known
protective factor); previous early pregnancy loss; and assisted
reproductive technology (ART), defined as in vitro fertilization
and related techniques (including gamete intrafallopian transfer
and embryo transfer). To address the possibility that some
infections may be more likely to be recorded among women
who consult with their GP more frequently, we measured the
number of consultations and duration of follow-up each woman
had prior to pregnancy. This allowed comparison of cases’ and
controls’ pre-pregnancy consultation behaviour.
Statistical Analysis
We used multivariable conditional logistic regression to estimate
odds ratios (ORs) and 95% confidence intervals for pre-eclampsia
comparing pregnant women exposed and not exposed to each type
of infection or to antibiotic prescriptions. The primary analysis
assessed the effect of each exposure at any time during the
exposure period. Subsequent analyses explored the effects of
increasing episodes of infection over the exposure period. Potential
confounding factors associated with pre-eclampsia in crude
analyses were assessed in more complex models and retained if
they made an appreciable difference to the infection (or antibiotics)
OR. Maternal age (controlled for in five-year age groups) and pre-
existing renal disease were included in all models a priori.
Likelihood ratio tests were used to assess statistical significance.
Figure 1. Identification of study participants included in the primary analysis: A) cases (n=1533); B) controls (n =14236).
doi:10.1371/journal.pone.0073047.g001
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To reduce the possibility of misdiagnosis of UTI among women
with pre-eclampsia due to identification of proteinuria, we
repeated the analyses for UTI and antibiotics among cases who
developed pre-eclampsia in the third trimester and their matched
controls, and assessed the effect of exposure to UTI or antibiotics
in the first and second trimesters only versus no exposure at any
time in pregnancy. These third trimester pre-eclampsia cases were
unlikely to have proteinuria detected during the first two
trimesters, thus minimising the potential for such misclassification.
In sensitivity analyses, we excluded the following: women aged
less than 18 years as their pregnancy outcomes and underlying risk
profile may differ from older women; women with pre-existing
hypertension, to rule out the possibility of misdiagnosis of pre-
eclampsia; controls with new onset hypertension during pregnancy
which resolved shortly after delivery, as they may have had pre-
eclampsia even in the absence of a clinical diagnosis; and ART
pregnancies which may have a higher risk of developing pre-
eclampsia. To reduce the possibility that events we identified
throughout the exposure period (e.g. infections) may have referred
to past diagnoses that were recorded retrospectively within the first
few months after a patient joined a practice, we extended the up-
to-standard follow-up criterion to include only women with at least
six months up-to-standard follow-up prior to conception. To
address the possibility that pre-eclampsia diagnoses made in earlier
years were less exact, we restricted our analyses to pregnancies in
year 2000 onwards following publication of the first recommended
consensus definition of pre-eclampsia. [21] Finally, to assess
whether the effect of infection differed according to the timing of
onset of pre-eclampsia, or the severity, we conducted separate
analyses for cases with early-onset (,34 weeks’ gestation) versus
late-onset ($34 weeks’ gestation) pre-eclampsia, and for cases with
documented severe pre-eclampsia, eclampsia or HELLP syn-
drome.
Data were analysed using Stata, release 12 (StataCorp., College
Station, Texas).
Results
Data were obtained on all women with a clinical diagnosis of
pre-eclampsia during the study period (3362 potential cases) and a
large random sample of women who had a pregnancy during this
period and no recorded diagnosis of pre-eclampsia (93909
potential controls). After applying the eligibility, exclusion and
matching criteria, 1533 pre-eclampsia cases and 14236 controls
were included in the primary analysis (see Figure 1). The
commonest reason for not being eligible was uncertainty about the
timing of pregnancy. Table 1 summarizes the demographic and
risk profile of study participants. The median gestational age of
cases at pre-eclampsia diagnosis was 38.1 weeks (interquartile
range (IQR) 34.9 to 39.9 weeks), and most cases (79.5%) were late-
onset ($34 weeks’ gestation). The majority of pre-eclampsia
diagnoses were non-specific regarding severity (47.3%) or mild
(32.0%); the remaining 20.7% were severe pre-eclampsia,
eclampsia or HELLP syndrome. Cases and controls were of
similar age at delivery (median 28.3 years for cases; 28.2 years for
controls) and shared similar pre-pregnancy consultation behaviour
(median 11 consultations over 2.5 years). A higher proportion of
cases were overweight or obese (30.3%) compared to controls
(20.4%), and cases were less likely to smoke (18.5%) than controls
(23.3%).
During their first completed pregnancy, 528 (34.4%) cases and
4110 (28.9%) controls were prescribed an antibiotic drug, 182
(11.9%) cases and 1376 (9.7%) controls had one or more UTI, and
77 (5.0%) cases and 781 (5.5%) controls had one or more RTI.
The timing of each exposure by pregnancy trimester is shown in
Table 2. Less than half of women with an antibiotic prescription
in pregnancy had a record of UTI or RTI (42.8% of cases; 44.3%
of controls).
Crude and adjusted ORs for the association between maternal
infection and pre-eclampsia are summarized in Table 3. Antibi-
otic prescriptions (adjusted OR 1.28; 1.14–1.44) and UTI
(adjusted OR 1.22; 1.03–1.45) in pregnancy were associated with
an increased risk of pre-eclampsia after controlling for maternal
age; pre-gestational renal disease, diabetes and hypertension; and
multifetal gestation. We found no evidence for confounding by
prior early pregnancy loss. Findings were virtually identical when
we addressed the potential for differential misclassification of UTI
due to detection of proteinuria in cases by repeating analyses after
confining the exposure window for UTI and antibiotics to the first
two trimesters and excluding cases (n = 41) with very early onset
pre-eclampsia prior to the third trimester: adjusted OR for
antibiotics 1.26 (1.11–1.43) and UTI 1.22 (1.01–1.49). Further
adjustment for pre-pregnancy BMI and maternal smoking among
individuals with BMI and smoking data (1048 cases and 7216
controls) made no material difference to our findings (Table S1).
Women exposed to RTI in pregnancy were more likely to have
pre-existing asthma (29.5%) than women not exposed to RTI
(17.1%), and were more likely to smoke (28.6%) than those not
exposed (22.5%). We found no association between RTI and pre-
eclampsia in either the crude or adjusted analyses. The inclusion of
pre-existing asthma to our model did not alter the RTI OR.
The frequency distribution of the number of episodes (none,
one, more than one) of infection or antibiotic treatment is shown
in Table S2. No evidence of a dose-response association was
demonstrated (data not shown). Consistent with the primary
analysis, we observed an increased risk of both early- and late-
onset pre-eclampsia associated with maternal antibiotics prescrip-
tions and UTI, with no evidence for a clear difference between
these two sub-groups (Table S3). We conducted additional
sensitivity analyses as outlined in the methods. Each of these
analyses yielded estimates similar to those obtained in our primary
analysis (Table S4).
Discussion
Our study has shown that women who acquire UTI during
pregnancy, and women prescribed antibiotics during pregnancy (a
likely proxy for acute infection) are at an increased risk of pre-
eclampsia. The increased risk of pre-eclampsia developing in the
third trimester following UTI or antibiotic prescriptions in the first
two trimesters suggests that acute maternal infection may play a
role in the pathogenesis of pre-eclampsia. However, we found no
evidence for an increased risk of pre-eclampsia among women
who acquire RTI during pregnancy.
A major strength of our study is the use of a population-based
cohort of women from which we selected all cases of pre-eclampsia
in a first completed pregnancy and a random sample of
primiparous controls without pre-eclampsia. Our nested case-
control design avoids the common problem of selection bias
inherent in many case-control studies, particularly those in which
the base population giving rise to the cases is less well-defined.
Matching on GP practice allowed for variability in recording and
prescribing habits between practices, and helped ensure that cases
and controls were comparable on a range of socio-economic and
environmental indicators. The additional criterion of allowing no
more than 12 months between case and control delivery dates
ensured pregnancies within matched sets were contemporaneous.
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Another strength of this study is that we were able to include
data on a substantial number of well-known risk factors for pre-
eclampsia, some of which, most notably renal disease and diabetes,
were not accounted for in previous studies of UTI and pre-
eclampsia. [5,15,16] The associations with UTI and antibiotics
persisted even after adjustment for maternal age; pre-existing renal
disease, diabetes and hypertension; and multifetal gestation. We
cannot exclude the possibility of residual confounding if disease
risk factors were not recorded for some women; for example, the
low prevalence of pre-existing renal disease among cases (0.3%)
and controls (0.2%) suggests ascertainment of renal disease may be
limited to the more severe end of the disease spectrum. However,
this is unlikely to be a major concern since it is the more severe
disease (stages 3–5) which predisposes to pre-eclampsia, rather
than mild renal disease. [22] Missing information on maternal
smoking and pre-pregnancy BMI limited our ability to assess their
effects in the entire study population. Nevertheless, additional
adjustment for BMI and smoking made no material difference to
our findings. The similar pre-pregnancy consultation behaviour of
cases and controls suggests our findings are unlikely to be
explained by possible increased ascertainment of infection among
cases due to differential health-seeking behaviour.
We were able to restrict the study population to women in their
first documented completed pregnancy in their primary care
Table 1. Characteristics of study participants.
Characteristic n (%) Cases (N=1533) Controls (N=14236)
Maternal age at delivery (yrs)
,20 132 (8.6) 1470 (10.3)
20–24 340 (22.2) 2846 (20.0)
25–29 478 (31.2) 4492 (31.6)
30–34 406 (26.5) 3803 (26.7)
35–39 146 (9.5) 1348 (9.5)
40–44 29 (1.9) 239 (1.7)
$45 2 (0.1) 38 (0.3)
median, IQR 28.3, 23.9–32.3 28.2, 23.9–32.1
Pre-pregnancy BMI (kg/m2)
,18.5 (underweight) 26 (1.7) 526 (3.7)
18.5–25 (normal) 620 (40.4) 6618 (46.5)
25–30 (overweight) 272 (17.7) 1959 (13.8)
30+ (obese) 192 (12.5) 946 (6.7)
unknown 423 (27.6) 4187 (29.4)
median, IQR 24.1, 21.6–27.9 22.7, 20.7–25.6
Smoking status in pregnancy
non-smoker 834 (54.4) 6680 (46.9)
ex-smoker 166 (10.8) 1476 (10.4)
current smoker 283 (18.5) 3311 (23.3)
unknown 250 (16.3) 2769 (19.5)
Practice level socioeconomic statusa
IMD score [median, IQR] 16.2, 8.7–30.1 16.3, 8.4–30.2
Patient level socioeconomic status
IMD score [median, IQR] 14.3, 8.4–25.7 14.8, 8.3–26.4
unknown 744 (48.5) 6734 (47.3)
Pre-existing hypertension 161 (10.5) 875 (6.2)
Pre-existing renal disease 4 (0.3) 25 (0.2)
Pre-existing diabetes 28 (1.8) 166 (1.2)
Pre-existing asthma 291 (19.0) 2509 (17.6)
Previous miscarriage or termination 298 (19.4) 2869 (20.2)
Multiple pregnancy 25 (1.6) 121 (0.9)
ART pregnancy 11 (0.7) 84 (0.6)
Consultations with GP pre-pregnancy [median, IQR] 11, 4–27 11, 4–24
UTS follow-up pre-pregnancy (yrs) [median, IQR] 2.4, 0.9–5.1 2.5, 1.1–5.3
Abbreviations: IMD= Index of Multiple Deprivation score based on practice post-code (practice level socioeconomic status) or patient post-code (patient level
socioeconomic status). The higher the score the greater the deprivation. UTS =up-to-standard (i.e. data meeting GPRD quality standards). ART = assisted reproductive
technology.
amatching variable.
doi:10.1371/journal.pone.0073047.t001
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record, and excluded women with evidence of an earlier
(unrecorded) completed pregnancy, for example, a record
indicating parity.0 prior to the earliest delivery record. While
not guaranteeing that this was their first ever completed
pregnancy, it was likely to be the first for a large majority. In
addition, because the risk of infections is unlikely to have a strong
relationship with parity, the scope for confounding by parity is
limited. A further advantage of our approach is that it reduced the
potential for confounding by change in paternity or by inter-
pregnancy interval among multiparas [23].
While there is no universal agreement on the definition of pre-
eclampsia, [2] a diagnosis has major consequences for a pregnant
woman and is unlikely to be recorded speculatively. In 2000, the
National High Blood Pressure Education Program Working
Group developed diagnostic criteria for pre-eclampsia, [21]
recommended in the American College of Obstetricians and
Gynecologists practice guidelines for diagnosing pre-eclampsia.
[24] To improve the validity of our case definition we excluded
from the primary analysis women whose new onset hypertension
in pregnancy did not resolve following delivery, in line with this
consensus definition. While we cannot rule out the possibility of
misclassification of pre-eclampsia, this criterion helped distinguish
cases of pre-eclampsia from women with essential or secondary
hypertension that became clinically apparent during pregnancy.
Furthermore, restricting our analyses to pregnancies (and hence
pre-eclampsia diagnoses) in year 2000 onwards made no material
difference to our findings.
We used information from antenatal, perinatal and postnatal
records to estimate the date of conception, delivery, and trimesters
for all primiparous pregnancies. Although the timing may be
inexact, the same method was used for dating case and control
pregnancies, so any imprecision is likely to be non-differential. The
main consequence for this study is that some infections early in
pregnancy may have been missed if they were misclassified as
occurring prior to conception. We used the date of diagnosis (or
antibiotic prescription) rather than the date of onset of infection.
However, the majority of patients, even with upper RTIs, attend
their general practitioner within three days of onset. [25] This
small degree of imprecision is unlikely to materially affect our
results.
We recognize that not all infections lead to a GP consultation,
so some may not have been recorded. However, such infections
are more likely to be minor or asymptomatic; those severe enough
to cause systemic inflammation are more likely to result in a
consultation and be detected. We cannot rule out the possibility
that the observed associations with maternal UTI and antibiotic
prescriptions may in part be attributed to increased ascertainment
of infections among women with problematic pregnancies.
However, unlike previous studies we also investigated the effect
of acute RTI; the null effect we observed for RTI suggests that
ascertainment bias is unlikely.
Possible misclassification of UTI among women with pre-
eclampsia due to detection of proteinuria was addressed by
restricting the exposure period for infection to the first two
trimesters, prior to the onset of pre-eclampsia in the third
trimester. The resulting effect estimates for both UTI and
antibiotics were virtually identical to those obtained in the primary
analysis.
In our study, more than half of women with an antibiotic
prescription in pregnancy had no urinary or respiratory indication,
a finding which has previously been noted in primary care data.
[26] While some antibiotics might have been prescribed prophy-
lactically against recurrent infections, this is likely to be a small
minority: the majority will be given for acute infections such as
UTIs which are particularly common in pregnancy. [27]
Nevertheless, we cannot exclude the possibility that our finding
of an antibiotic effect may reflect an association with the drugs
Table 2. Frequency of maternal infection or antibiotic
treatment in pregnancy and by pregnancy trimester.
Exposure in pregnancya n (%)
Cases
(N=1533)
Controls
(N=14236)
Antibiotic treatment
Any time in pregnancy 528 (34.4) 4110 (28.9)
First trimester 221 (14.4) 1684 (11.8)
Second trimester 238 (15.5) 1952 (13.7)
Third trimester 203 (13.2) 1520 (10.7)
Urinary tract infection
Any time in pregnancy 182 (11.9) 1376 (9.7)
First trimester 64 (4.2) 463 (3.3)
Second trimester 81 (5.3) 606 (4.3)
Third trimester 57 (3.7) 487 (3.4)
Respiratory tract infection
Any time in pregnancy 77 (5.0) 781 (5.5)
First trimester 31 (2.0) 293 (2.1)
Second trimester 29 (1.9) 307 (2.2)
Third trimester 24 (1.6) 218 (1.5)
Note some women had more than one exposure in the same (or in another)
trimester.
aany time from 1st day of last menstrual period (LMP) to index date (for cases
this is the date of pre-eclampsia, for controls this is the date they reached the
same gestational age as their matched case at the case’s index date).
doi:10.1371/journal.pone.0073047.t002
Table 3. The association between maternal infection and pre-eclampsia: crude and adjusted odds ratios for matched cases
(n = 1533) and controls (n = 14236).
Exposure in pregnancya Matched crude OR (95% CI) Matched adjustedb OR (95% CI)
Antibiotic treatment 1.29 (1.15–1.44) 1.28 (1.14–1.44)
Urinary tract infection 1.23 (1.04–1.46) 1.22 (1.03–1.45)
Respiratory tract infection 0.91 (0.71–1.15) 0.91 (0.72–1.16)
aany time from 1st day of last menstrual period (LMP) to index date (for cases this is the date of pre-eclampsia, for controls this is the date they reached the same
gestational age as their matched case at the case’s index date).
bORs adjusted for maternal age; pre-gestational hypertension, diabetes and renal disease; and multifetal gestation. In addition, ORs for UTI and RTI are mutually
adjusted for.
doi:10.1371/journal.pone.0073047.t003
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themselves rather than an association with acute infection (the
main indication for their use).
Various hypotheses have been proposed to explain the
mechanism by which maternal infection may be associated with
pre-eclampsia. A key feature of pre-eclampsia is the greater
systemic inflammatory response of women who develop the
syndrome compared to women who have normal pregnancies,
[28] which suggests that inflammation may play an important role
in the pathogenesis. Acute infections such as UTI are an important
source of inflammation. Thus, the underlying mechanism of
infection may be indirect, by enhancing the maternal systemic
inflammatory response. It may also include direct effects of
infectious agents increasing the risk of acute uteroplacental
atherosis, [29] resulting in increased systemic inflammation and
vascular endothelial dysfunction preceding the clinical onset of
pre-eclampsia. Although the exact mechanism of the association is
uncertain, our finding of an increased risk of pre-eclampsia
associated with both acute UTI and maternal antibiotic prescrip-
tions lends support to the hypothesis that maternal infection may
play a pathogenic role. The relatively few individuals with more
than one episode of infection limited our ability to reliably
examine a dose-effect.
The absence of an association with RTI in our study is
intriguing and warrants further investigation, although it does not
preclude the possibility of a generic effect of infection on pre-
eclampsia risk. Our adjusted analyses suggest this finding is
unlikely to be explained by the higher prevalence of maternal
smoking (known to protect against pre-eclampsia) among women
with RTI. However, it may in part be due to incomplete
ascertainment of RTI consultations. We excluded from our
definition of RTI any non-specific RTI diagnoses (e.g. a record
of ‘‘Acute respiratory infection’’ or ‘‘Respiratory tract infection’’)
as it was unclear whether these were minor upper RTIs or more
severe lower RTIs. We expect any such non-differential misclas-
sification would lead to an underestimate of effect. The increased
risk of pre-eclampsia we observed among pregnant women with
UTI and with antibiotic prescriptions (a proxy for any acute
maternal infection, including but not restricted to UTI or RTI) is
consistent with a generic effect, suggesting as it does that the effect
may not be specific to one type of infection.
We conclude that acute maternal UTI and antibiotic drug
prescriptions in pregnancy (a likely proxy for infection) are
associated with an increased risk of pre-eclampsia. Further
research is required to elucidate the underlying mechanism of
this association and to determine whether, among women who
acquire infections in pregnancy, prompt treatment or prophylaxis
against infection might reduce the risk of pre-eclampsia.
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Appendix C Medline search strategies for the dental and pre-eclampsia study 
literature reviews  
All MeSH keywords were searched as exploded terms (thus including all sub-terms 
in the hierarchy). All subheadings were included. For free-text searches, mp=title, 
abstract and subject headings. Truncation of a search term is represented by an 
asterisk (*); the wildcard (?) within a term allows a character to be present or absent; 
the adjacency operator (ADJn) retrieves records containing terms within “n” words 
of each other, in any order. 
Table C.1 Medline search algorithm for studies of invasive dental treatment and vascular 
events. 
 Search History MEDLINE 
1 exp dentistry, operative/ or exp endodontics/ or exp oral surgical procedures/ or exp 
periodontics/ or exp surgery, oral/ 
2 ((dental or periodont* or oral surgical) adj1 (treatment* or procedure* or therap* or 
surgery or extraction* or operation*)).mp. 
3 exp Myocardial Infarction/ 
4 (myocardial infarct* or MI or AMI or cardiac infarct* or acute infarct* or heart infarct* or 
coronary infarct* or STEMI or coronary event* or cardiovascular event* or vascular 
event* or coronary attack* or heart attack* or q wave infarct* or myocardial thrombosis 
or coronary thrombosis).mp. 
5 brain ischemia/ or exp stroke/ 
6 (ischemic stroke or brain attack or acute isch?emic cerebrovascular syndrome or 
cerebral infarct* or brain isch?emia or anterior circulation infarct* or TACI or PACI or 
lacunar infarct* or LACI or posterior circulation infarct* or POCI or cerebral isch?emia 
or cerebrovascular accident* or CVA or cerebrovascular event*).mp. 
7 1 or 2 
8 3 or 4 or 5 or 6 
9 7 and 8 
10 limit 9 to (english language and (classical article or clinical conference or clinical trial or 
comparative study or controlled clinical trial or government publications or journal 
article or meta analysis or randomized controlled trial)) 
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Table C.2 Medline search algorithm for studies of maternal infection and pre-eclampsia. 
 Search History MEDLINE 
1 exp Inflammation/ 
2 exp Infection/ 
3 (inflammation or infection).mp. 
4 exp Hypertension, Pregnancy-Induced/ 
5 (pre?eclampsia or eclampsia or pre?eclamptic pregnancy or HELLP or gestosis or 
EPH?gestosis or (pregnancy adj2 tox?emia) or maternal tox?emia or 
pregnancy?induced hypertension or hypertensive disorders of pregnancy or 
gestational hypertension or pregnancy?associated hypertension or pregnancy 
hypertension or proteinuric hypertension).mp. 
6 1 or 2 or 3 
7 4 or 5 
8 6 and 7 
9 limit 8 to (english language and yr="2007 -Current" and (classical article or clinical 
conference or clinical trial or comparative study or controlled clinical trial or 
government publications or journal article or meta analysis or randomized controlled 
trial)) 
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Appendix D Invasive dental procedure codes 
Table D.1 Current Dental Terminology codes for invasive dental procedures. 
CDTa 
code 
Description of procedure 
D3410 Apicoectomy/periradicular surgery-anterior 
D3421 Apicoectomy/periradicular surgery-bicuspid (first root) 
D3425 Apicoectomy/periradicular surgery-molar (first root). 
D3426 Apicoectomy/periradicular surgery (each additional root) 
D3450 Root amputation-per root 
D3920 Hemisection (including any root removal), not including root canal therapy 
D4210 Gingivectomy or gingivoplasty - four or more contiguous teeth or bounded teeth spaces per 
quadrant 
D4211 Gingivectomy or gingivoplasty - one to three contiguous teeth or bounded teeth spaces per 
quadrant 
D4230 Anatomical crown exposure - four or more contiguous teeth per quadrant 
D4231 Anatomical crown exposure - one to three teeth per quadrant 
D4240 Gingival flap procedure, including root planing - four or more contiguous teeth or bounded 
teeth spaces per quadrant 
D4241 Gingival flap procedure, including root planing - one to three contiguous teeth or bounded 
teeth spaces per quadrant 
D4245 Apically positioned flap 
D4249 Clinical crown lengthening-hard tissue 
D4260 Osseous surgery (including flap entry and closure) - four or more contiguous teeth or 
bounded teeth spaces per quadrant 
D4261 Osseous surgery (including flap entry and closure) - one to three contiguous teeth or 
bounded teeth spaces per quadrant 
D4263 Bone replacement graft - first site in quadrant 
D4264 Bone replacement graft - each additional site in quadrant 
D4266 Guided tissue regeneration - resorbable barrier, per site 
D4267 Guided tissue regeneration - nonresorbable barrier, per site, (includes membrane removal) 
D4268 Surgical revision procedure, per tooth 
D4270 Pedicle soft tissue graft procedure 
D4271 Free soft tissue graft procedure (including donor site surgery) 
D4273 Subepithelial connective tissue graft procedures, per tooth 
D4274 Distal or proximal wedge procedure (when not performed in conjunction with surgical 
procedures in the same anatomical area) 
D4275 Soft tissue allograft 
D4276 Combined connective tissue and double pedicle graft, per tooth 
D4341 Periodontal scaling and root planing - four or more teeth per quadrant 
D4342 Periodontal scaling and root planing - one to three teeth, per quadrant 
D6010 Surgical placement of implant body:  endosteal implant 
D6012 Surgical placement of interim implant body for transitional prosthesis: endosteal implant 
D6040 Surgical placement:  eposteal implant 
D6050 Surgical placement:  transosteal implant 
D7111 Extraction, coronal remnants - deciduous tooth 
D7140 Extraction, erupted tooth or exposed root (elevation and/or forceps removal) 
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CDTa 
code 
Description of procedure 
D7210 Surgical removal of erupted tooth requiring elevation of mucoperiosteal flap and removal of 
bone and/or section of tooth 
D7220 Removal of impacted tooth-soft tissue 
D7230 Removal of impacted tooth-partially bony 
D7240 Removal of impacted tooth-completely bony 
D7241 Removal of impacted tooth-completely bony, with unusual surgical complications 
D7250 Surgical removal of residual tooth roots (cutting procedure) 
D7260 Oral antral fistula closure 
D7261 Primary closure of a sinus perforation 
D7270 Tooth reimplantation and/or stabilization of accidentally evulsed or displaced tooth 
D7272 Tooth transplantation (includes reimplantation from one site to another and splinting and/or 
stabilization) 
D7280 Surgical access of an unerupted tooth 
D7281 Surgical exposure of impacted or unerupted tooth to aid eruption 
D7285 Biopsy of oral tissue - hard (bone, tooth) 
D7286 Biopsy of oral tissue - soft 
D7290 Surgical repositioning of teeth 
D7292 Surgical placement: temporary anchorage device [screw retained plate] requiring surgical 
flap 
D7293 Surgical placement: temporary anchorage device requiring surgical flap 
D7294 Surgical placement: temporary anchorage device without surgical flap 
D7310 Alveoloplasty in conjunction with extractions - four or more teeth or tooth spaces, per 
quadrant 
D7311 Alveoloplasty in conjunction with extractions - one to three teeth or tooth spaces, per 
quadrant 
D7320 Alveoloplasty not in conjunction with extractions - four or more teeth or tooth spaces, per 
quadrant 
D7321 Alveoloplasty not in conjunction with extractions - one to three teeth or tooth spaces, per 
quadrant 
D7340 Vestibuloplasty-ridge extension (second epithelialization) 
D7350 Vestibuloplasty-ridge extension (including soft tissue grafts, muscle re-attachments, 
revision of soft tissue attachment, and management of hypertrophied and hyperplastic 
tissue) 
D7410 Excision of benign lesion up to 1.25 cm 
D7411 Excision of benign lesion greater than 1.25 cm 
D7412 Excision of benign lesion, complicated 
D7413 Excision of malignant lesion up to 1.25 cm 
D7414 Excision of malignant lesion greater than 1.25 cm 
D7415 Excision of malignant lesion, complicated 
D7440 Excision of malignant tumor-lesion diameter up to 1.25 cm 
D7441 Excision of malignant tumor-lesion diameter greater than 1.25 cm 
D7450 Removal of benign odontogenic cyst or tumor-lesion diameter up t0 1.25 cm 
D7451 Removal of benign odontogenic cyst or tumor-lesion diameter greater than 1.25 cm 
D7460 Removal of benign nonodontogenic cyst or tumor-lesion diameter up to 1.25 cm 
D7461 Removal of benign nonodontogenic cyst or tumor-lesion diameter greater than 1.25 cm 
D7471 Removal of lateral exostosis (maxilla or mandible) 
D7472 Removal of torus palatinus 
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CDTa 
code 
Description of procedure 
D7473 Removal of torus mandibularis 
D7485 Surgical reduction of osseous tuberosity 
D7490 Radical resection of maxilla or mandible 
D7510 Incision and drainage of abscess-intraoral soft tissue 
D7511 Incision and drainage of abscess - intraoral soft tissue - complicated (includes drainage of 
multiple fascial spaces) 
D7520 Incision and drainage of abscess-extraoral soft tissue 
D7521 Incision and drainage of abscess - extraoral soft tissue - complicated (includes drainage of 
multiple fascial spaces) 
D7530 Removal of foreign body from mucosa, skin, or subcutaneous alveolar tissue 
D7540 Removal of reaction-producing foreign bodies-musculoskeletal system 
D7550 Partial ostectomy/sequestrectomy for removal of non-vital bone 
D7560 Maxillary sinusotomy for removal of tooth fragment or foreign body 
D7610 Maxilla-open reduction (teeth immobilized if present) 
D7630 Mandible-open reduction (teeth immobilized if present) 
D7650 Malar and/or zygomatic arch-open reduction 
D7671 Alveolus - open reduction, may include stabilization of teeth 
D7680 Facial bones-complicated reduction with fixation and multiple surgical approaches 
D7710 Maxilla-open reduction 
D7730 Mandible-open reduction 
D7750 Malar and/or zygomatic arch-open reduction 
D7770 Alveolus - open reduction stabilization of teeth 
D7771 Alveolus, closed reduction stabilization of teeth 
D7780 Facial bones-complicated reduction with fixation and multiple surgical approaches 
D7810 Open reduction of dislocation 
D7840 Condylectomy 
D7850 Surgical discectomy; with/without implant 
D7854 Synovectomy 
D7856 Myotomy 
D7858 Joint reconstruction 
D7860 Arthrotomy 
D7865 Arthroplasty 
D7873 Arthroscopy-surgical: lavage and lysis of adhesions 
D7874 Arthroscopy-surgical: disc repositioning and stabilization 
D7875 Arthroscopy-surgical: synovectomy 
D7876 Arthroscopy-surgical: discectomy 
D7877 Arthroscopy-surgical: debridement 
D7911 Complicated suture-up to 5 cm 
D7912 Complicated suture-greater than 5 cm 
D7920 Skin graft (identify defect covered, location, and type of graft) 
D7940 Osteoplasty-for orthognathic deformities 
D7941 Osteotomy - mandibular rami 
D7943 Osteotomy - mandibular rami with bone graft; includes obtaining the graft 
D7944 Osteotomy-segmented or subapical 
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code 
Description of procedure 
D7945 Osteotomy-body of mandible 
D7946 Le Fort i (maxilla-total) 
D7947 Le Fort i (maxilla-segmented) 
D7948 Le Fort ii or Le Fort iii (osteoplasty of facial bones for midface hypoplasia or retrusion)-
without bone graft 
D7949 Le Fort ii or Le Fort iii-with bone graft 
D7950 Osseous, osteoperiosteal, or cartilage graft of the mandible or maxilla - autogenous or 
nonautogenous, by report 
D7951 Sinus augmentation with bone or bone substitutes 
D7953 Bone replacement graft for ridge preservation - per site 
D7955 Repair of maxillofacial soft and/or hard tissue defect 
D7960 Frenulectomy (frenectomy or frenotomy)-separate procedure 
D7963 Frenuloplasty 
D7970 Excision of hyperplastic tissue-per arch 
D7971 Excision of pericoronal gingiva 
D7972 Surgical reduction of fibrous tuberosity 
D7980 Sialolithotomy 
D7981 Excision of salivary gland, by report 
D7982 Sialodochoplasty 
D7983 Closure of salivary fistula 
D7991 Coronoidectomy 
D7996 Implant-mandible for augmentation purposes (excluding alveolar ridge), by report 
D7999 Unspecified oral surgery procedure, by report 
a Current Dental Terminology 
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Appendix E Participant flow for secondary analyses of ischaemic stroke and 
myocardial infarction  
 
Figure E.1 Participant flow - Ischaemic stroke. 
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Figure E.2 Participant flow - Myocardial infarction. 
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Appendix F Results of sensitivity analyses of the effect of invasive dental 
treatment on vascular event risk 
Table F.1 Results including unexposed cases. 
Outcome and risk period No. of cases  IRa (95% CI) 
Vascular event (N=13894b)   
Baseline periodc 13717 1 
Post-procedure risk period   
Weeks 1-4 40 1.50 (1.09-2.06) 
Weeks 5-8 29 1.11 (0.77-1.61) 
Weeks 9-12 30 1.16 (0.80-1.67) 
Weeks 13-16 25 0.95 (0.64-1.42) 
Weeks 17-24 53 1.09 (0.83-1.44) 
a IR denotes age-adjusted incidence ratio. 
b note that 6475 unexposed cases were dropped from the analysis as they only contributed to a single age-band (and hence did 
not contribute to the age effects). 
c Baseline period is all observation time except for the 24 week period following an invasive dental procedure.  
 
Table F.2 Results with finer adjustment for age in 2-year age groups. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=1152)   
Baseline periodb 975 1 
Post-procedure risk period   
Weeks 1-4 40 1.49 (1.09-2.06)  
Weeks 5-8 29 1.11 (0.76-1.60) 
Weeks 9-12 30 1.16 (0.80-1.67) 
Weeks 13-16 25 0.96 (0.64-1.42) 
Weeks 17-24 53 1.07 (0.81-1.42) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
Table F.3 Results excluding individuals with an antiplatelet or salicylate drug prescription 
record prior to invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=666)   
Baseline periodb 543 1 
Post-procedure risk period   
Weeks 1-4 33 2.23 (1.56-3.18) 
Weeks 5-8 24 1.63 (1.08-2.46) 
Weeks 9-12 21 1.42 (0.91-2.20) 
Weeks 13-16 15 1.00 (0.60-1.68) 
Weeks 17-24 30 1.04 (0.72-1.51) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
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Table F.4 Results excluding individuals with a rheumatoid arthritis diagnosis prior to invasive 
dental treatment or an NSAID prescription in the period four weeks prior to four weeks post 
invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=465)   
Baseline periodb 386 1 
Post-procedure risk period   
Weeks 1-4 20 1.84 (1.17-2.89) 
Weeks 5-8 15 1.40 (0.83-2.35) 
Weeks 9-12 12 1.13 (0.63-2.01) 
Weeks 13-16 8 0.74 (0.37-1.50) 
Weeks 17-24 24 1.17 (0.77-1.77) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
Table F.5 Results excluding individuals with an earliest diagnosis of diabetes within 12 months 
prior to invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=928)   
Baseline periodb 781 1 
Post-procedure risk period   
Weeks 1-4 31 1.46 (1.02-2.10) 
Weeks 5-8 25 1.21 (0.81-1.80) 
Weeks 9-12 24 1.17 (0.78-1.76) 
Weeks 13-16 20 0.97 (0.62-1.52) 
Weeks 17-24 47 1.21 (0.90-1.63) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
Table F.6 Results excluding individuals with an earliest diagnosis of hypertension within 12 
months prior to invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=754)   
Baseline periodb 641 1 
Post-procedure risk period   
Weeks 1-4 28 1.64 (1.12-2.40) 
Weeks 5-8 17 1.02 (0.63-1.65) 
Weeks 9-12 20 1.20 (0.76-1.87) 
Weeks 13-16 17 1.01 (0.62-1.64) 
Weeks 17-24 31 0.97 (0.67-1.40) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
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Table F.7 Results excluding individuals with an earliest diagnosis of coronary heart disease 
within 12 months prior to invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=913)   
Baseline periodb 762 1 
Post-procedure risk period   
Weeks 1-4 35 1.70 (1.21-2.40) 
Weeks 5-8 24 1.19 (0.79-1.79) 
Weeks 9-12 25 1.25 (0.84-1.87) 
Weeks 13-16 21 1.04 (0.67-1.61) 
Weeks 17-24 46 1.20 (0.89-1.62) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
Table F.8 Results excluding individuals who died during their hospital stay following admission 
for a vascular event or whose enrolment ended within a month after their event. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=1069)   
Baseline periodb 904 1 
Post-procedure risk period   
Weeks 1-4 39 1.62 (1.17-2.24) 
Weeks 5-8 27 1.15 (0.78-1.69) 
Weeks 9-12 26 1.12 (0.76-1.66) 
Weeks 13-16 23 0.98 (0.65-1.49) 
Weeks 17-24 50 1.14 (0.86-1.52) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
Table F.9 Results excluding individuals with multiple invasive dental procedures with 
overlapping risk periods. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=948)   
Baseline periodb 810 1 
Post-procedure risk period   
Weeks 1-4 34 1.65 (1.17-2.33) 
Weeks 5-8 22 1.08 (0.71-1.66) 
Weeks 9-12 22 1.11 (0.72-1.70) 
Weeks 13-16 20 1.03 (0.66-1.60) 
Weeks 17-24 40 1.06 (0.77-1.47) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
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Table F.10 Results for individuals exposed only to dental extractions (the three most common 
procedures*). 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=1017)   
Baseline periodb 863 1 
Post-procedure risk period   
Weeks 1-4 36 1.58 (1.13-2.21) 
Weeks 5-8 25 1.12 (0.75-1.67) 
Weeks 9-12 26 1.18 (0.79-1.74) 
Weeks 13-16 21 0.94 (0.61-1.46) 
Weeks 17-24 46 1.09 (0.81-1.47) 
*D7210: surgical removal of erupted tooth requiring elevation of mucoperiosteal flap and removal of bone and/or section of 
tooth; D7250: surgical removal of residual tooth roots (cutting procedure); D7310: alveoloplasty in conjunction with extractions 
- four or more teeth or tooth spaces, per quadrant 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
Table F.11 Results excluding individuals with a diagnosis of diabetes, coronary heart disease or 
hypertension at any time prior to invasive dental treatment. 
Outcome and risk period  No. of cases  IRa (95% CI) 
Vascular event (N=228)   
Baseline periodb 192 1 
Post-procedure risk period   
Weeks 1-4 10 1.76 (0.92-3.36) 
Weeks 5-8 6 1.05 (0.46-2.38) 
Weeks 9-12 5 0.84 (0.34-2.06) 
Weeks 13-16 4 0.66 (0.24-1.78) 
Weeks 17-24 11 0.93 (0.50-1.73) 
a IR denotes age-adjusted incidence ratio. 
b Baseline period is all observation time except for the 24 week period following an invasive dental procedure. 
 
182 
 
Appendix G Read and OXMIS codes defining exposure to UTI and RTI and 
frequency distribution of delivery codes 
Table G.1 Urinary tract infection medical codes. 
Medical code Medical term 
READ  
1AG..00 Recurrent urinary tract infections 
1J4..00 Suspected UTI 
46B3.00 Urine bacteria test: positive 
46H..11 Bacteria in urine O/E 
46H4.00 Urine microscopy: bacteria present 
A981100 Acute gonococcal cystitis 
A981111 Bladder gonorrhoea - acute 
K100600 Calculous pyelonephritis 
K101.00 Acute pyelonephritis 
K101000 Acute pyelonephritis without medullary necrosis 
K101100 Acute pyelonephritis with medullary necrosis 
K101200 Acute pyelitis 
K101300 Acute pyonephrosis 
K101z00 Acute pyelonephritis NOS 
K102.00 Renal and perinephric abscess 
K102000 Renal abscess 
K102100 Perinephric abscess 
K102200 Renal carbuncle 
K102z00 Renal and perinephric abscess NOS 
K10y.00 Pyelonephritis and pyonephrosis unspecified 
K10y000 Pyelonephritis unspecified 
K10y100 Pyelitis unspecified 
K10y200 Pyonephrosis unspecified 
K10y400 Pyelitis in diseases EC 
K10yz00 Unspecified pyelonephritis NOS 
K15..00 Cystitis 
K150.00 Acute cystitis 
K152000 Subacute cystitis 
K155.00 Recurrent cystitis 
K15z.00 Cystitis NOS 
K190.00 Urinary tract infection, site not specified 
K190000 Bacteriuria, site not specified 
K190011 Asymptomatic bacteriuria 
K190200 Post operative urinary tract infection 
K190300 Recurrent urinary tract infection 
K190311 Recurrent UTI 
K190z00 Urinary tract infection, site not specified NOS 
K213.00 Prostatocystitis 
Kyu5100 [X]Other cystitis 
L09y400 Urinary tract infection following abortive pregnancy 
L165.00 Asymptomatic bacteriuria in pregnancy 
L165000 Asymptomatic bacteriuria in pregnancy unspecified 
L165100 Asymptomatic bacteriuria in pregnancy - delivered 
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L165200 Asymptomatic bacteriuria in pregnancy - delivered with p/n complication 
L165300 Asymptomatic bacteriuria in pregnancy - not delivered 
L165400 Asymptomatic bacteriuria in pregnancy with p/n complication 
L165z00 Asymptomatic bacteriuria in pregnancy NOS 
L166.00 Genitourinary tract infections in pregnancy 
L166.11 Cystitis of pregnancy 
L166000 Genitourinary tract infection in pregnancy unspecified 
L166100 Genitourinary tract infection in pregnancy - delivered 
L166200 Genitourinary tract infection in pregnancy - delivered +p/n complication 
L166300 Genitourinary tract infection in pregnancy - not delivered 
L166400 Genitourinary tract infection in pregnancy with p/n complication 
L166500 Infections of kidney in pregnancy 
L166600 Urinary tract infection following delivery 
L166800 Urinary tract infection complicating pregnancy 
L166z00 Genitourinary tract infection in pregnancy NOS 
L166z11 UTI - urinary tract infection in pregnancy 
L177.00 Infections of bladder in pregnancy 
Lyu2300 [X]Infections of other parts of urinary tract in pregnancy 
Lyu2400 [X]Other+unspecified genitourinary tract infection in pregnancy 
Lyu6100 [X]Other genitourinary tract infections following delivery 
OXMIS  
5901 Pyelitis 
5901A Pyelitis acute 
5901NA Pyelonephritis acute 
5901PC Pyelocystitis 
5901PN Pyelonephritis 
592 PN Pyelonephritis calculous 
595 Cystitis 
595 A Cystitis acute 
595 AH Cystitis acute haemorrhagic 
595 BR Recurrent cystitis 
599 A UTI (urinary tract infection) 
599 AA Urinary tract infection acute 
599 AR Abscess urinary 
599 D Urinary tract infection recurrent 
599 GI Genito-urinary infection 
6350CG Pyelocystitis pregnancy 
6350CP Pyelocystitis puerperium 
6350G Pyelitis pregnancy 
6350P Pyelitis puerperium 
6359A Pregnancy cystitis 
6359B Puerperal cystitis 
6359G Urinary infection pregnancy 
6359P Urinary infection puerperium 
7891 Bacilluria 
7891A Bacteriuria asymptomatic 
7891AA Bacteriuria 
7891BP Pyuria bacterial 
O/E=on examination; NOS=not otherwise specified; EC=elsewhere classified; p/n=postnatal; 
The prefix [X] is used for codes introduced with the migration to ICD10 in April 1995.   
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Table G.2 Respiratory tract infection medical codes. 
Medical code Medical term 
READ  
16L..00 Influenza-like symptoms 
2DB5.00 O/E - tonsils - quinsy present 
2DB5.11 O/E - quinsy present 
2DB6.00 O/E - follicular tonsillitis 
2DB7.00 O/E - exudate on tonsils 
65VA.00 Notification of whooping cough 
7531100 Drainage of peritonsillar abscess 
7531111 Drainage of quinsy 
A022200 Salmonella pneumonia 
A320.00 Faucial diphtheria 
A321.00 Nasopharyngeal diphtheria 
A322.00 Anterior nasal diphtheria 
A323.00 Laryngeal diphtheria 
A32z.00 Diphtheria NOS 
A33..00 Whooping cough 
A330.00 Bordetella pertussis 
A331.00 Bordetella parapertussis 
A33y.00 Whooping cough - other specified organism 
A33yz00 Other whooping cough NOS 
A33z.00 Whooping cough NOS 
A34..00 Streptococcal sore throat and scarlatina 
A340300 Streptococcal tonsillitis 
A380300 Septicaemia due to streptococcus pneumoniae 
A383000 Fusobacterial necrotising tonsillitis 
A3BXA00 Mycoplasma pneumoniae [PPLO] cause/dis classifd/oth chaptr 
A3By400 Pleuropneumonia-like organism (PPLO) infection 
A521.00 Varicella pneumonitis 
A54x400 Herpes simplex pneumonia 
A551.00 Postmeasles pneumonia 
A730.00 Ornithosis with pneumonia 
A785000 Cytomegaloviral pneumonitis 
A789300 HIV disease resulting in pneumocystis carinii pneumonia 
A79A.00 Respiratory syncytial virus infection 
AB24.11 Pneumonia - candidal 
AB40500 Histoplasma capsulatum with pneumonia 
AB41500 Histoplasma duboisii with pneumonia 
AB4z500 Histoplasmosis with pneumonia 
AD04.00 Toxoplasma pneumonitis 
AD63.00 Pneumocystosis 
Ayu3800 [X]Diphtheria, unspecified 
Ayu3900 [X]whooping cough due to other bordetella species 
Ayu3A00 [X]whooping cough, unspecified 
AyuK900 [X]mycoplasma pneumoniae [PPLO]cause/dis classifd/oth chaptr 
F030800 Encephalitis due to influenza-specific virus not identified 
F030A00 Encephalitis due to influenza-virus identified 
G520300 Acute myocarditis - influenzal 
H03..00 Acute tonsillitis 
H03..11 Throat infection - tonsillitis 
H03..12 Tonsillitis 
H031.00 Acute follicular tonsillitis 
H034.00 Acute gangrenous tonsillitis 
H035.00 Acute bacterial tonsillitis 
H036.00 Acute viral tonsillitis 
H037.00 Recurrent acute tonsillitis 
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H03z.00 Acute tonsillitis NOS 
H04..00 Acute laryngitis and tracheitis 
H040.00 Acute laryngitis 
H040400 Acute haemophilus influenzae laryngitis 
H040600 Acute suppurative laryngitis 
H040w00 Acute viral laryngitis unspecified 
H041.00 Acute tracheitis 
H041000 Acute tracheitis without obstruction 
H041100 Acute tracheitis with obstruction 
H041z00 Acute tracheitis NOS 
H042.00 Acute laryngotracheitis 
H042.11 Laryngotracheitis 
H042000 Acute laryngotracheitis without obstruction 
H042100 Acute laryngotracheitis with obstruction 
H042z00 Acute laryngotracheitis NOS 
H043.00 Acute epiglottitis (non strep) 
H043.11 Viral epiglottitis 
H043000 Acute epiglottitis without obstruction 
H043100 Acute epiglottitis with obstruction 
H043200 Acute obstructive laryngitis 
H043211 Croup 
H043z00 Acute epiglottitis NOS 
H044.00 Croup 
H04z.00 Acute laryngitis and tracheitis NOS 
H052.00 Pharyngotracheitis 
H053.00 Tracheopharyngitis 
H055.00 Pharyngolaryngitis 
H06..00 Acute bronchitis and bronchiolitis 
H060.00 Acute bronchitis 
H060.11 Acute wheezy bronchitis 
H060100 Acute membranous bronchitis 
H060200 Acute pseudomembranous bronchitis 
H060300 Acute purulent bronchitis 
H060400 Acute croupous bronchitis 
H060500 Acute tracheobronchitis 
H060600 Acute pneumococcal bronchitis 
H060700 Acute streptococcal bronchitis 
H060800 Acute haemophilus influenzae bronchitis 
H060900 Acute neisseria catarrhalis bronchitis 
H060A00 Acute bronchitis due to mycoplasma pneumoniae 
H060B00 Acute bronchitis due to coxsackievirus 
H060C00 Acute bronchitis due to parainfluenza virus 
H060D00 Acute bronchitis due to respiratory syncytial virus 
H060E00 Acute bronchitis due to rhinovirus 
H060F00 Acute bronchitis due to echovirus 
H060w00 Acute viral bronchitis unspecified 
H060x00 Acute bacterial bronchitis unspecified 
H060z00 Acute bronchitis NOS 
H061.00 Acute bronchiolitis 
H061000 Acute capillary bronchiolitis 
H061200 Acute bronchiolitis with bronchospasm 
H061300 Acute exudative bronchiolitis 
H061500 Acute bronchiolitis due to respiratory syncytial virus 
H061600 Acute bronchiolitis due to other specified organisms 
H061z00 Acute bronchiolitis NOS 
H062.00 Acute lower respiratory tract infection 
H06z.00 Acute bronchitis or bronchiolitis NOS 
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H06z000 Chest infection NOS 
H06z011 Chest infection 
H06z100 Lower resp tract infection 
H06z112 Acute lower respiratory tract infection 
H06z200 Recurrent chest infection 
H07..00 Chest cold 
H0y..00 Other specified acute respiratory infections 
H14y500 Caseous tonsillitis 
H15..00 Peritonsillar abscess - quinsy 
H15..11 Quinsy 
H1y2100 Pharynx or nasopharynx cellulitis 
H1y2200 Parapharyngeal abscess 
H1y2600 Pharynx or nasopharynx abscess 
H1yz000 Abscess of trachea 
H2...00 Pneumonia and influenza 
H20..00 Viral pneumonia 
H20..11 Chest infection - viral pneumonia 
H200.00 Pneumonia due to adenovirus 
H201.00 Pneumonia due to respiratory syncytial virus 
H202.00 Pneumonia due to parainfluenza virus 
H20y.00 Viral pneumonia NEC 
H20z.00 Viral pneumonia NOS 
H21..00 Lobar (pneumococcal) pneumonia 
H21..11 Chest infection - pneumococcal pneumonia 
H22..00 Other bacterial pneumonia 
H22..11 Chest infection - other bacterial pneumonia 
H220.00 Pneumonia due to klebsiella pneumoniae 
H221.00 Pneumonia due to pseudomonas 
H222.00 Pneumonia due to haemophilus influenzae 
H222.11 Pneumonia due to haemophilus influenzae 
H223.00 Pneumonia due to streptococcus 
H223000 Pneumonia due to streptococcus, group B 
H224.00 Pneumonia due to staphylococcus 
H22y.00 Pneumonia due to other specified bacteria 
H22y000 Pneumonia due to escherichia coli 
H22y011 E.coli pneumonia 
H22y100 Pneumonia due to proteus 
H22y200 Pneumonia - legionella 
H22yX00 Pneumonia due to other aerobic gram-negative bacteria 
H22yz00 Pneumonia due to bacteria NOS 
H22z.00 Bacterial pneumonia NOS 
H23..00 Pneumonia due to other specified organisms 
H23..11 Chest infection - pneumonia organism OS 
H230.00 Pneumonia due to Eaton's agent 
H231.00 Pneumonia due to mycoplasma pneumoniae 
H232.00 Pneumonia due to pleuropneumonia like organisms 
H233.00 Chlamydial pneumonia 
H23z.00 Pneumonia due to specified organism NOS 
H24..00 Pneumonia with infectious diseases EC 
H24..11 Chest infection with infectious disease EC 
H240.00 Pneumonia with measles 
H241.00 Pneumonia with cytomegalic inclusion disease 
H242.00 Pneumonia with ornithosis 
H243.00 Pneumonia with whooping cough 
H243.11 Pneumonia with pertussis 
H244.00 Pneumonia with tularaemia 
H245.00 Pneumonia with anthrax 
187 
 
Medical code Medical term 
H246.00 Pneumonia with aspergillosis 
H247.00 Pneumonia with other systemic mycoses 
H247000 Pneumonia with candidiasis 
H247100 Pneumonia with coccidioidomycosis 
H247200 Pneumonia with histoplasmosis 
H247z00 Pneumonia with systemic mycosis NOS 
H24y.00 Pneumonia with other infectious diseases EC 
H24y000 Pneumonia with actinomycosis 
H24y100 Pneumonia with nocardiasis 
H24y200 Pneumonia with pneumocystis carinii 
H24y300 Pneumonia with Q-fever 
H24y400 Pneumonia with salmonellosis 
H24y500 Pneumonia with toxoplasmosis 
H24y600 Pneumonia with typhoid fever 
H24y700 Pneumonia with varicella 
H24yz00 Pneumonia with other infectious diseases EC NOS 
H24z.00 Pneumonia with infectious diseases EC NOS 
H25..00 Bronchopneumonia due to unspecified organism 
H25..11 Chest infection - unspecified bronchopneumonia 
H26..00 Pneumonia due to unspecified organism 
H26..11 Chest infection - pnemonia due to unspecified organism 
H260.00 Lobar pneumonia due to unspecified organism 
H260000 Lung consolidation 
H261.00 Basal pneumonia due to unspecified organism 
H262.00 Postoperative pneumonia 
H27..00 Influenza 
H270.00 Influenza with pneumonia 
H270.11 Chest infection - influenza with pneumonia 
H270000 Influenza with bronchopneumonia 
H270100 Influenza with pneumonia, influenza virus identified 
H270z00 Influenza with pneumonia NOS 
H271.00 Influenza with other respiratory manifestation 
H271000 Influenza with laryngitis 
H271100 Influenza with pharyngitis 
H271z00 Influenza with respiratory manifestations NOS 
H27y.00 Influenza with other manifestations 
H27y000 Influenza with encephalopathy 
H27y100 Influenza with gastrointestinal tract involvement 
H27yz00 Influenza with other manifestations NOS 
H27z.00 Influenza NOS 
H27z.11 Flu like illness 
H27z.12 Influenza like illness 
H28..00 Atypical pneumonia 
H29..00 Avian influenza 
H2y..00 Other specified pneumonia or influenza 
H2z..00 Pneumonia or influenza NOS 
H30..11 Chest infection - unspecified bronchitis 
H300.00 Tracheobronchitis NOS 
H301.00 Laryngotracheobronchitis 
H3y0.00 Chronic obstruct pulmonary disease with acute lower respiratory infection 
H501400 Purulent pleurisy 
H510900 Pneumococcal pleurisy 
H510A00 Staphylococcal pleurisy 
H510B00 Streptococcal pleurisy 
H511.00 Bacterial pleurisy with effusion 
H511000 Pneumococcal pleurisy with effusion 
H511100 Staphylococcal pleurisy with effusion 
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H511200 Streptococcal pleurisy with effusion 
H511z00 Bacterial pleurisy with effusion NOS 
H530200 Gangrenous pneumonia 
H530300 Abscess of lung with pneumonia 
H564.00 Bronchiolitis obliterans organising pneumonia 
Hyu0400 [X]Flu+oth respiratory manifestations,'flu virus identified 
Hyu0500 [X]influenza+other manifestations,influenza virus identified 
Hyu0600 [X]influenza+other respiratory manifestations,virus not identified 
Hyu0700 [X]influenza+other manifestations, virus not identified 
Hyu0800 [X]other viral pneumonia 
Hyu0900 [X]pneumonia due to other aerobic gram-negative bacteria 
Hyu0A00 [X]other bacterial pneumonia 
Hyu0B00 [X]pneumonia due to other specified infectious organisms 
Hyu0C00 [X]pneumonia in bacterial diseases classified elsewhere 
Hyu0D00 [X]pneumonia in viral diseases classified elsewhere 
Hyu0E00 [X]pneumonia in mycoses classified elsewhere 
Hyu0F00 [X]pneumonia in parasitic diseases classified elsewhere 
Hyu0G00 [X]pneumonia in other diseases classified elsewhere 
Hyu0H00 [X]other pneumonia, organism unspecified 
Hyu1.00 [X]other acute lower respiratory infections 
Hyu1000 [X]acute bronchitis due to other specified organisms 
Hyu1100 [X]Acute bronchiolitis due to other specified organisms 
Hyu2800 [X]Other abscess of pharynx 
SP13200 Post operative chest infection 
OXMIS  
331 Parapertussis 
339 Whooping cough 
0339P Pertussis 
0340L Streptococcal laryngitis 
0340PN Septic pharyngitis 
0340T Tonsillitis streptococcal 
136 C Pneumocystosis 
136 LG Legionnaires' disease 
460 C Influenza-like illness 
463 Tonsillitis acute 
463 A Tonsillitis 
463 B Follicular tonsillitis 
463 BC Tonsillitis bacterial 
464 A Laryngitis acute 
464 B Laryngitis 
464 BV Laryngitis viral 
464 C Tracheitis acute 
464 D Tracheitis 
464 E Croup 
464 LA Laryngotracheitis acute 
464 LT Laryngotracheitis 
464 P Tracheitis purulent 
464 TP Tracheal suppuration 
465 LP Pharyngolaryngitis 
465 TP Tracheopharyngitis 
466 A Bronchiolitis 
466 B Bronchiolitis acute 
466 C Bronchitis acute 
466 CR Croup bronchial 
466 D Bronchitis purulent 
466 V Viral bronchitis 
470 Influenza 
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470 F Flu 
470 P Parainfluenza virus infection 
471 Pneumonia influenzal 
472 A Influenzal bronchitis 
472 B Tracheitis influenzal 
472 H Influenza haemorrhagic 
472 L Laryngitis with influenza 
480 Virus pneumonia 
480 A Syncytial virus respiratory infection 
481 A Pneumonia pneumococcal 
481 B Lobar pneumonia 
481 BA Pneumonia basal 
481 BC Consolidation lung 
4820K Pneumonia klebsiella 
4823 Pneumonia staphylococcal 
483 AP Pneumonia primary atypical 
483 AT Pneumonia atypical 
483 E Pneumonia eaton's agent 
483 M Pneumonia mycoplasal 
485 Bronchopneumonia 
486 Pneumonia 
486 CA Pneumonia cold agglutinin positive 
490 CT Catarrhal bronchitis 
490 LT Laryngotracheobronchitis 
490 T Tracheobronchitis 
491 AC Bronchitis acute on chronic 
500 B Tonsillitis recurrent 
500 TD Tonsils discharging 
501 CP Cellulitis peritonsillar 
501 CT Cellulitis tonsil 
501 LA Abscess lingual tonsil 
501 N Quinsy 
501 NA Abscess intratonsillar 
501 PA Abscess tonsillopharyngeal 
501 PB Abscess peritonsillar 
501 PC Peritonsillar abscess 
501 PD Peritonsillitis 
501 PT Abscess post-tonsillar 
501 TA Abscess tonsil 
508 GC Abscess postpharyngeal 
508 GD Abscess retropharyngeal 
508 GM Abscess postnasal 
508 GN Abscess nasopharyngeal 
508 GP Abscess postlaryngeal 
508 GR Abscess retrolaryngeal 
508 K Abscess upper respiratory 
508 KA Abscess throat 
508 KE Abscess epiglottis 
508 KF Abscess fauces 
508 KL Abscess larynx 
508 KP Abscess pharyngeal 
508 L Epiglottitis 
508 LP Cellulitis pharynx 
5192LN Lung infection 
5199DP Respiratory tract infection postoperative 
5199E Infection chest 
5199RN Recurrent chest infection 
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K2301 Drainage abscess tonsillar 
O/E=on examination; OS=otherwise specified; NOS=not otherwise specified; EC=elsewhere classified; NEC=not elsewhere 
classified; The prefix [X] is used for codes introduced with the migration to ICD10 in April 1995.   
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Table G.3 Frequency distribution of end-of-pregnancy Read/OXMIS codes used to estimate the 
timing of delivery for study participants’ first recorded completed pregnancies (1533 cases and 
14236 controls). 
Medical 
code 
Medical term Case records 
(N=2815) 
Control records 
(N=26068) 
  n % n % 
63...00 Birth details 738 26.2 7312 28.0 
7F19.00 Normal delivery 322 11.4 5177 19.9 
635..00 Maturity of baby 186 6.6 1778 6.8 
L20..11 Spontaneous vaginal delivery 58 2.1 1087 4.2 
650 AM Normal delivery (mother) 53 1.9 851 3.3 
L34..00 Trauma to perineum and vulva during delivery 62 2.2 673 2.6 
632..00 Length of labour 54 1.9 594 2.3 
L398.00 Caesarean delivery 126 4.5 488 1.9 
L398400 Delivery by emergency caesarean section 116 4.1 399 1.5 
Ly0..00 Spontaneous vertex delivery 26 0.9 405 1.6 
L398200 Caesarean section - pregnancy at term 81 2.9 266 1.0 
7F13.00 Other caesarean delivery 65 2.3 267 1.0 
7F17.11 Ventouse delivery 17 0.6 262 1.0 
L396.11 Ventouse delivery 17 0.6 261 1.0 
L395.00 Forceps delivery 26 0.9 249 1.0 
650 AP SVD (spontaneous vertex delivery) 15 0.5 237 0.9 
7F12.00 Elective caesarian delivery 21 0.7 227 0.9 
K755 AB Forceps delivery 21 0.7 195 0.7 
63E2.00 Normal birth 18 0.6 186 0.7 
L3495P Postnatal visit 23 0.8 178 0.7 
7F16.00 Forceps cephalic delivery 21 0.7 176 0.7 
7F13111 Lower uterine segment caesarean section 
(LSCS) NEC 
42 1.5 150 0.6 
7F13300 Emergency caesarean section 42 1.5 147 0.6 
K755 M Forceps delivery (mother) 21 0.7 166 0.6 
K769 M Delivery caesarian section (mother) 43 1.5 137 0.5 
7F17.00 Vacuum delivery 14 0.5 163 0.6 
7F16z00 Forceps cephalic delivery NOS 15 0.5 149 0.6 
K766 Caesarian section lower segment 39 1.4 124 0.5 
K7581M Ventouse extraction delivery (mother) 17 0.6 136 0.5 
T318 Child born 13 0.5 124 0.5 
7F17z00 Vacuum delivery NOS 10 0.4 103 0.4 
62R..00 Postnatal visits 21 0.7 88 0.3 
633..00 Outcome of delivery 11 0.4 91 0.3 
635..11 Full term baby 6 0.2 95 0.4 
7F12111 Elective lower uterine segment caesarean 
section (LSCS) 
15 0.5 82 0.3 
633a.00 Birth of child 9 0.3 82 0.3 
63D2.00 Placenta normal O/E 9 0.3 81 0.3 
650 AA Labour 7 0.2 80 0.3 
L20..00 Normal delivery in a completely normal case 3 0.1 79 0.3 
63Z..11 Apgar normal 5 0.2 77 0.3 
ZV27.00 [V]Outcome of delivery 9 0.3 71 0.3 
63Z..00 Birth details NOS 10 0.4 63 0.2 
L36..00 Postpartum haemorrhage (PPH) 16 0.6 56 0.2 
Z257.14 FTND - Full term normal delivery 4 0.1 65 0.2 
K750 AB Induction labour 21 0.7 47 0.2 
Y61  N Postnatal examination normal 13 0.5 50 0.2 
650 A Pregnancy normal delivery 3 0.1 60 0.2 
K7581 Ventous assisted delivery 4 0.1 59 0.2 
62S..11 Postnatal exam. - maternal 16 0.6 43 0.2 
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Medical 
code 
Medical term Case records 
(N=2815) 
Control records 
(N=26068) 
  n % n % 
650 BP Premature labour 1 0.0 57 0.2 
7F13100 Lower uterine segment caesarean delivery NEC 12 0.4 44 0.2 
L341.00 Second degree perineal tear during delivery 2 0.1 51 0.2 
7F12z00 Elective caesarean delivery NOS 4 0.1 48 0.2 
14Y6.00 Born by emergency caesarean section 4 0.1 48 0.2 
L398300 Delivery by elective caesarean section 9 0.3 41 0.2 
L3z..00 Complications of labour and delivery NOS 4 0.1 44 0.2 
62S..00 Maternal P/N 6 week exam. 9 0.3 38 0.1 
6313.00 Consultant unit birth 3 0.1 43 0.2 
L222.12 Breech delivery 5 0.2 38 0.1 
6331.00 Single live birth 4 0.1 36 0.1 
7F17.12 Ventouse extraction 2 0.1 36 0.1 
ZV27.11 [V]Live birth 3 0.1 34 0.1 
7799B Stillbirth 8 0.3 28 0.1 
Z251.00 Mother delivered 2 0.1 34 0.1 
64B2.11 Baby normal at birth 4 0.1 31 0.1 
Q032.00 Fetus or neonate affected by forceps delivery 2 0.1 32 0.1 
7789CF Caesarian section (baby) 5 0.2 28 0.1 
7789TE Ventouse birth extraction (baby) 3 0.1 30 0.1 
633..11 Livebirth 2 0.1 30 0.1 
63E1.00 Spontaneous onset of labour 6 0.2 26 0.1 
7F16400 Low forceps cephalic delivery 0 0.0 32 0.1 
634..13 Male baby 5 0.2 25 0.1 
7789A1 Baby normal at birth 3 0.1 26 0.1 
L210100 Twin pregnancy - delivered 5 0.2 22 0.1 
7789NA Normal apgar rating 2 0.1 25 0.1 
K769 EC Elective caesarian section 2 0.1 24 0.1 
Q034.00 Fetus or neonate affected by caesarean section 6 0.2 20 0.1 
7789CE Caesarian section birth (baby) 5 0.2 20 0.1 
Z257.15 ND - Normal delivery 0 0.0 24 0.1 
7789NB Normal birth (baby) 0 0.0 24 0.1 
6311.00 Home birth 0 0.0 23 0.1 
0389B Umbilical sepsis 0 0.0 23 0.1 
K760 Episiotomy 1 0.0 22 0.1 
K7581B Ventouse extraction delivery (baby) 1 0.0 20 0.1 
6341.00 Baby male 0 0.0 21 0.1 
7F21000 Manual removal of placenta from delivered 
uterus 
3 0.1 17 0.1 
7F1B000 Episiotomy to facilitate delivery 1 0.0 18 0.1 
634..12 Female baby 1 0.0 18 0.1 
657 B Twin pregnancy delivery 2 0.1 16 0.1 
Z257.11 Normal delivery 3 0.1 15 0.1 
Q4z..15 Stillbirth NEC 6 0.2 11 0.0 
6342.00 Baby female 2 0.1 15 0.1 
Y61  M Postnatal examination minor problem 5 0.2 11 0.0 
7F12100 Elective lower uterine segment caesarean 
delivery 
4 0.1 11 0.0 
L14..11 Premature labour 3 0.1 12 0.0 
Q48D.00 [X] stillbirth 5 0.2 10 0.0 
637..00 Birth head circumference 2 0.1 13 0.0 
650 N Delivery no details 0 0.0 15 0.1 
Z257.00 Delivery normal 0 0.0 15 0.1 
64B2.00 Child birth exam. - normal 3 0.1 12 0.0 
Q033.00 Fetus or neonate affected by vacuum extraction 
delivery 
0 0.0 14 0.1 
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L340.00 First degree perineal tear during delivery 2 0.1 12 0.0 
14Y5.00 Born by ventouse delivery 0 0.0 14 0.1 
L395.12 Neville - Barnes forceps delivery 0 0.0 13 0.0 
L360.11 Retained placenta NOS 1 0.0 12 0.0 
14Y2.00 Born by elective caesarean section 1 0.0 12 0.0 
62R1.00 P/N - first day visit 1 0.0 11 0.0 
Q41y111 Perinatal transient vaginal bleeding 1 0.0 11 0.0 
661 J Premature delivery  (mother) 8 0.3 4 0.0 
L142.11 Premature delivery 10 0.4 2 0.0 
7775DH Hospital confinement (baby) 1 0.0 10 0.0 
62SZ.00 Maternal P/N 6 week exam. NOS 2 0.1 9 0.0 
14Y0.00 Born by caesarean section 1 0.0 10 0.0 
650 CA Normal labour 1 0.0 10 0.0 
7F11z00 Other induction of labour NOS 2 0.1 9 0.0 
658 Perineal laceration at delivery 0 0.0 11 0.0 
6351.00 Baby premature 36-38 weeks 3 0.1 7 0.0 
L397.00 Breech extraction 0 0.0 10 0.0 
652 R Retained placenta 0 0.0 10 0.0 
650 C Normal birth (confinement) 1 0.0 9 0.0 
L396.00 Vacuum extractor delivery 0 0.0 10 0.0 
635..13 Premature baby 5 0.2 5 0.0 
L395200 Low forceps delivery 1 0.0 9 0.0 
Z257.12 Spontaneous vaginal delivery 2 0.1 7 0.0 
657 D Labour difficult 0 0.0 9 0.0 
Z257100 Spontaneous vertex delivery 0 0.0 9 0.0 
653 PPH (postpartum haemorrhage) 2 0.1 7 0.0 
L142.00 Early onset of delivery 1 0.0 8 0.0 
635..12 Postmature baby 0 0.0 9 0.0 
T801 Labour induction nonsurgical 4 0.1 5 0.0 
633..14 Twin birth 3 0.1 6 0.0 
6349E Labour premature 0 0.0 8 0.0 
656 B Delivery breech 0 0.0 8 0.0 
L28y.13 Amniotic fluid leaking 0 0.0 8 0.0 
14Y3.00 Born by normal vaginal delivery 0 0.0 8 0.0 
L342.00 Third degree perineal tear during delivery 1 0.0 7 0.0 
K755 AA Forceps extraction midcavity 0 0.0 8 0.0 
Z254500 Delivered by caesarean section - pregnancy at 
term 
2 0.1 6 0.0 
7789CG Delivery caesarian section (baby) 1 0.0 7 0.0 
7F14.00 Breech extraction delivery 1 0.0 6 0.0 
63E..00 Labour details 1 0.0 6 0.0 
L1A..00 Sublux of symphysis pubis in pregnancy 
childbirth and puerperium 
0 0.0 7 0.0 
Z241100 Onset of labour induced 2 0.1 5 0.0 
K7561 Forceps extraction low with episiotomy 1 0.0 6 0.0 
7F16900 Kielland forceps cephalic delivery with rotation 1 0.0 6 0.0 
K7562 Forceps extraction low 0 0.0 6 0.0 
7F18.00 Cephalic vaginal delivery abnormal presentation 
head - no instrument 
0 0.0 6 0.0 
7789ND Neonatal death 3 0.1 3 0.0 
Z257.13 SVD - Spontaneous vaginal delivery 0 0.0 6 0.0 
7F10z12 ARM (Artificial rupture of the membranes) 0 0.0 6 0.0 
7789FC Forceps birth (baby) 2 0.1 4 0.0 
650 DB Delivery gp unit (mother) 0 0.0 6 0.0 
7F19100 Water birth delivery 0 0.0 6 0.0 
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6333.00 Twins - both live born 2 0.1 4 0.0 
7789AH Normal baby delivered normally 2 0.1 4 0.0 
L112100 Placental abruption - delivered 1 0.0 5 0.0 
656 BM Delivery breech (mother) 0 0.0 5 0.0 
7F16300 Mid forceps cephalic delivery NEC 2 0.1 3 0.0 
Q213.11 Fetal distress in labour - liveborn 1 0.0 4 0.0 
7F11.00 Other induction of labour 1 0.0 4 0.0 
7F15100 Assisted breech delivery 0 0.0 5 0.0 
14Y1.00 Born by forceps delivery 0 0.0 5 0.0 
63F..00 Birth details not known 1 0.0 4 0.0 
7F13z00 Other caesarean delivery NOS 3 0.1 2 0.0 
K7551KD Keillands delivery (mother) 0 0.0 5 0.0 
657 BB Twins non identical delivered 0 0.0 5 0.0 
Z254200 Delivered by low forceps delivery 2 0.1 3 0.0 
6349LA Leaking amniotic fluid 0 0.0 5 0.0 
Z254900 Vaginal delivery 1 0.0 4 0.0 
6371PP Eclampsia post partum 5 0.2 0 0.0 
ZV27.12 [V]stillbirth 1 0.0 4 0.0 
636..00 Birthweight of baby 1 0.0 4 0.0 
Q4z..12 Neonatal death 1 0.0 4 0.0 
7F19z00 Normal delivery NOS 0 0.0 4 0.0 
L340000 First degree perineal tear during delivery, 
unspecified 
0 0.0 4 0.0 
Q421.11 ABO isoimmunisation of the newborn 0 0.0 4 0.0 
L356.14 Symphysis pubis separation 3 0.1 1 0.0 
650 DA Delivery domicillary (mother) 0 0.0 4 0.0 
L360.00 Third-stage postpartum haemorrhage 1 0.0 3 0.0 
656 TR Transverse lie delivery 0 0.0 4 0.0 
K7601 Episiotomy repair 0 0.0 4 0.0 
7789NC Birth no details 0 0.0 4 0.0 
L341000 Second degree perineal tear during delivery, 
unspecified 
0 0.0 4 0.0 
L291.00 Failed medical or unspecified induction 2 0.1 2 0.0 
639..00 Apgar at 1 minute 1 0.0 3 0.0 
657 T Delay 2nd stage (labour) 0 0.0 4 0.0 
6335.00 Twins - both still born 0 0.0 4 0.0 
9N05.00 Seen in postnatal clinic 0 0.0 4 0.0 
62O5.00 Spontaneous membrane rupture 0 0.0 3 0.0 
633Z.00 Outcome of delivery NOS 0 0.0 3 0.0 
650 AN Pregnancy uncomplicated delivery 0 0.0 3 0.0 
L452400 Obstetric nonpurulent mastitis with postnatal 
complication 
0 0.0 3 0.0 
L200.00 Normal delivery but ante- or post- natal 
conditions present 
0 0.0 3 0.0 
L222.11 Assisted breech delivery 0 0.0 3 0.0 
Q212.00 Liveborn with prelabour fetal distress 0 0.0 3 0.0 
7F1B300 Manual dilatation of cervix 0 0.0 3 0.0 
7789BB Breech birth (baby) 1 0.0 2 0.0 
7F10.00 Surgical induction of labour 3 0.1 0 0.0 
62S7.00 Postnatal examination normal 0 0.0 3 0.0 
Z254300 Delivered by mid-cavity forceps delivery 0 0.0 3 0.0 
L213200 Multiple delivery, all by caesarean section 0 0.0 3 0.0 
L304100 Persistent occipitopost/occipitoant position - 
delivered 
0 0.0 3 0.0 
7F14100 Forceps to aftercoming head (breech) 0 0.0 3 0.0 
195 
 
Medical 
code 
Medical term Case records 
(N=2815) 
Control records 
(N=26068) 
  n % n % 
661 D Postmature at delivery  (mother) 0 0.0 3 0.0 
63A..00 Apgar at 5 minutes 1 0.0 2 0.0 
7F1..00 Induction and delivery operations 1 0.0 2 0.0 
L126100 Eclampsia - delivered 3 0.1 0 0.0 
6G...00 Postnatal care 2 0.1 1 0.0 
L3X..00 Intrapartum haemorrhage, unspecified 1 0.0 1 0.0 
ZV27000 [V]Single live birth 0 0.0 2 0.0 
L182400 Anaemia in the puerperium - baby previously 
delivered 
0 0.0 2 0.0 
62NE.00 A/N 39 week examination 2 0.1 0 0.0 
777 B Premature baby 2 0.1 0 0.0 
653 A Postpartum haemorrhage immediate 0 0.0 2 0.0 
L452.00 Obstetric nonpurulent mastitis 0 0.0 2 0.0 
8CH..00 Post partum care 0 0.0 2 0.0 
7F16100 High forceps cephalic delivery NEC 0 0.0 2 0.0 
L342z00 Third degree perineal tear during delivery NOS 0 0.0 2 0.0 
62R6.00 P/N - sixth day visit 0 0.0 2 0.0 
7F21.00 Manual removal retained products conception 
delivered uterus 
0 0.0 2 0.0 
62RA.00 P/N - tenth day visit 0 0.0 2 0.0 
Z29..00 Postnatal examination observations 1 0.0 1 0.0 
650 DC Delivery in hospital (mother) 0 0.0 2 0.0 
634..11 Delivery - sex of baby 0 0.0 2 0.0 
L398z00 Caesarean delivery NOS 0 0.0 2 0.0 
L356.13 Pubic symphysis separation 0 0.0 2 0.0 
6779C Postpartum haemorrhage delayed 0 0.0 2 0.0 
657 SS Delivery delay in second stage 0 0.0 2 0.0 
L37z.00 Retained placenta or membranes with no 
haemorrhage NOS 
0 0.0 2 0.0 
L396z00 Vacuum extractor delivery NOS 1 0.0 1 0.0 
Z246311 Onset of labour pains 0 0.0 2 0.0 
ZV27.13 [V]Birth - type 2 0.1 0 0.0 
657 BA Twins identical delivered 0 0.0 2 0.0 
L341z00 Second degree perineal tear during delivery 
NOS 
1 0.0 1 0.0 
L305.00 Shoulder dystocia 0 0.0 2 0.0 
L312100 Other uterine inertia - delivered 0 0.0 2 0.0 
L340400 Fourchette tear during delivery 0 0.0 2 0.0 
651 AD Delivery after antepartum haemorrhage 1 0.0 1 0.0 
L330.00 Prolapse of cord 0 0.0 2 0.0 
62Q..00 Postnatal care provider 0 0.0 2 0.0 
62Q2.00 P/N care from G.P. 0 0.0 2 0.0 
6353.00 Baby extremely prem.28-32 week 2 0.1 0 0.0 
ZV24.11 [V]Postnatal care and examination 0 0.0 2 0.0 
L340500 Vulval tear during delivery 0 0.0 2 0.0 
Q404.11 Umbilical stump infection of the newborn 0 0.0 2 0.0 
L395.11 Keilland's forceps delivery 1 0.0 1 0.0 
L15..00 Prolonged or post-term pregnancy 2 0.1 0 0.0 
Q30..00 Respiratory distress syndrome 2 0.1 0 0.0 
62R3.00 P/N - third day visit 0 0.0 2 0.0 
L442.12 Episiotomy breakdown 0 0.0 2 0.0 
L400.00 Puerperal endometritis 1 0.0 1 0.0 
62RZ.00 Postnatal visit NOS 1 0.0 1 0.0 
650 EP Delivery epidural 0 0.0 2 0.0 
6349PL Premature labour undelivered 0 0.0 2 0.0 
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Z254700 Deliveries by vacuum extractor 0 0.0 2 0.0 
6352.00 Baby v. premature 32-36 weeks 1 0.0 1 0.0 
Z254A00 Abnormal delivery 0 0.0 2 0.0 
6779E Postnatal haemorrhage 0 0.0 1 0.0 
Ly1..00 Spontaneous breech delivery 0 0.0 1 0.0 
L343.00 Fourth degree perineal tear during delivery 0 0.0 1 0.0 
L340600 Vaginal tear during delivery 0 0.0 1 0.0 
L282z00 Prolonged spontaneous/unspecified rupture of 
membranes NOS 
0 0.0 1 0.0 
656 A Malpresentation at delivery 0 0.0 1 0.0 
L309.00 Failed ventouse extraction unspecified 0 0.0 1 0.0 
6355.00 Baby post-mature 0 0.0 1 0.0 
L142100 Early onset of delivery - delivered 0 0.0 1 0.0 
Q31y500 Neonatal snuffles 0 0.0 1 0.0 
L340100 First degree perineal tear during delivery - 
delivered 
0 0.0 1 0.0 
Q031600 Fetus/neonate affected by disproportion during 
labour/delivery 
0 0.0 1 0.0 
L344000 Unspecified perineal laceration during delivery, 
unspecified 
0 0.0 1 0.0 
ZV29100 [V]Newborn receiving special care 0 0.0 1 0.0 
7F13y00 Other specified other caesarean delivery 0 0.0 1 0.0 
6779G Retained placenta fragments  puerperium 0 0.0 1 0.0 
Q206100 Birth plexus injury - Erb-Duchenne 0 0.0 1 0.0 
L322.00 Prolonged second stage 1 0.0 0 0.0 
62R7.00 P/N - seventh day visit 0 0.0 1 0.0 
L250100 Fetus with central nervous system malformation 
- delivered 
0 0.0 1 0.0 
6359.00 Baby premature 38 weeks 1 0.0 0 0.0 
6363.00 Baby BW = 10%-24% (2850-3149g) 0 0.0 1 0.0 
K762 Delivery assisted breech 0 0.0 1 0.0 
Z254E00 Multiple birth 0 0.0 1 0.0 
L341200 Second degree perineal tear during delivery 
with p/n problem 
0 0.0 1 0.0 
F4F5400 Neonatal nasolacrimal duct obstruction 0 0.0 1 0.0 
678 BL Mastitis lactating 0 0.0 1 0.0 
636..11 Birthweight 0 0.0 1 0.0 
7F1A000 Caesarian hysterectomy 0 0.0 1 0.0 
7F15y00 Other specified other breech delivery 0 0.0 1 0.0 
Q214.11 Fetal distress, unspecified when, liveborn 0 0.0 1 0.0 
L37..00 Retained placenta or membranes with no 
haemorrhage 
0 0.0 1 0.0 
Q030.11 Fetus affected by breech delivery 0 0.0 1 0.0 
6332.00 Single stillbirth 0 0.0 1 0.0 
M261700 Acne neonatorum 0 0.0 1 0.0 
L39y.00 Other complications of labour and delivery 0 0.0 1 0.0 
L4...00 Complications of the puerperium 0 0.0 1 0.0 
Q404100 Omphalitis 0 0.0 1 0.0 
Q036.00 Fetus or neonate affected by precipitate delivery 0 0.0 1 0.0 
L181500 Postpartum thyroiditis 0 0.0 1 0.0 
L391.00 Obstetric shock 0 0.0 1 0.0 
Z263F00 Spontaneous forewater rupture of membranes 0 0.0 1 0.0 
7F19000 Manually assisted vaginal delivery 0 0.0 1 0.0 
Q....00 Perinatal conditions 0 0.0 1 0.0 
7F25.13 Monitoring during labour 0 0.0 1 0.0 
197 
 
Medical 
code 
Medical term Case records 
(N=2815) 
Control records 
(N=26068) 
  n % n % 
L344.00 Unspecified perineal laceration during delivery 0 0.0 1 0.0 
7F11100 Induction of labour using prostaglandins 1 0.0 0 0.0 
7F10z00 Surgical induction of labour NOS 1 0.0 0 0.0 
L3...00 Complications occurring during labour and 
delivery 
0 0.0 1 0.0 
L341100 Second degree perineal tear during delivery - 
delivered 
0 0.0 1 0.0 
L354.12 High vaginal tear - obstetric 0 0.0 1 0.0 
ZV27200 [V]Twins, both live born 0 0.0 1 0.0 
L125400 Severe pre-eclampsia with postnatal 
complication 
1 0.0 0 0.0 
Q48D100 [X]Macerated stillbirth 0 0.0 1 0.0 
L244400 Other uterine/pelvic floor abnormality - baby 
delivered previously 
0 0.0 1 0.0 
ZV29200 [V]Newborn receiving intensive care 0 0.0 1 0.0 
7F16000 High forceps cephalic delivery with rotation 0 0.0 1 0.0 
Z241.00 Labour established 0 0.0 1 0.0 
Q11z.00 Born premature NOS 1 0.0 0 0.0 
Q48y600 Early neonatal death 0 0.0 1 0.0 
7710C Cord compressed  (baby) 0 0.0 1 0.0 
7F23.11 Immediate repair of obstetric tear 0 0.0 1 0.0 
Q215.00 Severe birth asphyxia - apgar score less than 4 
at 1 minute 
0 0.0 1 0.0 
L125100 Severe pre-eclampsia - delivered 1 0.0 0 0.0 
Z246211 Start of labour 0 0.0 1 0.0 
63B..00 Apgar at 10 minutes 0 0.0 1 0.0 
6354.00 Baby full term maturity 0 0.0 1 0.0 
L126600 Eclampsia in labour 1 0.0 0 0.0 
657 E Dystocia 0 0.0 1 0.0 
K7551 Forceps extraction midcavity with episiotomy 0 0.0 1 0.0 
Q214.00 Liveborn with fetal distress, unspecified 0 0.0 1 0.0 
L281.00 Premature rupture of membranes 1 0.0 0 0.0 
L213100 Multiple delivery, all by forceps and vacuum 
extractor 
0 0.0 1 0.0 
L345.12 Vulval and perineal haematoma during delivery 0 0.0 1 0.0 
650 G Delivery premature in hospital/maternity 1 0.0 0 0.0 
L394600 Haematoma of obstetric wound 0 0.0 1 0.0 
L394500 Infection of obstetric surgical wound 0 0.0 1 0.0 
657 C Labour difficult atony uterus 0 0.0 1 0.0 
L321.00 Prolonged labour unspecified 0 0.0 1 0.0 
Lyu6A00 [X]Infection of caesarian section wound 
following delivery 
0 0.0 1 0.0 
6312.00 GP unit birth 0 0.0 1 0.0 
777 D Dysmaturity newborn 0 0.0 1 0.0 
L452100 Obstetric nonpurulent mastitis - delivered 0 0.0 1 0.0 
L150100 Post-term pregnancy - delivered 1 0.0 0 0.0 
L281z00 Premature rupture of membranes NOS 0 0.0 1 0.0 
63D6.00 Placenta incomplete 0 0.0 1 0.0 
L225.00 Face presentation 0 0.0 1 0.0 
L291.11 Failed medical induction of labour 1 0.0 0 0.0 
L398100 Caesarean delivery - delivered 0 0.0 1 0.0 
K777 AC Suture obstetric laceration 0 0.0 1 0.0 
62T..00 Misc. Postnatal data 0 0.0 1 0.0 
L395500 Mid-cavity forceps with rotation 0 0.0 1 0.0 
Z239100 Uterine contractions present 0 0.0 1 0.0 
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Medical 
code 
Medical term Case records 
(N=2815) 
Control records 
(N=26068) 
  n % n % 
L126400 Eclampsia with postnatal complication 1 0.0 0 0.0 
L371.00 Retained portion of placenta or membranes - no 
haemorrhage 
0 0.0 1 0.0 
7781 Postmature  (baby) 0 0.0 1 0.0 
L396100 Vacuum extractor delivery - delivered 0 0.0 1 0.0 
L395z00 Forceps delivery NOS 0 0.0 1 0.0 
L127100 Pre-eclampsia or eclampsia with hypertension - 
delivered 
1 0.0 0 0.0 
L30..00 Obstructed labour 0 0.0 1 0.0 
L124200 Mild or unspecified pre-eclampsia - delivered 
with p/n comp 
1 0.0 0 0.0 
L34zz00 Vulval/perineal trauma during delivery NOS 0 0.0 1 0.0 
K7541 Forceps extraction high with episiotomy 0 0.0 1 0.0 
L28y300 Ragged membranes 1 0.0 0 0.0 
63E3.00 Normal labour 0 0.0 1 0.0 
L461.00 Cracked nipple in pregnancy, the puerperium or 
lactation 
0 0.0 1 0.0 
L340300 Labial tear during delivery 0 0.0 1 0.0 
Q48D000 [X]Fresh stillbirth 0 0.0 1 0.0 
ZV27100 [V]Single stillbirth 0 0.0 1 0.0 
7F23.00 Immediate repair of obstetric laceration 0 0.0 1 0.0 
NEC=not elsewhere classified; NOS=not otherwise specified; O/E=on examination; the prefix [V] is used for codes 
corresponding to the ICD10 chapter that records reasons other than illness for contact with the Health Service (e.g. childbirth); 
P/N=postnatal; the prefix [X] is used for codes introduced with the migration to ICD10 in April 1995; A/N=antenatal; 
BW=birth weight 
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Appendix H Odds ratios for pre-eclampsia associated with smoking (seven 
category variable) 
Table H.1 Odds ratios for the association between pre-eclampsia and maternal smoking (seven 
categories using information on smoking status during and pre-pregnancy). 
Maternal smoking status Cases N=1533 
n (%) 
Controls N =14236 
n (%) 
Pre-eclampsia 
odds ratio  
(95% CI) 
In pregnancy    
1. non-smoker  162 (10.6) 1184 (8.3) 1.00 
2. ex-smoker  66 (4.3) 590 (4.1) 0.82 (0.60-1.12) 
3. current smoker  65 (4.2) 720 (5.1) 0.65 (0.48-0.88) 
In pregnancy, pre-pregnancy    
4. unknown, non-smoker  672 (43.8) 5496 (38.6) 0.87 (0.72-1.06) 
5. unknown, ex-smoker 100 (6.5) 886 (6.2) 0.80 (0.61-1.05) 
6. unknown, current smoker  218 (14.2) 2591 (18.2) 0.58 (0.46-0.72) 
7. unknown, unknown 250 (16.3) 2769 (19.5) 0.60 (0.48-0.76) 
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Appendix I Participant flow through the dating pregnancy algorithm 
 
Figure I.1 Deriving the estimated date of delivery (EDD) of potential cases’ first recorded 
completed pregnancies (n=3362). 
Initial sample 
N=3362
≥ 1 delivery 
record
Yes n=3254
≥ 1 late pregnancy record 
for an earlier pregnancy
Yes n=0 No n=3254
Information on 
days/weeks postpartum 
within delivery records
Yes n=27
EDD=date of earliest delivery 
record minus no. days postpartum
No n=3227
≥ 1 late pregnancy record for first 
recorded completed pregnancy
Yes n=22
EDD=earlier of i) date of latest late pregnancy record 
plus no. days to latest post-term delivery (42 weeks' 
gestation); and ii) date of earliest delivery record 
No n=3205
EDD=date of earliest 
delivery record
No n=108
≥ 1 late pregnancy 
record 
Yes n=0 No n=108
Excluded from 
study
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Figure I.2 Deriving the estimated date of delivery (EDD) of potential controls’ first recorded 
completed pregnancies (n=93909). 
Initial sample 
N=93909
≥ 1 delivery 
record
Yes n=93853
≥ 1 late pregnancy record 
for an earlier pregnancy
Yes n=12
EDD=date of latest late 
pregnancy record for 
earliest pregnancy plus 
no. days to full term
No n=93841
Information on 
days/weeks 
postpartum within 
delivery records
Yes n=800
EDD=date of earliest delivery 
record minus no. days postpartum
No n=93041
≥ 1 late pregnancy record for first 
recorded completed pregnancy
Yes n=1114
EDD=earlier of i) date of latest late pregnancy 
record plus no. days to latest post-term delivery (42 
weeks' gestation); and ii) date of earliest delivery 
record 
No n=91927
EDD=date of earliest 
delivery record
No n=56
≥ 1 late pregnancy 
record 
Yes n=1
EDD=date of latest late 
pregnancy record for 
earliest pregnancy plus 
no. days to full term
No n=55
Excluded from 
study
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Figure I.3 Estimating the pregnancy start date for potential cases with an estimated date of 
delivery (EDD) (n=3254). 
Potential cases with 
an estimated date of 
delivery (EDD) 
N=3254
≥ 1 antenatal record of 
weeks' gestation
Yes n=303
Pregnancy start date=date 
of antenatal record with 
longest weeks' gestation 
minus no. weeks' gestation
No n=2951
≥  1 record of "Estimated 
date of conception" or 
"Expected delivery date"
Yes n=532
Pregnancy start date="Estimated date of 
conception" minus 2 weeks or "Expected 
delivery date" minus 40 weeks
No n=2419
≥ 1 delivery record with 
information on gestational age at 
delivery
Yes n=29
Pregnancy start date=date of 
earliest delivery record minus no. 
weeks' gestation
No n=2390
Pregnancy start 
date=EDD minus 40 weeks
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Figure I.4 Estimating the pregnancy start date for potential controls with an estimated date of 
delivery (EDD) (n=93854). 
  
Potential controls with 
an estimated date of 
delivery (EDD) 
N=93854
≥ 1 antenatal record of 
weeks' gestation
Yes n=14226
Pregnancy start date=date 
of antenatal record with 
longest weeks' gestation 
minus no. weeks' gestation
No n=79628
≥  1 record of "Estimated 
date of conception" or 
"Expected delivery date"
Yes n=26456
Pregnancy start date="Estimated date of 
conception" minus 2 weeks or "Expected 
delivery date" minus 40 weeks
No n=53172
≥ 1 delivery record with 
information on gestational age at 
delivery
Yes n=402
Pregnancy start date=date of 
earliest delivery record minus no. 
weeks' gestation
No n=52770
Pregnancy start 
date=EDD minus 40 weeks
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Appendix J Characteristics of cases and controls eligible for matching in the 
pre-eclampsia study 
Table J.1 Characteristics of potential study participants eligible for matching. 
Characteristic n (%) Potential cases 
(N=1535) 
Potential controls 
(N=84999) 
Maternal age at delivery (years)    
<20 133 (8.7) 9621 (11.3) 
20-24 340 (22.2) 17093 (20.1) 
25-29 478 (31.1) 25139 (29.6) 
30-34 407 (26.5) 22414 (26.4) 
35-39 146 (9.5) 8912 (10.5) 
40-44 31 (2.0) 1820 (2.1) 
median, IQR 28.3, 23.9-32.3 28.3, 23.5-32.3 
Pre-pregnancy BMI (kg/m2)    
<18.5 (underweight) 26 (1.7) 3377 (4.0) 
18.5-25 (normal)  620 (40.4) 40000 (47.1) 
25-30 (overweight)  272 (17.7) 12300 (14.5) 
30+ (obese)  192 (12.5) 5921 (7.0) 
missing  425 (27.7) 23401 (27.5) 
median, IQR 24.1, 21.6-27.9 22.8, 20.7-25.7 
Smoking status in pregnancy    
non-smoker 835 (54.4) 40869 (48.1) 
ex-smoker 166 (10.8) 9331 (11.0) 
current smoker 284 (18.5) 20014 (23.6) 
unknown 250 (16.3) 14785 (17.4) 
Practice level socioeconomic status    
IMD score [median, IQR] 16.2, 8.7-30.1 18.4, 9.9-33.9 
Patient level socioeconomic status    
IMD score [median, IQR]  14.3, 8.4-25.7 15.5, 8.8-28.3 
missing  745 (48.5) 38585 (45.4) 
Pre-existing hypertension  161 (10.5) 5509 (6.5) 
Pre-existing renal disease 4 (0.3) 159 (0.2) 
Pre-existing diabetes 28 (1.8) 1099 (1.3) 
Pre-existing asthma 291 (19.0) 16169 (19.0) 
Previous miscarriage or termination  298 (19.4) 17231 (20.3) 
Multiple pregnancy  25 (1.6) 722 (0.9) 
ART pregnancy 11 (0.7) 496 (0.6) 
Consultations with GP pre-pregnancy [median, 
IQR] 
11, 4-27 12, 5-27 
UTS follow-up pre-pregnancy (years) [median, 
IQR] 
2.4, 0.9-5.1 2.9, 1.2-6.0 
Abbreviations: IQR=interquartile range; BMI=body mass index; IMD=Index of Multiple Deprivation score based on practice 
post-code (practice level socioeconomic status) or patient post-code (patient level socioeconomic status): the higher the score, 
the greater the deprivation; UTS=up-to-standard (i.e. data meeting GPRD quality standards); ART=assisted reproductive 
technology  
 
